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The human GI tract has evolved to simultaneously absorb nutrients and be the frontline in 
host defence. These seemingly mutually exclusive goals are achieved by a single cell thick 
epithelial barrier, and a complex resident immune system which lives in symbiosis with the 
intestinal microflora and is also able to rapidly respond to invading pathogens. An 
immunological balance is therefore required to permit tolerance to the normal intestinal 
microflora, but also prevent the dissemination of pathogenic micro-organisms to the rest of 
the host. Inappropriate immune responses in genetically susceptible individuals are the 
hallmark of human inflammatory bowel disease (IBD) and are thus targeting effector immune 
cells and their cytokines remains the mainstay of treatment. However despite vigorous 
efforts to delineate the genetic contribution to IBD disease susceptibility using large 
multinational cohorts, the majority of disease heritability remains unknown. Epigenetics 
describes heritable changes in chromatin that are not conferred by DNA sequence. These 
incorporate changes to histones, chromatin structure and DNA methylation, which confer 
changes to gene transcription and thus gene expression and cellular function. Methyl-
binding proteins (MBD) have the ability to bind to methylated DNA and recruit large 
chromatin remodeling complexes that underpin a variety of epigenetic modifications. Methyl-
CpG-binding domain protein 2 (MBD2) is one such MBD that is required for appropriate 
innate (dendritic cell) and adaptive (T cell) immune function, though its role has not been 
investigated in the GI tract.  
 
We hypothesized that alterations in chromatin are central to the reprogramming of normal 
gene expression that occurs in disease states. By defining the phenotype of immune cells in 
the absence of MBDs we hope to understand the mechanisms of chromatin-dysregulation 
that lead to immune-mediated diseases such as IBD. We therefore aimed to assess the role 
of MBD2 in colon immune cells in the steady state and in murine models of GI tract 
inflammation, thereafter identifying the culprit cell types and genes responsible for any 
observed changes. We envisaged that investigating heritable, epigenetic changes in gene 
expression that are inherently more amenable to environmental manipulation than our DNA 
code, may provide novel insight to a poorly understood mechanism of disease 
predisposition. In addition identifying the cellular and gene targets of Mbd2 mediated 
changes to immune homeostasis that may provide exciting and novel approaches to 
therapeutic modulation of pathological inflammatory responses. 
 
In chapter 3 we assessed the expression of Mbd2/MBD2 in the murine/human GI tract. 
Consistent with existing mouse data, levels of Mbd2 mRNA increased between anatomical 
divisions of small (duodenum, ileum, terminal ileum) and large intestine (caecum, colon, 
rectum). In addition MBD2 mRNA was greater in the rectum versus ileum, with active IBD 
associated with lower rectal MBD2 mRNA compared to quiescent IBD controls. Thus we 
 15 
sought to understand the role of Mbd2 in the colon, where mRNA levels were the highest in 
the GI tract and where appropriate immune function is central to prevent damaging 
inflammation. To address these aims required the development of existing methods of cell 
surface marker expression analysis using flow cytometry techniques to simultaneously 
identify multiple innate and adaptive immune populations. Using naïve Mbd2 deficient mice 
(Mbd2-/-) we observed CD11b+ CD103+ DCs were significantly reduced in number in Mbd2 
deficiency. 
 
To understand the role of Mbd2 in colonic inflammation we employed a mouse model of 
chemical (DSS) and infectious (T. gondii) colitis comparing Mbd2-/- and littermate controls 
(WT). Mbd2-/- were extremely sensitive to DSS and T. gondii mediated colonic inflammation, 
characterized by increased symptom score, weight loss and histological score of tissue 
inflammation (DSS) and increased antibody specific cytokine responses (T. gondii) in Mbd2 
deficient animals. Flow cytometry analysis of colon LP cells in both infectious and chemical 
colitis revealed significant accumulation of monocytes and neutrophils in Mbd2-/-. Indeed 
monocytes and neutrophils were the principal myeloid sources of IL-1b and TNF in DSS 
colitis and the number of IL-1b/TNF+ monocytes/neutrophils was significantly greater in 
Mbd2-/-. Lastly we employed our colon LP isolation techniques to analyse immune 
populations in active and quiescent IBD and healthy controls, using endoscopically acquired 
biopsy samples. Analysis revealed that as in murine colitis, active human IBD is 
characterized by the accumulation of CD14High monocyte-like cells, with an associated 
increased ratio of macrophage:monocyte-like cells. 
In Chapter 4 we sought to understand the cellular sources of Mbd2 that may explain the pre-
disposition of Mbd2-/- to colitis. Firstly we restricted Mbd2 deficiency to haematopoietic cells 
using grafting Mbd2-/- bone marrow (BM) into lethally irradiated WT mice. These animals 
treated with DSS displayed increased weight loss, symptom score, neutrophil accumulation 
and histopathology score compared to mice irradiated and grafted with WT BM. Given the 
accumulation of monocytes in Mbd2-/- DSS treated mice, and existing literature supporting a 
pathogenic role in this model, we then investigated the role of Mbd2 in monocyte function. 
Colon monocytes sorted from Mbd2-/- and WT DSS treated mice displayed similar 
expression for many pro-inflammatory genes (Il6, Il1a, Il1b, Tnf), but demonstrated 
significantly dysregulated expression for some others (Regb, Lyz1, Ido1, C4a). To 
investigate this in a more refined model, we lethally irradiated WT mice and repopulated 
them with a WT:Mbd2-/- BM mix. This enabled the analysis of WT and Mbd2-/- haematopoietic 
cells in the same animal. Colon WT and Mbd2-/- monocyte recruitment and cytokine 
production in DSS treated mixed BM chimeras was equivalent between genotypes 
suggesting that Mbd2 deficiency in monocytes alone did not explain the increased 
susceptibility of Mbd2-/- to DSS colitis. We then restricted Mbd2 deficiency to CD11c 
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expressing cells, given the known role for Mbd2 in their function, and for CD11c+ cells in 
DSS, using a CD11cCreMbd2Fl/Fl system. DSS treated mice with Mbd2 deficient CD11c+ 
cells demonstrated increased weight loss, symptoms score, histolopathology score, 
monocyte and neutrophil colon accumulation compared to controls. To further explore the 
role of Mbd2 in colon CD11c+ cells, macrophage and DCs from DSS treated WT and Mbd2-/- 
mice were purified and their gene expression analysed. Mbd2-/- versus WT macrophages 
demonstrated significantly altered expression of both pro- (Il1a, C6, Ido1, Trem2) and anti-
inflammatory (Tgfbi, Retnla) pathways that we hypothesized was a method for attempted 
host control of excessive colon damage in Mbd2-/- mice. DC gene expression analysis was 
hampered by small sample size, but demonstrated a large number of small expression 
changes, including IL-12/IL-23 (Jak2) and autophagy (Lrrk2) pathways. Lastly levels of co-
stimualtory molecules (CD40/CD80) were increased in Mbd2-/- but not CD11cΔMbd2 colon 
LP DCs/macrophages suggesting that non-CD11c+ cellular sources of Mbd2 were required 
to produce increased activation phenotype in these cells.  
Finally in Chapter 5 we explored the role for Mbd2 in non-haematopoietic cells, namely the 
colonic epithelium. Here we first developed a novel method for identifying and purifying 
these cells using flow cytometry. Mbd2 deficient colonic epithelium demonstrated increased 
expression of activation markers MHC II and LY6A/E in the steady state and in DSS / T. 
muris mediated colonic inflammation. Indeed FACS purified colon epithelial cells from naive 
and DSS treated, Mbd2-/- and WT mice revealed conserved dysregulated gene expression 
independent of inflammation: Both naïve and inflamed Mbd2 deficient epithelium displayed 
significantly increased expression of genes responsible for antigen processing/presentation 
(MHC I, MHC II, immunoproteasome) and decreased expression of genes involved in cell-
cell adhesion (Cldn1, Cldn4). Lastly we investigated whether the observed differences in 
Mbd2-/- cell types conferred alterations in the makeup of the intestinal microflora. 
Interestingly independent of co-housing of Mbd2-/- and WT animals, Mbd2 deficiency 
consistently predicted the microbial composition, with increased levels of Clostridales and 
decreased levels of Parabacteroides bacteria. 
 
Collectively we have identified CD11c+ cells, monocytes and colon epithelial cells as key cell 
types for Mbd2 mediated changes in gene expression that affect mucosal immune 
responses. These data thus identify Mbd2 gene targets within these cell types as exciting 
new areas for investigation and therapeutic modulation to limit damaging GI tract 








The gastrointestinal tract is comprised of specialised tissues that permit the absorption of 
nutrients whilst also providing an important barrier to infection. The gastrointestinal immune 
system must therefore provide an ability to survey the bowel contents for potential infection, 
but not respond inappropriately to the ‘good bacteria’ that live in our gut, with the resultant 
damage that may cause. Inappropriate immune responses are therefore at the heart of many 
common illnesses today, in particular the inflammatory bowel diseases. These diseases 
affect young people, are in part genetic, and commonly require medicines and surgery to 
control bowel inflammation which is part driven by an overactive immune response. The way 
we understand how genetic information is passed onto our children has changed in recent 
years. In particular, an additional layer of information that co-ordinates how our DNA is 
folded and interpreted and used by our cells, but that doesn’t affect our DNA sequence is 
now appreciated. This layer of information is termed epigenetics and can passed down the 
generations. Because epigenetic information isn’t as tightly regulated as our DNA code, it 
can be altered much more easily in response to changes in our environment, such as 
infection, ageing, smoking etc. MBD2 is a protein that can affect epigenetic changes to our 
DNA and has previously been shown to be important in how immune cells function. The 
purpose of this thesis was therefore to understand if MBD2 can alter the way our immune 
cells function in our bowel, in particular in response to inflammation.  
 
We identified that without MBD2 the bowel was more susceptible to inflammation and that 
this was caused in part by altered immune cell function. In particular MBD2 was important in 
particular cell types called dendritic cells and macrophages that co-ordinate the detection 
and response to microorganisms. In an additional unexpected finding, we also observed that 
MBD2 acts in the epithelial lining of the bowel to prevent inappropriate surveillance of the 
‘good bacteria’. The combination of altered epithelial and immune cell function in the 
absence of MBD2 also resulted in an altered make-up of the ‘good bacteria’ that live in our 
bowel.  
 
Overall epigenetic mediated changes to how our DNA is expressed by immune and epithelial 
cells not only alters their function, but may explain why some people develop immune 
conditions like inflammatory bowel disease and others do not. Understanding how our 
immune system uses epigenetics may therefore in the future offer a different approach to 



























The human gastrointestinal (GI) tract comprises the oral cavity, oesophagus, stomach, small 
and large intestines (1). The small intestine is subdivided into the duodenum, jejenum and 
ileum and the large intestine into the caecum, colon, rectum and anus (1). Each of these 
discreet anatomical sub divisions also confers distinct morphological and functional traits to 
facilitate the main purpose of this organ system, namely the absorption of nutrients and 
expulsion of waste (1). The former is reliant on a large, 400m2 surface area of single cell 
thick epithelium formed of fingerlike villi projections that must not only permit the passage of 
vital nutrients, but also form a physical barrier to separate host from environment (1). A thin 
epithelial surface may facilitate the absorption of foodstuffs, but has the potential to 
compromise host defence. The human GI tract has therefore evolved a highly selectively 
permeable surface, with an abundant immune presence exemplified by the copious lymphoid 
tissue and immune cells it harbours (1). Indeed in addition to the diverse array of dietary 
antigens consumed each day, the GI tract is colonised by a dense population (1014) of micro-
organisms that numerically exceeds both the genetic material and cellularity of the host (2). 
Despite a robust epithelial barrier, luminal antigens are not entirely prevented from entering 
tissues. Intact food proteins can be detected in the blood and small numbers of GI tract 
dwelling micro-organisms can be found in the draining lymph nodes of healthy animals (3). 
An intimate relationship therefore exists between commensal organisms, the host immune 
system and selective barrier function. 
 
1.2 The inflammatory bowel diseases 
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease 
(CD), are chronic inflammatory conditions of the gastrointestinal tract. They most frequently 
present in the 2nd and 3rd decades with rectal bleeding, abdominal pain or diarrhoea (4), (5). 
Anti-inflammatory and/or immunomodulator therapy, although effective, does not completely 
eliminate the substantial morbidity associated with these conditions, which have a major 
population health impact given their preponderance in young people. CD is characterised by 
transmural inflammation, affecting any part of the GI tract, with a prevalence of 144/100,000 
population (6). The incidence is highest amongst young people in Scotland and continues to 
rise (1.9 per 105/year 1981-3, 2.9 per 105/year 1990-2) (7). UC is characterised by 
inflammation confined to the mucosa and may spread proximally from the rectum to 
encompass the entire colon. UC is similarly common with a reported UK incidence of 
between 6.5-15.1 per 105 / year and an age-sex adjusted point prevalence in Northern 
England of 243/100,000 population (6), (8).  
 
Historical data have shown up to 75% of patients will undergo surgery at least once during 
their disease course, with resection not curative and further surgical intervention often 
required (9), (10). Despite increasing use of immunomodulatory treatments such as 
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thiopurines, methotrexate and monoclonal antibodies against TNF, 25% of newly diagnosed 
patients managed with conventional medical treatment will still require intestinal surgery 
within 5 years of diagnosis (11). Operative management remains effective for managing 
disease complications and improving quality of life, but does not eliminate the pathogenic 
process, so most patients develop recurrence of the disease (12),(13),(14). 
 
1.3 The Gastrointestinal immune system 
Healthy individuals possess an abundant and highly active GI tract immune system that is 
tightly regulated to prevent excessive immune responses to foods and commensal 
microbiota (15). The host response to infection by pathogens are known as immune 
responses. A specific response to a particular pathogen or its products is known as an 
adaptive immune response, as it represents an organisms adaption to its environment (16). 
In many organisms this results in lifelong protection against said pathogen, mediated by 
immunological memory (16). In contrast the innate immune response mobilises immediately 
to combat a wide range of pathogens but does not lead to long lasting immunity or a specific 
response to a particular pathogen (16). The defence systems of the innate immune response 
rely on a limited number of receptors that recognize micro-organisms. Pattern recognition 
receptors (PRRs) recognize simple molecules and regular patterns of molecular structure 
known as pathogen-associated molecular patterns (PAMPs) present on micro-organisms but 
not host cells (16). PRRs include toll-like receptors (TLRs) that recognize PAMPs 
characteristic of bacteria, fungi and viruses (16). Stimulation of TLRs results in the release of 
antimicrobial peptides (AMP), with this pathway being conserved in all animals and plants 
(16). Another important family of PRRs are nucleotide-binding oligomerisation domain (NOD) 
like receptors that are intracellular sensors for microbial products that activate nuclear factor 
kappa-B (NF-κB) in a similar manner to TLRs (16).  
 
Cytokines are key effectors of the immune response. They are small proteins that are 
released from cells in response to an stimulus that can induce responses by binding to 
specific receptors on the cells that secrete them (autocrine), adjacent cells (paracrine) or 
distant cells (endocrine) (16). Among the first cytokines released in early immune response, 
is a group of chemoattractant cytokines termed chemokines. These small proteins induce 
chemotaxis in nearby cells, resulting in movement of cells towards the source of the 
chemokine (16).  
 
The systemic and mucosal immune systems differ in an anatomical separation of the 
inductive and effector sites. Lymphoid aggregates, such as Peyer’s patches (PP) in the small 
intestine, contain large numbers of T and B cells, which when activated migrate via the 
blood, back to the lamina propria (LP) and epithelium, a process mediated by their 
expression of α4β7 integrin and chemokine release by effector sites in the GI tract (17), (18). 
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The LP in addition contains large numbers of IgA-producing plasma cells, CD4+ T cells, 
macrophages, dendritic cells (DCs), mast cells and eosinophils, with a significant leucocyte 
population, notably CD8+ T cells expressing the γδ T cell receptor, residing within the 
epithelium (intra-epithelial lymphocytes (IEL)) (19),(20). We now consider these relative cell 
types and their contribution to mucosal immunity in health and disease. 
 
1.3.1 Neutrophils  
Polymorphonuclear leucocytes (PMN), also called neutrophils, are critical components of the 
innate immune response. They protect the host from microbial pathogens and from the 
damaging effects of injured cells. As such they possess an arsenal of antimicrobial functions 
including degranulation and phagocytosis that mitigate against invading pathogens by 
massive release of reactive oxygen species and other toxic molecules (21). As such 
neutrophil depletion exacerbates certain models of mucosal inflammation suggesting a 
beneficial role, perhaps by limiting translocation of bacteria and producing wound-healing 
mediators (22). However it is also clear that neutrophils can directly contribute to disease 
pathology whereby excessive recruitment, such as in IBD, and activation leads to release of 
toxic products, trans-epithelial migration and extensive mucosal injury (23). Neutrophils 
similarly have the ability to produce metalloproteases (MMP) that can cleave chemokine 
precursors augmenting their potency, and may acquire antigen presenting and T cell 
activation functions during colitis (24). Thus the regulatory or inflammatory phenotype of 
intestinal neutrophils is determined by a range of factors, including the type of stimulus, the 
production of chemoattractants and the interaction with other immune cells that modulate 
their function.  
 
1.3.2 Eosinophils  
Eosinophils develop from eosinophil progenitor cells that are derived from haematopoietic 
cells, express CD34 and interleukin (IL) 5Rα and undergo differentiation on exposure to IL-5, 
IL-3 and granulocyte-macrophage colony stimulating factor (GM-CSF). Eosinophils are able 
to detect pathogens and promote innate and adaptive immune responses via the expression 
of complement receptors (e.g. CD11b), Fc receptors (FcαR, FcγRII) and pattern recognition 
receptors (PRR) (25). Upon activation eosinopihls release a variety of mediators such as 
cytokines (IL-12, IFN-γ, IL-4 and TGF-β), chemokines and growth factors (26). Eosinophils in 
the GI tract are poorly described, traffic to non-oesophageal GI tract portions in an eotaxin-1 
dependent manner and are distinct phenotypically and functionally from eosinophils in other 
tissues (27). Eosinophils are regulated by epithelial derived cytokines such as thymic stromal 
lymphopoietin (TSLP) and IL-33 that directly activate eosinophils and promote their 
recruitment by augmenting Th2 responses (28). An important role is suggested by their 
abundance and low turnover in vivo with activated eosinophils found in greater numbers in 
those with active IBD compared to quiescent IBD and healthy controls (29) (30). Eosinophils 
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are capable of presenting antigen to CD4+ T cells and releasing secretory IgA (sIgA), 
suggesting a role in the initiation and polarisation of adaptive immune responses (31). 
Indeed, murine eosinophils are able to express major histocompatibility complex class II 
(MHC-II), and co-stimulatory molecules (CD40, CD80 and CD86) under certain conditions 
(32). In addition deficiency eotaxin-1 or eosinophils themselves protects against murine 
models of colitis, though not in all reports, with eotaxin-1 levels in the intestine or circulation 
correlating with disease severity in UC (33). Lastly, Griseri et al. have shown that eosinophils 
accumulate in an IL-23 driven model of colitis, with blockade of IL-5 or eosinophil depletion 
associated with ameliorated disease (34). They further show that GM-CSF is a potent 
activator of eosinophil function and that eosinophil peroxidase release promotes colitis, 
suggesting a direct tissue-toxic mechanism for eosinophils in this model of intestinal 
inflammation (34). Such is the interest in the pro-inflammatory potential of mucosal 
eosinophils that a phase II trial assessing the role of bertilimumab, an eotaxin-1 neutralising 
antibody is underway assessing eosinophil depletion in the treatment of acute UC (Clinical 
trials no. NCT01671956).  
 
1.3.3 Monocytes  
Monocytes are mononuclear phagocytes (MP) that originate from progenitors in the bone 
marrow and traffic via the bloodstream to peripheral tissues. Monocytes mediate 
antimicrobial defence, are implicated in inflammatory diseases such as atherosclerosis and 
inhibit tumour-specific immune-evading mechanisms.  Monocytes are divided on the basis of 
chemokine receptor expression and the presence of specific surface molecules (35,36). 
Murine expression of LY6C and CD11b defines a monocyte subset with high levels of CC-
chemokine receptor 2 (CCR2) and low levels of CX3C-chemokine receptor 1 (CX3CR1). 
These are termed inflammatory or LY6CHigh monocytes, account for 2-5% of circulating white 
blood cells in homeostatic conditions, and are rapidly recruited to sites of inflammation 
((37)). A second subset of circulating monocytes in mice expresses high levels of CX3CR1, 
low level LY6C and CCR2 and adheres to the luminal surface of endothelial cells in a 
process termed ‘patrolling’ (35,36). Human monocytes are divided into subsets on the basis 
of surface CD14 and CD16 expression (38). CD14+ CD16-  (classical) monocytes are the 
most numerous in human blood and, like murine LY6CHigh monocytes, express CCR2. 
CD16+ monocytes may be further subdivided into CD16++ CD14+ (intermediate) and CD16+ 
CD14++ (non-classical) monocyte groups (39). CD16++ CD14+ monocytes are thought similar 
to murine LY6CLow monocytes given their similar role in in vivo patrolling (40). Therefore 
whilst monocytes in humans and mice are not identical, their differentiation and function in 
immune response appear to be similar (41).  
 
It has recently been reported that blood monocytes are the precursors for intestinal 
macrophages (42,43). Indeed the murine colonic macrophage compartment is entirely 
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dependent on constant replenishment from LY6CHigh monocytes, in contrast to embryonic 
precursors propagating tissue macrophages in other sites (42). In addition to their role in 
replenishing tissue macrophages in the steady state, monocytes are recruited to infected 
tissue sites to mediate direct antimicrobial activity. For example infection with the 
intracellular Gram-positive bacterium Listeria monocytogenes is exacerbated in mice with 
CCR2 deficiency, reducing the recruitment of tumour necrosis factor (TNF) and inducible 
nitric oxide synthase (iNOS) capable monocytes and their progeny (44,45). However it has 
also been suggested that monocytes may have a regulatory role in limiting commensal-
mediated damage to the GI tract. Grainger et al. have eloquently shown that in response to 
commensals, inflammatory monocytes can directly inhibit neutrophil-mediated pathology in 
response to pathogen challenge by production of the lipoid mediator prostaglandin E2 
(PGE2) (46).  
 
Thus whilst monocytes maintain intestinal macrophages in the steady state via a low level 
constitutive presence, they accumulate in inflammation, expressing high levels of IL-1β, IL-6 
and PRRs, facilitating a vigorous inflammatory immune response and in addition may also 
have a dual regulatory role on other local inflammatory cells (43,46,47).  
 
1.3.4 Macrophages  
Macrophages are one of the most abundant immune cells in the mammalian intestine and 
are the largest population of MPs in the body (48). As described above, adult mouse 
intestinal macrophages are exclusively derived from blood-borne inflammatory monocytes, 
and are long-lived, present to at least 8 weeks post monocyte-differentiation (43). Within the 
mononuclear phagocyte pool, murine macrophages are often distinguished from DCs by 
differential expression of surface markers such as F4/80, CD11b, CD18, CD64, CD68 and 
Fc receptors (49). In contrast identifying macrophages and their M1 and M2 subsets in 
humans has proved challenging (49). For example human macrophages do not express 
Ym1 or Retnla, 2 of the most studied identifiers of alternatively activated macrophages in 
mice (49). Similarly neither ARG1 or iNOS are expressed by in vitro polarized macrophages 
stimulated with IL-4 or IFN-γ, perhaps suggesting that macrophage effector molecules will be 
diverse between species based upon the specific pathogen challenges that they face (49).  
 
Macrophage density in the intestine is poorly understood, though thought to correlate to 
bacterial load, and is thus highest in the colon where commensal bacteria number in excess 
of 1012 organisms/ml (50). Intestinal macrophages have been shown to demonstrate a 
tolerogenic phenotype, poorly responsive to TLR stimuli, which underlies one of the principal 
mechanisms for host control against inappropriate reactions to commensal microflora (51). 
As such, unlike macrophages from other tissues, mucosal macrophages in the steady state 
secrete low levels of pro-inflammatory cytokines and chemokines such as IL-12, Il-23, TNF, 
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IL-1, IL-6 or CXCL10 in response to TLR ligands but secrete higher levels of the anti-
inflammatory cytokine IL-10 (52), (53), (54), (55). However intestinal macrophages retain an 
avid phagocytic ability, able to uptake apoptotic cells via expression of CD36, and have 
potent anti-bacterial activity (56). Indeed in inflammatory conditions, macrophages are 
capable of upregulating the expression of TLRs, co-stimulatory molecules and pro-
inflammatory receptors, resulting in the production of large quantities of TNF, IL-6, iNOS, IL-
1 and MMPs (57), (50), (58). Thus macrophages are a fundamental component of innate 
responses in the healthy and inflamed GI tract, limiting inappropriate reaction to the resident 
commensal microflora, but capable of facilitating a robust response in disease states.  
 
1.3.5 Dendritic cells 
DCs are specialised antigen presenting cells (APCs) that orchestrate innate and adaptive 
immune responses. In the intestine, DCs are present in peyers patches (PP), isolated 
lymphoid follicles (ILF) and the LP, constitutively migrating in lymphatics to mesenteric lymph 
nodes (MLN) and presenting antigen to T lymphocytes - a process fundamental to the 
induction of oral tolerance (59),(3).  
 
Murine intestinal DCs are characterised by high expression of CD11c and MHC-II and a lack 
of expression of CD64. The majority of intestinal CD11c+ MHC-II+ CD64- cells express the 
integrin-αE (CD103) whose ligand E-cadherin is expressed on the basolateral surface of 
epithelial cells (60). It is thought that rather than representing a distinct lineage of DCs in the 
intestine, CD103 is likely induced on DCs during their residence in the intestine (61).  
 
Intestinal CD103+ DCs can be divided into 2 distinct populations on the basis of CD11b 
expression that differ in transcriptional factor requirements and function (Diagram 1.1). 
CD103+ CD11b- DCs are related to lymph node resident CD8α+ DCs and share with these 
cells expression of the chemokine receptor XCR1 (62), (63). In addition genetic deletion of 
the transcription factors Id2, Irf8 and Batf3 leads to selective loss of CD11b- CD103+ cells 
(64). By contrast, CD103+ CD11b+ intestinal DCs appear similar to CD11b+ lymph node 
resident DCs, sharing expression of signal regulatory protein-α (SIRPα) and DC inhibitory 
receptor 2 (DCIR2) and are dependent on different transcription factors in their development 
and maintenance, namely Irf4 and Notch2 (65), (66). Both CD103+/- CD11b+ DCs have been 
shown to promote TGF-β T helper (Th) 1 and Th17 cell differentiation with TLR5+ CD11b+ 
DCs able to induce B Cell IgA class switching via production of a proliferation inducing ligand 
(APRIL) (65), (67).  
 
There are also 2 distinct, less well-defined CD103- populations of DC that can similarly be 
described by expression of CD11b. CD103- CD11b+ DCs do not express CD64 or XCR1, but 
are under control of the DC-specific transcription factor Zbtb46 (62), (63), (65), (68) (Diagram 
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1.1). Lastly a population of CD103- CD11b- DCs have been described, that like CD103- 
CD11b+ DCs migrate to MLN in a CCR7 dependent manner, expand in response to Flt3 
ligand, prime T cell responses and induce T cell CCR9 (69). In addition both CD103- 
CD11b+/- cells have recently been shown to express higher levels of IL-12 and IL-23 mRNA 
and induce higher IFN-γ and IL-17 production from proliferating T cells compared to CD103+ 
LP DCs, even in the absence of TLR stimulation (65). 
 
Regarding the ontogeny of intestinal DCs, adoptive transfer of DC progenitors into CD11c 
depleted mice demonstrated that pre-cDCs but not LY6CHigh monocytes were able to give 
rise to CD103+ CD11b+ and CD103+ CD11b- DC in the intestinal mucosa, whereas 
macrophage and DC progenitor (MDP) were able to give rise to all DC and macrophage 
subsets (70), (71). Underlining the rapid advancement in our understanding of DC surface 
markers, this study was not able to address the ability of MDPs or pre-cDCs to produce 
CD103- DCs, as markers that would have distinguished them from macrophages (such as 
CD64) were not used (71). However other studies of LY6CHigh adoptive transfer have shown 
that they give rise exclusively to F4/80+ CD64+ cells suggesting CD103- DCs are not 
monocyte derived (72), (43). Lastly, it has been shown that removing the transcription factor 
Zbtb64 in Zbtb46-DTR mice decreases CD103+ CD11b+ DCs by 50%, in contrast to CD103+ 
CD11b- DCs which were almost completely removed (73).   
 
Many of the initial markers used to define DC subsets in mice and humans are not 
conserved, leading to difficulties in generalizing data between species. However a human 
intestinal CD103+ DC population has been identified, and can be further subdivided into 2 
subsets (65), (66). A CD103+ SIRPα- subset that display similarities to human CD8α-like 
cDCs, expressing CD141 and DNGR-1, that likely represent the human equivalent of murine 
CD103+ CD11b- DCs and a larger population of CD103+ SIRPα+ DCs that were CD141- and 
DNGR-1- that likely represent the murine equivalent of CD103+ CD11b+ DCs (74), (75), (76), 
(66). Lastly, a CD103- CD64- SIRPα+ DC population has been identified that likely represent 





Diagram 1.1 DC subsets in the mouse and human intestinal lamina propria  





























































































































































































































1.3.6 T cells 
The intestinal mucosa contains a large number of T cells localised within gut-associated 
lymphoid tissue (GALT) including PPs and ILFs, and throughout the LP and intestinal 
epithelium (19). Colon LP T cells express the surface markers TCRαβ and are then 
subdivided into 4 populations based on the expression of CD8αβ, CD8αα or CD4 (CD8αβ+, 
CD8αβ+ CD8αα+, CD4+ and CD4+CD8αα+). LP T cells display a previously activated or 
memory phenotype, entering the mucosa after priming in secondary lymphoid organs, drive 
excessive inflammation and cytotoxicity in response to microbiota derived antigens and may 
exacerbate IBD in humans (19). Intra epithelial lymphocytes (IELs) are more heterogeneous, 
their composition dependent on their anatomical location in the GI tract and are dominated 
by T lymphocytes (there are estimated to be more T cells in the intestinal epithelium than the 
spleen) (77), (78). Colon IELs contain the same LP T cell populations mentioned above, but 
in addition contain CD4- CD8- and CD8αα+ populations that express either TCRαβ or TCRγδ 
((79).  IELs display both protective and inflammatory qualities dependent on the stimuli they 
receive and their local environment. They can condition and repair the epithelial barrier and 
control epithelial cell growth and turnover by secreting TGFβ1/3, keratinocyte growth factor 
(KGF) and junctional adhesion-like (JAM) molecule which directly interacts with the 
epithelium to promote restoration of barrier integrity (80), (81), (82). In contrast they can also 
secrete TNF and IFNγ, are found in increased numbers in patients with active IBD and 
coeliac disease and may promote immunopathology in mouse models of intestinal 
inflammation (77).  
 
T cells can be further subdivided based upon their effector subtypes (Th1, Th2, Th17, and 
regulatory T cells). Th1 cells are induced by IL-12 and characteristically secrete copious 
amounts of IFNγ, TNF and IL-12 controlled by the master transcription factor TBET. Th2 
cells by contrast secrete IL-4, IL-5 and IL-13 controlled by the master transcription factor 
GATA3 (83). Th17 cells are a further subset of T cells induced by IL-6 and TGFβ, secreting 
large amounts of IL-17A, IL-17F, IL-21 and IL-22 and controlled by the master transcription 
factor RORγt (84), (85), (86). 
 
Regulatory T cells (Tregs) 
Tregs characterised by the expression of CD4, CD25 and FoxP3, are defined as T cells with 
an ability to supress naïve T cell proliferation in vitro and in vivo (87). Mice that are depleted 
of Tregs spontaneously develop multiorgan autoimmunity including gastrointestinal 
inflammation (88). Indeed a genetic defect in FOXP3 results in immune polyendocrinopathy 
enteropathy X-linked (IPEX) characterised by a lack of Tregs, producing a severe pan-
enteric inflammatory enteropathy that resembles CD (89). Tregs perform a vital role in 
tolerance supressing abnormal immune responses to commensal micro-organisms and 
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dietary antigen by the expression of anti-inflammatory cytokines IL-10 and TGF-β that 
prevent aberrant activation and effector function of other immune cells (90). 
 
1.3.7 Innate lymphoid cells 
ILCs are an emerging and diverse group of immune cells and derive from an ID2 expressing 
progenitor and are defined by 3 main features: They are of lymphoid morphology, are 
negative for other cell-lineage markers (CD3, B220, LY6G/C, CD11c, Ter119) and lastly then 
lack RAG-dependent antigen receptors (91). ILCs can further be sub categorized into 
groups: Group 1 ILCs are T-box expressed in T-cells (TBET) dependent and are comprised 
of ILC1 and NK cells. Group 2 ILCs are GATA-binding protein 3 (GATA3) and retinoic acid 
receptor ROR dependent and are comprised of ILC2 and lastly group 3 ILCs that are RORγt 
dependent and are comprised of ILC3s and lymphoid tissue-inducer (LTi) cells (92). ILCs 
tend to mirror the cytokine profile of T-helper cells and thus are thought to be the innate 
counterparts of T-helper lymphocytes. Group 1 ILCs produce Th1 associated cytokines, in 
particular IFNγ. Group2 ILCs produce Th2 cytokines, in particular IL-5 and IL-13 (93), (94). 
Group 3 ILCs are defined by their ability to secrete Th17 cytokines such as IL-17 and IL-22 
(95). Recent data has implicated Group3 ILCs in the development of IBD. Group 3 ILCs 
have been shown to be able to induce colitis in a Helicobacter hepaticus infection 
characterised by IL-17A and IFNγ production in Rag-/- mice (96). Subsequent data suggest 
that Group 3 ILCs can induce colitis in an IL-23R, IL-22 dependent mechanism, that Rorγt-/- 
mice do not develop CD40L induced colitis and lastly human ILC’s were found at increased 
levels in the LP in an IL-23 dependent manner (97), (96), (98), (99).  
 
1.3.8 Intestinal epithelial cells 
The intestinal epithelium is the largest mucosal surface in the human body (1). This surface 
is a single cell thick to permit efficient ion and nutrient absorption and yet must shield the 
host from a diverse and sustained antigenic load (100). At its most basic intestinal epithelial 
cells (IECs) regulate GI tract immunity by forming a physical barrier by separating luminal 
contents from the underlying LP. However IECs also display innate immune function through 
the production of anti-microbial products, including defensins, cathelicidins and calprotectin 
(101). Indeed IECs are able to process and present antigen via MHC II, express PRRs 
including TLRs, and secrete a number of immunoregulatory mediators such as IL-10, TGF-β 
and IL-12p70 (102). The epithelium covering ILFs contains a specialised sub division of 
epithelial cells termed M cells with the ability to directly uptake luminal antigen by 
endocytosis, presenting antigen unmodified to T cells given the lack of M cell lysosomes 
(103). IECs are therefore equipped with the necessary machinery to detect, process and 
respond to microbial signals in the intestinal lumen to facilitate local mucosal responses 
(Diagram 1.2).  
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1.4 IBD is characterised by a dysregulated immune response 
IBD is thought to be the result of a dysregulated immune system in genetically susceptible 
individuals. Genome wide association studies (GWAS) comparing patients with IBD to 
healthy controls have identified >100 polymorphic loci, including many genes involved in 
innate and adaptive immune response (104), (105). Susceptibility variants have been 
reported in genes associated with autophagy, (ATG16L1), the IL-23/Th17 pathway (IL-12B), 
TGFβ signaling (SMAD3) and T cell activation (TAGAP) (106), (104). NOD2 was the first CD 
susceptibility gene discovered and has the largest genetic effect on disease susceptibility to 
date (107), (108). A recent meta-analysis of over 2,500 patients with NOD2 mutations 
revealed the presence of any NOD2 mutation increased risk for surgery by 58% and 
complicated disease by 48% compared to IBD patients without NOD2 mutation (109).  
 
How these genes confer an increased risk of developing IBD is not clear, and is an area of 
research interest. Autophagy refers to the cellular process of ‘self-eating’, a process by 
which lysosomal degradation to intracellular organelles, unfolded proteins of extracellular 
material maintains cellular homeostasis under conditions of stress, such as infection or 
mitochondrial damage (110). Transgenic mice generated to express a hypomorphic isoform 
of the ATG16L1 protein display Paneth cell abnormalities similar to those found in ileal 
resections of CD patients, and are more susceptible to experimental colitis (111). Similarly 
DCs have been shown to require intact NOD2 and ATG16L1 pathways to permit effective 
autophagy processes, consistent with the hypothesis that the detection and isolation of 
intracellular pathogens are intimately linked (112).  
 
Infiltrating monocytes have been identified at increased levels in the intestinal mucosa of IBD 
patients (43). CD14High cells display increased production of TNF, IL-1β, IL-6 and respiratory 
burst activity and recruit other immune cells, such as eosinophils via release of eotaxin-1 
(113). It is hypothesised that monocytes are therefore key effector cells in mediating ongoing 
mucosal inflammation.  LP CD14High monocytes are derived from blood precursors, 
demonstrated using radio-labelled transfer of blood monocytes, and are recruited perhaps in 
response to increased circulating levels of chemokines such as CCL2 and CCL4 (47).  
 
Macrophage and DC subtypes form a central part of the functional mucosal barrier of the GI 
tract, however the exact definition of these cells using surface markers remains 
controversial. One such marker is CX3CR1, which appears to be highly expressed on 
macrophages but not cDCs (114), (52). CX3CR1+ LP macrophages are located in close 
proximity to the epithelium and are able to extend processes to sample luminal antigen 
(103). However it has also been shown that CD103+ CX3CR1- DC also present antigen via 
intestinal goblet cells, thus uptake of luminal antigen may not be confined to a particular MP 
cell subset (115). Genetic deletion of CX3CR1 results in decreased LP macrophage 
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numbers, increased bacterial translocation of commensal bacteria and increased 
susceptibility to experimental colitis that can be rescued by administration of CX3CR1 
sufficient macrophages or blockade of IL-17A (103), (116).  
 
Recent studies in man have also identified intestinal monocytes and monocyte-derived 
macrophages as critical perpetrators in driving inflammation in IBD (113), (117), (72). The 
human gastrointestinal mucosa represents the largest reservoir of macrophages in the body 
and, as in mice, resting human GI tract macrophages are relatively inert (118), (119). Human 
intestinal macrophages express CD68, CD33 and low levels of CD14, CX3CR1, CD11c and 
CD163 (113), (42). However under inflammatory conditions a discreet CD14High monocyte 
population accumulates which, like the analogous LY6C+ MHC-II- monocyte population seen 
in mice, is also present at reduced numbers in the steady state (113), (120). These CD14High 
cells seem to be derived from circulating classical blood monocytes, express higher levels of 
CD11c, CD64, CD163 and are heterogeneous in expression of HLA-DR and CD209 (120), 
(121). In addition CD14High cells can produce large amounts of inflammatory cytokines such 
as IL-6, IL-23 and TNF (113), (57). 
 
The evidence for the role of DCs in IBD pathogenesis is currently limited to observational 
studies in man, and transgenic studies in mice. DCs accumulate in the mucosa of IBD 
patients and experimental models of and interference with T cell-DC interactions via 
CD40/CD40L blockade can prevent T cell mediated colitis (122), (123), (124).  
 
GWAS have identified several IBD risk susceptibility loci involving Th17 cells and their 
differentiation including IL-23R, IL12B, JAK2, STAT3, CCR6 and TNFSF15 (105), (125). 
Indeed IBD patients have greater IL17A expression in the GI tract, and display greater 
numbers of Th17 cells (126), (127), (128).!However animal models suggest conflicting roles 
for the IL-17 axis in conferring susceptibility to colitis. IL-17A deficient mice, or those treated 
with IL-17A neutralising antibodies are more resistant to the development of experimental 
colitis using trinitrobenzene sulfonic acid (TNBS) (129). IL-17A has also been shown to 
directly inhibit Th1 cells and suppress the development of inflammation; experimental 
autoimmune encephalomyelitis is suppressed in Il17-/- mice and bone erosion is reduced in 
rats treated with IL-17 receptor IgG1 Fc fusion protein (130), (131). However using a model 
of chemical colitis, mucosal inflammation was ameliorated by IL-17F deficiency (132), (133).! 
 
In summary the patchy transmural inflammation of CD is associated with activation of Th1 
and Th17 cells in response to the production of IL-12, IL-18, IL-23 and TGFβ by APCs. In 
turn activated Th1 and Th17 cells increase section of pro-inflammatory mediators such as IL-
2, IL-17, IFNγ and TNF. This reinforces APC, macrophage and endothelial release of TNF, 
IL-1, IL-6, IL-8, IL-12 and IL-18. In contrast the mucosal inflammation in UC may be 
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associated with a Th2 immune response mediated by IL-4, IL-5 and IL-13 (134). However 
other reports have shown increased IFNγ and reduced IL-13 from intestinal biopsies of UC 
versus CD patients so distinguishing between IBD subtypes based on T cell cytokine profile 
alone may not be robust (126). In both CD and UC, T cells respond to presented antigen and 
can be regulated by anti-inflammatory mediators such as IL-10 in a similar manner. 
Therefore the bulk of current and emerging IBD treatments have focused on the reducing the 
action of pro-inflammatory cytokines, increasing anti-inflammatory cytokines, blocking T cell 
co-stimulation or inducing T cell apoptosis.  
 
Tregs have a marked anti-inflammatory capability in animal models of colitis, and are found 
in reduced numbers in the blood of active IBD patients (135), (136), (137). However Tregs 
are paradoxically found in increased levels in the LP of patient with active IBD, and 
demonstrate equivalence in suppressing effector T cells compared to healthy patients ex 
vivo, suggesting normal function (138), (139). This may be explained by the observation that 
T cells that experience TCR activation in the presence of TGF-β turn on FoxP3 expression 
(induced Tregs) (140). Whether iTregs maintain the same anti-inflammatory functions as 
constitutive Foxp3 expressing T cells (natural Tregs) is debated (141). 
 
Therefore decreased anti-inflammatory mechanisms may be equally important targets for 
therapeutic intervention as enhanced effector mechanisms. Lastly it has been noted that a 
large proportion of mucosal Tregs from IBD patients are able to produce IL-17, promoting 
further inflammation and neutrophil recruitment. Thus by sharing characteristics of potentially 
pathogenic T cells, copious Tregs in IBD may paradoxically promote rather than suppress 
intestinal inflammation (142), (143).  
 
Taken together there is a strong genetic association with immunological gene 
polymorphisms and the likelihood of developing IBD. However our understanding of the role 
of the innate immune system in IBD pathogenesis is poor, with conflicting evidence for pro 
and anti-inflammatory effects of the adaptive immune response.  
 
1.5 The Microbiome 
The human body harbours trillions of microbes located at host-environmental interfaces such 
as skin, gut, genital and respiratory surfaces (2). The genetic load of our microbial co-
habitants constitutes the microbiome, and outweighs the genetic contribution of the host by 
10 fold (2). The last decade has permitted identification of the microbial community via 
sequencing and high throughput technologies and analysis of their function. Numerous 
studies have now profiled the healthy human microbiome, with over 90% of all phylotypes 
belonging to 2 divisions; Bacteroidetes and Firmicutes (144). In addition whole-genome 
shotgun sequencing of faecal samples from a European adult cohort revealed 98% of genes 
 32 
were bacterial, with the rest constituting yeasts, viruses, archaea and protozoa (145). Indeed 
commensal fungi interact with the innate immune receptor DECTIN-1 and its gene Clec7a in 
mice. Clec7a-/- mice are more susceptible to DSS colitis mediated by altered responses to 
commensal fungi, with CLEC7A polymorphisms in man predisposing to a severe form of UC 
(146). Thus it is likely the identification of non-bacterial facets of the microbiome will become 
increasingly recognised and analysed over the following decade as sequencing 
methodologies continue to advance.  
 
It has subsequently become apparent that our microbiota have evolved with us and are 
critical for normal development and homeostasis. The intestinal microflora interacts with the 
adjacent mucosal environment directly, affecting intestinal permeability and local immune 
responses, but also indirectly via microbial metabolites such as in the production of short 
chain fatty acids (SCFA) that mediate host responses including Treg induction (147), (148). 
The microbiota is a dynamic entity, its composition changing in response to age, sex, 
geography, diet and medication (149). Alteration in the dynamics of this balance may result 
in a dysbiosis, which is associated with the susceptibility to an array of GI tract and non-GI 
tract diseases, such as IBD, coeliac disease, obesity, multiple sclerosis, malignancy and 
liver disease (150).  
 
Evidence supporting the role of luminal antigens in exacerbating IBD comes from treatments 
that modify the faecal stream. Notably diversion of faeces from active inflammation induces 
remission and mucosal healing and infusion of faeces re-activates the disease (151). In 
addition specific taxonomic shifts have been reported in IBD. Enterobacteriaceae are 
increased in relative abundance in both patients with IBD and animal models of intestinal 
inflammation (152). Adherent invasive E. coli (AIEC) strains in particular have been isolated 
from ileal CD biopsies and are enriched in patients with UC (153). This may simply represent 
an increased preference of these organisms to survive in an inflammatory environment, with 
administration of anti-inflammatory treatments, such as mesalazine, reducing their frequency 
(154), (155). In contrast some bacteria have known protective effects on host immunity. 
Bacteroiodes and Clostridium species for example have been shown to induce the 
expansion of Tregs, thereby reducing intestinal inflammation, with other organisms shown to 
attenuate inflammation by regulating NF-κB activation (156). Similarly the Bifidobacterium, 
Lactobacillus and Faecalibacterium genera may protect the host from inflammation by down-
regulating inflammatory cytokines or augmenting IL-10 production (157,158). F. prausnitzii 
has received much attention in recent years, underrepresented in IBD patients, with lower 
levels of mucosa associated F. prausnitzii correlating with higher risk of recurrent CD after 
surgery (158), (159). Conversely, recovery of F. prausnitzii after relapse is associated with 
clinical remission in UC (160). In addition to the immunomodulatory effects noted above, the 
Faecalibacterium genus is also responsible for the fermentation of dietary fibre to produce 
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SCFAs, which are the primary energy source for colon IECs (161). Indeed IECs express a 
range of PRRs to sense the presence of the microflora (162). TLRs and NLRs are the best 
documented and play a key role in the induction of innate effectors and inflammation (162). 
PRR signaling in IECs therefore serves to maintain the barrier functions of the epithelium, 
including the production of sIgA, and setting a tolerogenic phenotype of the mucosa to inhibit 
overreaction to the innocuous luminal dietary and microbial antigens (163).  
 
Host-microbial interactions are therefore pivotal in protection from pathogenic bacterial 
invasion. This consists of a first line defence comprised of facets of the innate immune 
system described above, namely mucins, the epithelium and immune cells such as DCs, 
monocytes and macrophages. Mice that lack an adaptive immune system, such as Rag-/- 
and severe combined immunodeficient (SCID) mice do not develop spontaneous colitis, 
though this can be potently induced by chemical (DSS), immunological (anti-CD40) and 
infectious (Helicobacter hepaticus) challenge (164), (165,166). This would suggest that the 
innate immune system is sufficient for IBD development. Taken together the intestinal 
microbial community performs a range of useful functions for the host including digesting 
substrate inaccessible to host enzymes (163). In addition the microbiota shape host immune 
responses and vice versa, with dysbiosis strongly associated with disease states (163). GI 
tract microflora therefore represent an attractive, potentially modifiable, candidate to account 



































































































































1.6 Animal models of IBD 
Much of the recent progress in understanding mucosal immunity has been achieved by the 
study of experimental animal models of intestinal inflammation. However no one model yet 
replicates all the complex facets of human IBD, nor replaces the value of studies using 
human material. Indeed the clinical manifestation and disease course of IBD is extremely 
heterogeneous; an observation reflected in the increasing transgenic mouse strains all 
displaying IBD-like intestinal changes (167). However animal models provide an opportunity 
to explore mechanisms of host response to GI tract inflammation that are not yet possible 
using human tissues. Animal models of intestinal inflammation can be broadly subdivided 
into infection, chemical induction, immune cell transfer or gene targeting (168).  
 
A compromised epithelial barrier may be a key component in the pathogenesis of IBD by 
permitting increased translocation of luminal antigen and micro-organism into the mucosa, 
resulting in a florid inflammatory response (169). A seminal paper by Hermiston et al. 
demonstrated that decreased intestinal epithelial cell-cell adhesion mediated by replacing E-
cadherin with a N-cadherin transgene resulted in LP inflammation but only at areas of 
defective epithelium, suggesting micro-organism entry can induce an inflammatory response 
(170). Indeed asymptomatic IBD patients display increased intestinal permeability prior to 
clinical relapse with variants in epithelial organic cation transporters (OCTN) 1 and OCTN2 
risk susceptibility loci for IBD (171). 
 
1.6.1 DSS colitis 
DSS is a sulphated polysaccharide of highly variable molecular weight ranging from 5kDa to 
1400kDa. Administration of 40kDa DSS to mice in drinking water can readily traverse the 
mucosal membrane, found in LP macrophages and MLN within 24hrs, resulting in distal 
colitis, rectal bleeding, diarrhoea and weight loss (164), (166). Molecular weight of DSS, 
manufacturer, mouse sex or strain, and intestinal microflora, but not volume of DSS 
ingested, have all been shown to affect the disease severity (167). It is believed that DSS is 
directly toxic to IECs, thereby affecting the integrity of the mucosal barrier. As T and B cell 
deficient, SCID or Rag1-/- mice also develop a severe colitis to DSS, the adaptive immune 
system is not thought to play a dominant role in the acute phase of this model (166). 
Therefore the acute DSS model is a useful tool for investigating the role of the innate 
immune system in intestinal inflammation. Typical histological changes of acute DSS colitis 
include mucin depletion, epithelial degeneration and eventually epithelial necrosis (167). 
This is accompanied by the infiltration of the LP and submucosa by neutrophils, resulting in 
cryptitis and crypt abscesses. Cycles of continuous DSS treatment (7 days) interspersed 
with normal drinking water (14 days) results in a chronic colitis which, if combined with the 
carcinogen azoxymethane results in inflammation-associated colorectal cancer (CAC) (172).  
 36 
 
1.6.2 TNBS/Oxazolone colitis 
Intra-rectal administration of the haptenating agents TNBS or oxazolone renders autologous 
colonic or microbial proteins immunogenic to the host immune system (173), (174). This 
results in severe diarrhoea, weight loss and colonic thickening (175).  
 
Intra-rectal TNBS to SJL/L or C57BL/10 mice results in transmural colonic inflammation, 
driven by Th1 mediated responses and characterised by the accumulation of CD4+ T cells, 
neutrophils and macrophages in the LP (175). Given the dependence of chronic TNBS colitis 
on CD4+ T cells, this model has proved an important vehicle for investigating T-helper 
mucosal responses. TNBS colitis is associated with elevated IFNγ levels, with anti-IL-12p40 
treatments able to prevent its production and abrogate nascent and established disease 
(175), an observation that led to the development of humanised anti-IL12p40 antibody 
treatment for CD. However a Cochrane review of anti-IL12p40 efficacy assessed 4 
randomised trials of 955 patients and revealed only a very modest treatment benefit of 
inducing clinical response (176). TNBS has also contributed to our knowledge of oral 
tolerance, with mice fed TNBS-haptenised colonic proteins less susceptible to TNBS colitis 
due to TGFβ producing Tregs, a process dependent on IL-10 (177), (178). TNBS colitis 
susceptibility varies widely among mouse strains. BALB/c mice for example develop Th2 
mediated colonic hypertrophy, accentuated in the absence of IFNγ, with a Th2 component 
also observed in C57BL/6 mice deficient in IL-12 and IFNγ (179), (180). BALB/c mice are 
therefore used for modeling chronic TNBS-colitis induced fibrosis, given elevated IL-13 
drives TGFβ mediated fibrosis involving early growth response protein-1 (EGR-1), IGF-1 and 
myofibroblast production of collagen (181). Thus TNBS has proved a useful model for 
investigating Th1 and Th2 immune responses as well as the factors guiding the initiation and 
resolution of fibrosis in the GI tract.  
 
Oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one) is also an intra-rectally 
administered haptenating agent, which like TNBS elicits colonic inflammation (182). 
However in contrast to the transmural inflammation observed in TNBS colitis, single dose 
administration of oxazolone produces acute superficial inflammation more akin to the UC 
pathology seen in man (183), (184). Cellular and cytokine responses in oxazolone colitis 
also differ compared in TNBS. Data suggest that the host response to oxazolone is 
controlled by IL-13 production from LP CD4+ natural killer (NK) T cells, as IL-13 blockade 
and NKT deficient mice do not develop colitis (183). The IL-13 response in oxazolone colitis 
is poorly defined, but may be a result of IL-33 and IL-25 release from damaged epithelial 
cells (185). UC-like oxazolone colitis is characterised by increased IL-9 and IL-13 production 
and an LP infiltrate containing IL-13 producing NKT cells (186), (187). Thus the importance 
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and value of oxazolone colitis lies in its resemblance to human UC not only in respect to 
morphology, but in addition to immunopathogenesis.   
 
 
1.6.3 Adoptive transfer of CD45RBHigh+ T cells 
The balance of regulatory and effector T cells in the development of intestinal inflammation 
was first highlighted in the transfer of distinct T cell populations into immunodeficient mice 
(188). The transfer of naïve CD4+CD45RBHigh T cells from donor mice into immunodeficient 
SCID or Rag1-/- mice results in a wasting disease characterised by chronic colonic 
inflammation developing over 5-10 weeks (189), (188). Conversely the transfer of 
CD4+CD4RBLow cells does not produce colonic inflammation, owing to the presence of 
CD4+CD25+Foxp3+ Tregs that antagonise effector T cell function in the gut by the production 
of IL-10, TGFβ and IL-35 (188,189), (190), (191). Indeed Tregs deficient in the IL-10 receptor 
fail to protect mice from this model of colitis, and lose the ability to express FoxP3 
suggesting IL-10 signaling is required for the maintenance of their function (88). In addition 
TGFβ deficient Tregs, or the administration of anti-TGFβ antibodies, are unable to protect 
recipient mice from colitis (192). Indeed if naïve T cells are rendered incapable of responding 
to TGFβ by overexpression of a negative TGFβ receptor, Treg TGFβ production is unable to 
suppress colitis (193). Despite these insights into Treg and Teffector roles, the mechanism 
and source of inflammatory stimuli in this transfer model of colitis have been difficult to 
ascribe. Early studies suggested the model to rely on Th1 mediated responses, due to the 
presence of IFNγ and TNF producing LP T cells and the observation that transferred T cells 
lacking T-bet, the master transcription factor for Th1 responses, fail to induce colitis (189), 
(194). Subsequent studies support a role for T cell differentiation into IL-17 producing Th17 
cells under the influence of IL-23 in this transfer model, whereby transferred T cells lacking 
the IL-23 receptor or the Th17 master regulator RORγt and Rag1-/- recipient mice deficient in 
IL-23p19 do not develop colitis (195), (196). These mutually exclusive hypotheses have 
been combined with the observation that Th17 responses are plastic, able also to give rise to 
IFNγ producing Th1 cells (196), (197). Taken together, current data suggest that colitis 
induced by the adoptive transfer of T cells produces a Th1 IFNγ producing population that 
originates indirectly from a Th17 differentiation pathway dependent on IL-23, rather than 
exclusively from a Th1, IL-12 dependent mechanism. In addition, it underlines the 
importance of balance in mucosal homeostasis: balance between pro-inflammatory effector 
cell function and anti-inflammatory regulatory function, a balance that may be tipped by 
quantitative or qualitative defects in these cells in IBD. It also highlights that, as in other 
models of experimental colitis, bacterial antigens play a crucial role in mediating pathology, 




1.6.4 Il10-/- transgenic mice 
IL-10 is a well-known suppressor of multiple facets of the immune system (198). Several 
studies have suggested that IL-10 inhibits IL-12 and TNF production, T cell proliferation and 
promotes the formation of antigen-specific Tregs (199). Mice with specific deletion of IL-10 
develop spontaneous colitis in specific pathogen free (SPF), but not germ free, conditions 
(198) suggesting an important role for the microbiota in generating IL-10 dependent immune 
responses. Indeed IL10 polymorphisms are risk susceptibility loci for IBD, with a familial form 
of paediatric onset CD identified that is due to mutations in the IL-10 receptor, which was 
rescued by bone marrow transplantation (200). Intestinal inflammation in IL-10 deficient mice 
is characterised by a Th1 T cell LP infiltrate that is reduced by the administration of anti-IL-
12p40 or anti-IFNγ (201). In addition IL-10 specific deletion in T cells or Tregs also results in 
spontaneous colitis, suggesting that T cell sources of IL-10 are necessary to maintain 
mucosal homeostasis (202), (203).  Similarly IL-10R deficient macrophages or systemic anti-
IL-10R antibody treatment, rendering the host unable to respond to IL-10, leads to a pro-
inflammatory phenotype and spontaneous colitis (204), (205). Finally, macrophages 
extracted from patients with CD as a result of a loss of function mutations in the IL-10R 
display impaired differentiation and function (206). Taken together this model of intestinal 
inflammation has identified LP naïve T cells, Tregs and macrophages as important sources 
and response elements to the IL-10 axis that are required to prevent damaging spontaneous 
enterocolitis (206).  
 
1.6.5 Other transgenic models 
There are numerous other transgenic animals which display altered susceptibility to 
intestinal inflammation and therefore have provided vital inflammation for our understanding 
of mucosal homeostasis. These include mice deficient in TBET and RAG2 proteins (TRUC 
mice), which develop spontaneous inflammation and a colitogenic microflora, that can 
transmit colitis to WT mice when co-housed (such as Proteus mirabilis and Helicobacter 
typhlonius) (207). Mice deficient in Mucin 2 (MUC2), a large gel-forming protein secreted by 
the intestinal epithelium, also develop spontaneous colitis as a result of increased barrier 
function, resulting in increased susceptibility to DSS and colorectal cancer models, 
characterised by the infiltrate of TNF and IL-1β producing lymphocytes (208), (209). 
Intestinal epithelial specific deletion of IKK-γ (also known as NEMO) disrupts NF-κB 
signaling, leading to a heightened sensitivity to TNF, epithelial apoptosis and translocation of 
bacteria, and increased susceptibility to the nematode parasite Trichuris muris, highlighting a 
role for pro-inflammatory cytokines such as TNF in barrier protection and defence as well as 
disruption (210). SAMP1/YitFc (SAMP) mice represents an excellent model system to 
understand the disease mechanisms of CD as it one of the only animal models that produce 
severe inflammation in the terminal ileum, the commonest location for CD in man (211). 
SAMP mice were discovered by in-breeding a colony of AKR/J mice, selecting for 
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accelerated senescence, noticing an autoimmune phenotype (212). Genome wide scanning 
of cohorts of SAMP mice with ileal inflammation versus healthy controls identified 4 areas of 
chromosomal loci that were strongly linked to the presence of inflammatory change, 
including allelic differences in IL-18, PPARγ and IL-10 receptor genes (212).  Therefore 
these mice are do not require genetic, chemical or immunological manipulation to produce 
intestinal symptoms.  
 
1.6.6 Trichuris muris 
Gastrointestinal infection with the parasite Trichuris muris, a mouse model of the human T. 
trichiura infection, is a much-studied model of colonic inflammation (213). Ingested infective 
eggs accumulate in the caecum, hatching within 2 hours, adhering and anchoring to the 
caecal epithelium, maturing from larval to adult life stages over the ensuing 32 days which, 
in the absence of appropriate immunity and expulsion, results in chronic local tissue 
destruction and inflammation (214). Successful resolution of infection requires a polarised 
Th2 immune response, with susceptibility conferred by a Th1, IFN- ! dominated response 
(215). The load of infected eggs delivered to the host is also critical in determining 
polarisation of the host immune response and thus susceptibility to chronic infection: Low 
dose (20 eggs) results in a Th1 polarised immune response, and therefore chronic 
inflammation, in immunocompetent animals. However, high dose (200eggs) results in an IL-
4, IL-13 polarised Th2 response (216), (217). Supporting the role of parasite-host evolution, 
wild mice are thought to accumulate worms through repeated low-level infections of 5-15 
eggs, with heavy infections confined to only a few individuals (218). Therefore T. muris 
infection load in nature favours parasite persistence and chronic infection by negating an 
expulsive Th2 response from the host. Thus the therapeutic use of helminths has been 
attempted in IBD to antagonise damaging host Th1 responses. Utilising the ability of 
helminths to modulate a Th2 host response and thus evade expulsion was hypothesised to 
explain the lack of IBD in less developed areas where parasites are endemic (219). However 
results have been conflicting with no consistent treatment benefit shown, which may be 
secondary to differences in methodology, dose, species and IBD phenotype (220), (219).  
 
Clearance of T. muris infection requires an intact adaptive immune system. Current data 
support the requirement for CD4+ but not CD8+ or NK T cells for an effective host response, 
with conflicting evidence for DCs or B cells, with eosinophils and basophils in addition 
showing redundant functions (221), (222), (223), (224), (225). Epithelial barrier function is 
also key to successful parasite clearance, with susceptible mice displaying reduced mucin 





1.6.7 Citrobacter rodentium 
C. rodentium is a murine mucosal pathogen that induces a self-limiting colitis or death 
depending on strain susceptibility (228), (229). It shares several pathogenic mechanisms 
with enteropathogenic Escherichia coli (EPEC) and enterohaemorrhagic E. coli (EHEC), two 
clinically important human GI pathogens, such as the formation of attaching and effacing 
(A/E) lesions, characterised by the intimate attachment of bacteria to the intestinal epithelium 
(228), (229). C. rodentium is transmitted via the faecal-oral route, with most infection studies 
favouring delivery by oral gavage with laboratory culture bacteria (230). After colonic 
colonisation, adherent bacteria undergo a virulence switch that facilitates further 
colonisation, with the infection clearing in less susceptible strains, mediated by epithelial 
shedding of colonised cells into the intestinal lumen (231). Myeloid differentiation primary 
response protein 99 (MYD88) is a key adaptor protein in innate immune signaling 
downstream of TLR and IL1R families, and plays a key role in response to C. rodentium 
infection by recruiting neutrophils, macrophages and DCs to the LP, expression of iNOS and 
triggering the proliferation of epithelial cells (232), (233). As such TLR2 deficient mice 
develop severe colonic pathology, weight loss and mortality (232).  
 
C. rodentium has also yielded insight into the role of inflammasomes in mucosal 
homeostasis. Inflammaosomes are scaffolds in the cytoplasm of immune cells that are 
responsible for the maturation of caspases and IL-1 family cytokines (234). Caspase-1 and 
NLRP3 mediated responses are crucial for resistance to C. rodentium, with caspase-1 and 
NLRP3 deficient mice displaying increased bacterial loads, severe immunopathology and 
rapid weight loss (235). C. rodentium triggers a florid Th17 cell response that exceeds the 
Th1 cell response, that is caused by epithelial cell apoptosis, as blocking apoptosis impairs 
Th17 responses in the LP (236). Similarly blockade of IL-17A and IL-17F results in increased 
mucosal inflammation, bacterial load and systemic translocation of bacteria (237). In addition 
to IL-17, ILC3s and other Th17 cells are important sources of IL-22, which is essential for C. 
rodentium protection (238). IL-22 is part of the IL-10 superfamily and triggers protection to C. 
rodentium by inducing the production of RegIII AMPs and promoting epithelial barrier 
integrity (238).  
 
Lastly, recent investigations have suggest that transfer of the microbiota from mice resistant 
to C. rodentium to mice that are susceptible, renders protection to infection to recipient mice, 
with neutralisation of IL-22 removing this protective effect (239), (240). Resistance to 
infection is associated with increased Bacteriotedes and reduced Firmicutes at phylum level, 
although segmented filamentous bacteria (SFB) that promote IL-17 protective mucosal 
responses, are equivalent (239), (240). Taken together C. rodentium elicits a co-ordinated 
immune response dependent on Th17 and innate cell responses also underlining the 




Epigenetics is one of the most rapidly expanding fields of biology that, like the microbiome, 
demonstrates an ability to interact with genetic and environmental factors. Waddington 
defined the term “epigenetics” as “the causal interactions between genes and their products, 
which bring the phenotype into being” (241). Subsequently, this term has been used to 
describe the molecular mechanisms that reinterpret the genetic code into a multitude of 
phenotypic outcomes. This has led to the modern definition of epigenetics as the heritable 
marking of DNA that leads to the alteration of gene expression independent of genetic 
information carried in the primary DNA sequence (242).  
 
Epigenetic modifications of DNA permit an ability to influence phenotype in a heritable 
fashion, retained after cell division and directly or indirectly affecting the transcription of the 
genetic code. DNA methylation, histone posttranslational modifications and nucleosome 
positioning are the best described epigenetic processes, but more recently have expanded 
to include microRNAs (miRNAs), chromatin remodeling complexes and polycomb group 
proteins (243), (244). Through changes in gene transcription, DNA-protein interactions, 
protein translation, and gene silencing epigenetic processes determine key developmental 
processes including growth, differentiation, genomic imprinting and immunity (245), (246).  
 
Epigenetic marks that are incorrectly established may confer human disease. Monozygotic 
twins who contain the same DNA sequence may have differing susceptibilities to 
autoimmune and malignant pathologies due to discordant DNA and histone modification 
profiles (247), (248). Whilst the relative plasticity of epigenetic marks is advantageous in 
adding an additional layer of cellular genetic control, it also renders them susceptible to 
environmental perturbations such as diet, nutrition, stress, chemical and pharmaceutical 
agents (249). Thus epigenetic processes may be mediators of gene-environment 
interactions and so may contribute to the penetrance of polygenic, environmentally 
influenced disorders such as IBD (250). It is now appreciated from studies in animals that 
environmental insult may induce specific phenotypes mediated by epigenetic processes and 
that are heritable (251), (252).  
 
1.7.1 DNA methylation 
DNA methylation occurs by the addition of a methyl group to the 5’ carbon of the cytosine 
residue of cytosine-guanine (CpG) dinucleotides. Methylation occurs at approx. 70% of CpG 
dinucleotides with marked region specific variation (253). Non-methylated CpG dinucleotides 
are often, but not exclusively clustered together at gene promoter sites and are referred to 
as CpG islands (253). Highly methylated areas of the mammalian genome are less 
transcriptionally active leading to gene silencing, a principle that is exploited by neoplastic 
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processes by aberrant de novo methylation of tumour suppressor genes, abrogating their 
function in favour of tumour development (254). DNA methylation is therefore strongly 
correlated with gene silencing and is widely believed to participate directly in transcriptional 
repression (255). Methyl-CpG-binding proteins (MBDs) serve as essential contributors for 
DNA demethylation independent of cell division and have potential roles in transcript splicing 
and chromatin compaction (256). MBDs and histone deacetylase (HDAC) recruitment may 
therefore represent mediators of transcriptional control through induction of heterochromatin 
(255). This is a developing area, and thus conflicting hypotheses exist regarding the causal 
nature of DNA methylation in mediating transcriptional repression (257), (258). Whether 
DNA methylation is a cause or consequence of repression therefore remains to be fully 
elucidated. DNA methyltransferases are a key family of enzymes responsible for the 
remethylation of hemi-methylated CpGs during cell division (DNMT1) (259). Indeed they also 
undertake de novo methylation in early development (DNMT3a/b), thereby conserving DNA 
methylation patterns, the importance of which is underlined by the embryonic lethality of 
DNMT1, DNMAT3a and DNMT3b deficiency (260), (261). Taken together genome 
methylation requires coordinated expression and function of DNMTs and MBDs to permit 
appropriate gene expression in normal growth and development. It is therefore perhaps 
unsurprising that altered DNA methylation and DNMT expression/regulation were amongst 
the first epigenetic changes reported in IBD and in CAC (262), (263), (264). 
 
1.7.2 Histone modification 
Eukaryotic DNA is tightly folded around specialised proteins termed histones (H) to from 
chromatin (265). The histone octamer forms the structural basis for which the fundamental 
unit of chromatin, nucleosomes, may form around (265). The nucleosome is a repeating 
subunit of 146base pairs of chromatin in a double helix around a core of H2A, H2B, H3 and 
H4 histone proteins (265). Current evidence suggest that each histone subtype maybe 
altered by numerous post-translational modifications including acetylation, methylation, 
ubiquitination, phosphorylation, sumoylation, citrullination, ADP ribosylation and proline 
isomerization, of which acetylation and methylation are the most widely described (266).  
These modifications determine the accessibility of DNA to transcriptional, replicative, 
recombination, condensation and mRNA splicing machinery (265). As a result, post-
translational modification of histones confer a diverse range of heritable transcriptional 
promotion or repressive abilities. For example, trimethylation of lysine residues on H3 
proteins can be associated with both open (H3K4, H3K36 and H3K79) and closed (H3K9 
and H3K27) regions of chromatin (267). In contrast highly acetylated regions are generally 
associated with euchromatin and leads to active transcription by increasing chromatin 
accessibility (267). This has led to hypothesis of a ‘histone code’ whereby the overall pattern, 
rather than individual histone marks, of post-translational histone modification fine-tunes 
higher order chromatin structural organisation, expression and repression (266). Enzymes 
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that catalyse the addition or removal of acetyl or methyl groups to HDACs; histone 
acetyltransferases (HATs) and histone methyltransferases (HMTs) therefore represent 
important mechanisms for mediating epigenetic patterns for inheritance (268). The 
mechanism(s) by which histone acetylation or methylation affects transcription is poorly 
understood. This may be the result of acetyl neutralisation of lysine positivity, destabilising 
negatively charged DNA promoting dissociation from histone to an ‘open’ position (268).  
 
1.7.3 Nucleosome remodeling 
Whilst the structure of individual nucleosomes is highly regulated and ordered, the overall 
structure of nucleosomes along DNA is highly variable (269). The precise positioning of 
nucleosomes can therefore be regulated by transcription factors and other accessory 
proteins and results in functional changes in gene expression (269). Nucleosomes can 
therefore represent a physical barrier to gene transcription, impeding the progression of RNA 
polymerases, demonstrated by the eviction of nucleosomes from transcriptionally active start 
sites (270). Nucleosome positioning may therefore impede or facilitate gene expression and 
is controlled by chromatin remodeling complexes, large multi protein scaffolds that alter the 
composition or organisation of nucleosome core proteins. There are currently 5 recognised 
families of chromatin remodeling complexes, SWI/SNF, ISWI, NuRD, INO80 and SWR1 
(271). Some associated family members, including the MBDs, facilitate the eviction or lateral 
sliding of nucleosomes and therefore gene activation. MBDs may also possess HDAC 
and/or methyl-CpG binding properties and thus promoting gene repression (272), (273).  
 
1.7.4 Methyl-CpG-binding proteins 
DNA methylation constitutes the addition of a methyl group to the cytosine of a CpG 
dinucleotide and is correlated to transcriptional repression ((274)). Approximately 70% of 
CpG dinucleotides in the mammalian genome are methylated (275) excluding areas of high 
CpG density termed ‘CpG islands’ that are usually unmethylated (276), but acquire 
methylation during differentiation (277) or be aberrantly methylated in cancer. It has been 
suggested that mechanisms for transcriptional repression mediated by CpG methylation 
involves MBDs binding to methylated cytosine and recruitment of a co-repressor complex 
(278). MBDs may be divided into the methyl-CpG-binding domain proteins (MBDs), Kaiso 
and SRA domain proteins (Table 1.1) (279). The MBD group includes MeCP2, MBD1, MBD2 
and MBD4 that have methyl-CpG binding domains, and MBD3, MBD5 and MBD6 that do not 
bind methylated DNA (280). Using tagged MBD proteins it has recently been shown that 
MBD1, MBD2, MBD4 and MeCP2 binding to chromatin increases linearly with methylation 
density, with binding not appearing to plateau with increased local density of methylated 
cytosines (280). Indeed in the absence of genome methylation, MBD binding is substantially 
reduced (280). The same authors find a strong negative correlation with MBD binding and 
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promotor activity and enhancer accessibility supporting a role for MBD proteins in DNA-
methlyation mediated genome regulation (280).  
 
MBD2 is capable of recruiting a large 2MDa nucleosome-remodelling (NuRD) complex 
(281). This complex contains a chromatin remodelling protein (Mi-2), HDACs 1 and 2, and 
has been shown to establish transcriptional repression in vertebrates, invertebrates and 
fungi (281). MBD2 is thought to recruit the NuRD complex to methylated sites within the 
genome to effect chromatin remodelling, histone deacetylation and methylation (281).  Given 
promoter methylation is a hallmark of cancer it was initially suggested that MBD2 may 
regulate genes critical during carcinogenesis, however more recent studies suggest that 
MBD2 may also regulate the activity of target genes (282). It was also initially thought from in 
vitro data that MBD2 selectively binds methylated DNA, recent data in vivo using genome 
wide mapping in mouse embryonic stem cells suggests that whilst binding largely occurs at 
highly methylated CpG regions, a subset of binding sites occurred at active unmethylated 
promoters (283), (280). Thus in one study 80% of MBD2 binding sites had DNA methylation 
levels between 80-100% with preferential binding to promoter and exon regions rather than 
introns or intergenic regions (279). The binding of MBD2 to non-methylated chromatin 
required protein interactions with the NuRD complex was demonstrated by engineering an 
MBD2 protein that lacked an MBD and assessing genome wide associations (280): Non-
methylated binding sites were also DNAse I hypersensitive, low in CpG density but enriched 
for H3K4me1 and H3K27ac, thus showing the hallmarks of active regulatory regions (280). 
In contrast to methylation-dependent binding, methylation independent binding was largely 
cell type specific, as most binding was seen to occur at tissue-specific regulatory regions 
(280).   
 
Thus based on their ability to bind methylated DNA, MBDs are prime candidates for 
interpreting the DNA methylome and may also be a role for binding non-methylated 
chromatin in a tissue specific manner. MBDs therefore represent attractive targets for 
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1.7.5 Epigenetics in innate and adaptive immunity 
Emerging evidence supports a role for epigenetic mechanisms in affecting the innate and 
adaptive immune response (284). Indeed the inflammatory process itself may confer 
epigenetic reprogramming to drive or abate aberrant responses (242). Studies of epigenetic 
marks in tissue macrophages are currently predominantly limited to profiling of histone 
acetylation and methylation, but suggest combinations of active and repressive histone 
marks regulate the expression of key cytokines required for appropriate M1 ‘classical’ or M2 
‘alternatively activated’ polarisation (285). Defined combinations of active and repressive 
histone marks regulate the chromatin states of inflammatory cytokines, permitting a rapid, 
polarised immune response into classically activated M1 and alternatively activated M2 
macrophages (286). Epigenetic mechanisms might therefore explain the gene-specific 
signatures of tolerant GI tract macrophages.  
 
Likewise epigenetic processes can affect monocyte programming and response to bacterial 
pathogens. For example H3K4 tri methylation of NOD2 by mycobacterial components 
enhances innate immune responses (287). In addition bacillus Calmette-Guérin (BCG) 
vaccination induces methylation of cytokine promoters in human monocytes that can be 
reversed with methyltransferase inhibitors, suggesting plasticity of epigenetic programming 
(287). Thus epigenetic reprogramming may hold preventative and therapeutic roles in 
modulating aberrant immune response in autoimmunity and pathological inflammatory states 
(288).  
 
In addition, the chemotactic ability of monocyte derived DCs and macrophages can be 
modulated by nucleosome remodeling. The lipid-modulating agent simvastatin, which is 
widely used for its cholesterol synthesis blocking properties, also has immunomodulatory 
function (289). Simvastatin can induce closed heterochromatin at the chemokine ligand 2 
(CCL2) locus, accompanied by increased histone repressive marks (H3K27 and H3K9) and 
decreased active marks (H3ac and H3K4me3) at the CCL2 promoter resulting in decreased 
gene expression in monocyte derived cells (289).  
 
Genome-wide DNA methylation mapping of DC maturation revealed significant loss of DNA 
methylation across regions of binding sites for transcription factors affiliated with DC lineage 
fate and response to immune stimuli (290). Chronic repression of Il12 in DCs from mice 
recovering from severe sepsis correlates to promoter enrichment of histone marks H3K4me3 
and H3K27me2 (290). Similarly regulation of H3K9me2/3 marks by DC specific histone 
methyltransferases or demethylases are required for DC development and differentiation 
(291).  Lastly, neutrophils as noted above are key cells in pathogen clearance with potent 
antimicrobial activity, but their migration can be paradoxically impaired in severe sepsis and 
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is associated with reduction in H3ac marks at the CXCR2 promoter that mediates neutrophil 
migration to inflamed areas (292).  
 
The strongest evidence for epigenetic control of immune cell development comes from CD4+ 
T cell fate. CD4+ Th1, Th2, Th17 and Treg cells display a variety of distinguishing epigenetic 
motifs including different profiles of DNA methylation, repressive histone marks, RNA 
interference, with MBDs associated with active, inactive and silenced loci in Th cell types 
(293),  (294). The combination of these epigenetic processes ensure that lineage specific 
cytokines e.g. IFNγ for Th1 and IL-4 for Th2 are expressed by the appropriate cell types 
(293), (294), (295). Th1 cells for example demonstrate a demethylated Ifng promoter and 
repressive histone modifications at the Il4 locus, with the reverse in Th2 cells (296). Similarly 
active histone modifications (H3Kac and H3K4me3) were associated with Il17a and Il17f 
promoters in Th17 cells with DNA methylation at the Il17a promoter preventing STAT3-Il17a 
promoter binding, inhibiting the regulatory effect of STAT3 on Th17 differentiation (293),  
(297). In addition Tregs, which constitutively express FoxP3 to maintain their 
immunosupressive qualities, display histone modification in a FoxP3 dependent manner of a 
variety of genes (298), (299). Genes activated by FoxP3 show enrichment of active marks, 
H3K4me3, H3K9/14ac and H4K16ac and genes repressed by FoxP3 show enrichment of 
the repressive mark H3K27me3 (299), (298).  
 
Taken together, epigenetic regulation of cytokines and transcription factors within cells of the 
adaptive and innate immune systems can control their development, differentiation and 
function. This interaction between the genome and epigenome will likely have important 
implications for understanding the pathophysiology of heritable, immune mediated diseases 
such as IBD, the ultimate test of which will be the design of cell specific therapeutic 
epigenomic interventions to promote a favourable immunological phenotype.  
 
1.7.6 Epigenetics and the microbiome 
Recent data now suggest that intestinal bacteria can regulate epithelial cell immune 
responses through epigenetic mechanisms (300). Butyrate is a bacterial metabolite formed 
by the fermentation of dietary fibre, and is a powerful inhibitor of HDAC activity (301). 
Butyrate-dependent HDAC inhibition increases the expression of NOD2 and intestinal 
alkaline phosphatase (iALP), responsible for the metabolism of LPS, by increasing histone 
acetylation at these loci (301). Similarly the probiotic bacteria Bifidobacterium breve and 
Lactobacillus rhamnosus may confer anti-inflammatory effects by modulating host production 
of IL-23 and IL-17 by inhibiting histone acetylation and enhancing DNA methylation (302). 
The microbiota may also exert anti-inflammatory responses by direct interaction with the 
intestinal epithelium. TLR4, which detects the presence of LPS from Gram-negative bacteria, 
is suppressed by epigenetic mechanisms in IECs, presumably to prevent overactive host 
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response to commensals (303). In addition Tlr4 methylation levels are directly linked to the 
presence of bacteria, with levels significantly lower in germ free mice, suggesting that 
intestinal symbiosis is promoted by bacterial-led host epigenetic modifications (304). NKT 
cells are recruited to the intestinal LP during inflammation under the action of the chemokine 
CXCL16 released from intestinal epithelial cells (184). Germ free mice display 
hypermethylation of the Cxcl16 locus that normalises on the colonization of infant, but not 
adult murine GI tract, with commensals with corresponding reduction in Cxcl16 expression 
and NKT recruitment (184).  In keeping with age-related effects of the microbiome on the 
host epigenome, infant but not adult mice were more susceptible to DSS colitis after the 
administration of maternal, pre-natal methyl-donor diet that confers change in mucosal DNA 
methylation (184,304). These data support the intriguing assertion that dietary pre-natal 
modification of offspring epigenome confers long lasting reprogramming of the mucosal 
immune system.  
 
These emerging studies have highlighted an important area of microbial-host crosstalk, 
namely that the microbiota and their products can directly influence mucosal epigenetic 
marks, mediating changes in expression of immune related genes and pathways. Likewise 
changes in host gene expression can alter the composition and function of the luminal 
environment, underlining the intimate inter-relationship therein.  
 
1.7.7 Epigenetics and the “missing heritability” of IBD 
To date, relatively little is understood of the role of epigenetics in IBD. Data addressing the 
role of epigenetic processes in IBD are thus limited to DNA methylation analyses of intestinal 
biopsies or peripheral blood (262), (305), (263) (264). Comparison of affected IBD patients 
versus healthy controls revealed several pathways previously associated with IBD, namely 
differentially methylated IL-23/Th17, IL-12/Th1 and host response to bacteria loci. In 
corroboration of GWAS loci with epigenome-wide methylation loci reveal conserved genes 
including TNF, NOD2, IL19, IL27 and CARD9. miRNA and histone modifications on 
epigenetic processes and IBD susceptibility are currently poorly  described and remain a 
research focus ((263), (125)).  
 
MHC-II gene control represents a complex model of how immune regulatory genes are 
regulated by epigenetic control: The MHC is exposed to numerous modifications such as 
histone acetylation and deacetylation, histone methylation, and DNA methylation (306). The 
class II transactivator (CIITA) in particular is considered as the main factor responsible for 
MHC-II gene expression, and a target for epigenetic processes (307). Indeed CIITA recruits 
histone-modifying enzymes and ATPase–remodeling complexes to MHC-II promoters, and is 




The advent of GWAS has identified numerous variants conferring risk for complex disease, 
the primary purpose of gene discovery being to ultimately further our understanding of 
disease biology (105)), (308), (104).  However, the possibility of using an individual’s 
genotype to quantify risk prediction in a clinical setting based on statistical modeling (e.g. the 
cumulative number of risk variants) is an exciting prospect. There are >100 susceptibility loci 
for IBD to date with considerable overlap between CD & UC, with an area under the curve of 
0.71 for CD prediction compared to 0.56 for family history alone (309). However despite 
successes in identifying novel areas of IBD pathogenesis such as autophagy and ER stress 
using these methods, <30% of the heritability of IBD is explained using the aforementioned 
susceptibility loci (104). The reasons for this are complex, and include an overestimation of 
monozygotic disease concordance, underestimation of loci effects due to multiple allelic 
variants (most notable the NOD2 risk variant after deep re-sequencing increased its disease 
heritability from 0.8-5% after the identification of 3 novel causative variants), stringent 
statistical genome wide statistical cut-offs, gene-gene and gene-protein interactions (105), 
(310), (311). Intriguingly somatic alterations associated with methylation, acetylation or 
remodeling changes may alter gene expression, function and therefore disease susceptibility 
(250). It is indeed plausible that these somatic alterations may occur separately from 
germline variations in response to environmental stimuli such as cigarette smoking and diet, 
therefore altering gene expression in the absence of inherited variants.  
 
Taken together it has been suggested that the establishment of stable patterns of gene 
expression is a prerequisite of normal differentiation and is accomplished in part by a layer of 
lineage specific epigenetic information incorporated onto the genome. This information is 
plastic, changing with time and exposure to the environment, and has been shown 
particularly vulnerable at specific stages of human development. Intriguingly, long-term 
changes in gene expression patterns could therefore represent an attractive molecular 
hypothesis for early life experiences affecting adult phenotype. Understanding the role of 
DNA transcription and translation in the context of epigenomics may therefore have 
important and thus far poorly understood effects on human physiology, particularly in 










1.8 Thesis Aims 
The GI tract immune system is complex and its research rapidly evolving thanks to an ever-
expanding understanding of cells within it. Indeed the GI tract immune system is not 
homogenous, and varies throughout its length to likely accommodate and react to the 
changing microbial and luminal composition therein. Importantly epigenetic processes are 
increasingly believed to be involved in controlling immune response at mucosal surfaces.  
 
The main aims of this thesis are therefore: 
1. Establish protocols that permit the simultaneous identification of multiple colonic LP 
immune populations by flow cytometry in mice and humans. 
2. Establish the role of the methyl-CpG-binding protein, MBD2, in the steady state colon LP 
using Mbd2 deficient mice.  
3. Establish the GI tract expression of MBD2 in healthy and IBD patients 
4. Establish the role of Mbd2 in chemical (DSS) and infectious (T. muris) models of colonic 
inflammation 
5. Identify the colon cell types and genes dysregulated in the absence of Mbd2 using 
targeted cell depletion and gene expression analyses 
6. Establish if Mbd2 deficient cells in the GI tract alter the steady state intestinal microbiota.  
 
Existing data suggest that alterations in chromatin are central to the reprogramming of 
normal gene expression that occurs in disease states. Defining the complex and diverse 
epigenetic profiles that underpin phenotypic plasticity will be a crucial starting point in 
understanding the mechanisms of chromatin dysregulation that leads to disease. We hope to 
understand if methyl-CpG-binding proteins such as MBD2 can explain altered immune 
responses in innate cells that confer altered responses to GI tract inflammation. Despite vast 
investment in advancing our understanding of the genetic contribution to common heritable 
disease states, we can only explain a fraction of this heritability with conventional 
approaches. Thus investigating heritable, epigenetic changes in gene expression that are 
inherently more amenable to environmental manipulation than our DNA code, may provide 
novel insight to a poorly understood mechanism of disease predisposition. This work will 
therefore aim to identify the cellular and gene targets of Mbd2 mediated changes to immune 
homeostasis that may provide exciting and novel approaches to therapeutic modulation of 










































All mice were maintained under SPF conditions in the School of Biological Sciences, 
University of Edinburgh or the Faculty of Life Sciences at the University of Manchester. Mice 
were used between 8-24 weeks of age on a C57BL/6 background unless specified 
otherwise. Table 2.1 details the mouse strains used in experiments. All procedures were 
carries out under license with UK Home Office Animals (Scientific Procedures) Act 1986.  
 
2.2 Isolation of Mesenteric Lymph node cells 
To obtain leucocytes from MLN, an established laboratory protocol, published by the 
MacDonald laboratory was used (312). Whole MLN were removed and placed in ice cold 
HBSS 2% FCS before mechanical disruption through a 70µm filter to liberate a single cell 
suspension. 
 
2.3 Isolation of Colon LP cells 
To obtain leucocytes from the colon LP, a laboratory protocol was adapted from the Mowatt 
Lab, University of Glasgow. The large intestines of mice were excised and soaked in ice cold 
PBS. Removing excess fat and faeces was an important step in improving cell yield and 
viability, and was performed before the intestines were opened longitudinally washed in 
Hank’s balanced salt solution (HBSS; Gibco) 2% foetal calf serum (FCS) and cut into 0.5cm 
sections. The tissue was then shaken vigorously in 10ml HBSS 2% FCS and the 
supernatant discarded. Tissue was then incubated in 10ml of calcium and magnesium free 
(CMF) HBSS containing 2mM EDTA at 37oC in a shaking incubator at 180rpm for 15mins to 
remove mucus. The supernatant was discarded, tissue washed in a further 20ml of CMF 
before a second incubation in CMF HBSS/2mM EDTA for 25mins to ensure removal of 
mucus layer and begin disruption of epithelial tight junctions. Tissue was once again washed 
with pre-warmed CMF HBSS before digestion in complete RPMI (RPMI 1640. 2mM L-
glutamine, 100µg/ml penicillin, 100µg/ml streptomycin and 10% FCS) containing 0.5U/ml 
Liberase TM (Roche) and 0.1mg/ml Type IV DNAse from bovine pancreas (SimgaAldrich) for 
45mins in a shaking incubator at 180rpm, 37OC. Enzyme digestion of the tissue is essential 
to disrupt the tissue and isolation single cell suspensions. To aid successful digestion of 
tissue, tissue was shaken vigorously every 5-10mins until complete digestion of tissue was 
achieved. The resulting suspension was passed through a 40µm cell strained (BD Falcon) 
and then washed in complete RMPI to remove residual enzymes. Cells were pelleted for 
5mins 500G at 4OC before re-suspension in 1ml of complete RPMI for cell counting. Cells 
were kept on ice until use.  
 
2.4 Isolation of colon epithelial cells 
Optimisation of colon epithelial cell isolation is described in detail in Chapter 5.2  
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2.5 Processing of whole blood 
Blood was isolated by cardiac puncture and combined with 200µl of 2mM EDTA 3% FCS to 
prevent coagulation. Serum was aspirated after pelleting of whole blood at 500G, 4OC for 
5mins before re-suspension of haematocrit in 5ml of red cell lysis buffer (SigmaAldrich) for 




1cm sections of distal colon were taken for histological analysis in selected experiments. 
Sections were taken from the most distal 1cm to the rectum for consistency. Samples were 
placed directly into 10% neutral buffered formalin for 24 hours before being transferred into 
20% ethanol. Samples were processed by the Queen’s Medical Research Institute Shared 
University Research Facilities at the University of Edinburgh, for sectioning and 
haematoxylin and eosin staining. This allowed the identification of nuclei, cytoplasm and 
collagen to permit assessment of inflammation by light microscopy.  
 
2.7 Flow Cytometry and Antibodies 
2.7.1 Surface Staining 
1-3x106 cells were washed in PBS and stained with LIVE/DEAD Blue (Invitrogen) at a 
1:2000 dilution in 10ul PBS, for 10mins at room temperature (RT) to remove any background 
staining artefact generated by apoptotic cells. Surface markers as described in Table 2.2 
and FcR block (αCD16/CD32, 2.4G2, produced in-house) were then added to cells in 50µl of 
PBS 1% FCS (FACS buffer), for 20mins at 4OC to identify different cell populations. Antibody 
dilutions for staining were derived by titrating a range of antibody concentrations in pilot 
experiments for optimum compensation parameters. Cells were then fixed in 1% 
paraformaldehyde (PFA) for 10mins at RT to prevent dissociation of antibody from target 
molecules. Marker expression was measured on BD Fortessa or LSRII (both BD 
Biosciences) flow cytometers and data analysed using FlowJo software (Tree Star). Flow 
cytometer photomultiplier tube (PMT) voltages were applies to ensure the best 
compensation whilst aligning with the latest cytometer setup and tracking (CS&T) settings.  
 
2.7.2 Intracellular staining 
For detection of intracellular proteins, 2x106 cells were plated in a 96-well round bottom plate 
(Costar) and cultured with 1µl/ml GolgiStop (BD) alone, in combination with 0.5µg/ml PMA 
(SigmaAldrich) and 1µg/ml ionomycin (SigmaAldrich), or with the following TLR ligands: LPS 
1µg/ml, Pam3Cys 1µg/ml, CpG 50mmol or Poly I:C 1µg/ml. Cells were cultured for 3hours at 
37OC with 5% CO2..  
 
 54 
Cells were then stained with LIVE/DEAD, surface markers and fixed with PFA as described 
above. Cells were washed three times in FACS buffer and fixed or 20mins at 4OC in 
Cytofix/Cytoperm (BD Biosciences). Following this, cells were permeabilised to allow 
intracellular antibody staining by being washed three times in Perm/Wash (BD Biosciences) 
and stained with antibodies in 50µl of Perm/Wash at the concentrations described in Table 
2.2 for 60mins at 4OC. FoxP3 staining was performed using the eBioscience Foxp3 staining 
kit, as per the manufacturers instructions. Marker expression was measured on BD Fortessa 
or LSRII (both BD Biosciences) flow cytometers and data analysed using FlowJo software 
(Tree Star). Flow cytometer photomultiplier tube (PMT) voltages were applies to ensure the 
best compensation whilst aligning with the latest cytometer setup and tracking (CS&T) 
settings. 
 
2.7.3 Flow cytometry assisted cell sorting (FACS) 
For FACS and purification of target populations, cells were isolated and stained in the same 
manner as detailed above and acquired using a BD influx cell sorter (BD Biosciences). To 
establish optimum antibody concentrations for cell sorting, antibody concentrations were 
titrated across a range of dilutions over several pilot experiments to derive optimal conditions 
for cell yield and purity.   
 
2.8 Induction of DSS colitis 
To induce acute colitis, a well established protocol was used (Chapter 1.6), whereby mice 
received 2% dextran sodium sulphate (DSS) salt (reagent grade; MW 36,000-50,000 kDa; 
MP Biomedicals) in drinking water for up to 8 days. Mice were monitored daily for change in 
weight, rectal bleeding and diarrhoea to generate a symptom score (See Table 2.3). Mice 
scoring >9 as defined in the symptom score, that developed >20% weight loss of their initial 
body weight or that developed rectal prolapse were sacrificed immediately as per Home 
Office regulations.  
 
Assessment of histological severity was performed blinded using a well-established scoring 
method of DSS (Xu et al. 2008) using transverse sections of 1cm sections H&E stained 
colon.  
 
2.9 Induction of T. muris colitis  
Gastrointestinal infection with the parasite Trichuris muris, a mouse model of the human 
T.trichiura infection, is a much-studied model of colonic inflammation (Chapter 1.6). Ingested 
infective eggs accumulate in the caecum, hatching within 2 hours, adhering and anchoring to 
the caecal epithelium, maturing from larval to adult life stages over the ensuing 32days 
which in the absence of appropriate expulsion results in chronic local tissue destruction and 
inflammation (Hurst et al. 2013).  
 55 
 
Stock infections of T. muris were maintained in susceptible mouse strains and adult worms 
harvested at day 42 post infection. 20-200 embryonated eggs were gavaged into mice and 
response to infection assessed at day 32. T. muris excretory antigen (ES) was prepared as 
described by Hayes et al. 2014: Adult worms were cultured in RPMI 1640 (Gibco) and the 
supernatant collected after 4 hours. ES was pelleted to remove eggs, concentrated using a 
Centriprep YM-10 (Ambicon) and then dialysed against PBS. Protein concentration was 
determined using a Lowry assay. ES was then used in restimulation assays at 50µg/ml: 
2x106 MLN cells in cRPMI obtained as per Chapter 2.2 were cultured for 24hours at 37oC for 
24hours, pelleted to remove cells and supernatant stored at -20oC until use to permit 
assessment of antigen specific cytokine responses. 
  
2.10 Enzyme Linked immunosorbent assays (ELISAs) 
To determine levels of cytokine, ELISAs were performed on culture supernatants of murine 
cells using paired mAb purified in house, purchased from eBioscience or BD Pharmingen 
and recombinant cytokine standards purchased from PeproTech or PBL. Primary/capture 
antibodies were coated onto 96 well plates (NUNC) in a volume of 50µl in PBS overnight at 
4ΟC (IL-4, IL-5, IL-6, IL-10, IL-12p40, IL-12p70, IL-13, IL-17). Plates were blocked using 10% 
NCS in PBS for>1hour. Supernatants and doubling concentrations of recombinant protein 
standards were added to 96 well plates in a volume of 50µl in duplicate or triplicate. 
Secondary/detection antibodies were added in a volume of 50µl in 10% neonatal calf 
serum(NCS)/PBS and allowed to bind for 1hour at 37OC (IL-4, IL-10, IL-13), 1hour at RT (IL-
12p40, IL-12p70, IL-5, IL-6, IL-17). Streptavidin-peroxidase was added to all plates in a 
volume of 50µl and incubated at 37OC for 30min. 100µl of the colorimetric substrate of 
peroxidase, TMB (Sigma) was added to each well, following development of blue colour, 
reaction was stopped by addition of 0.18M H2SO4 acid (Sigma). Between steps, plates were 
washed suing PBS 0.05% Tween-20 (Sigma). 
 
2.11 Human samples 
Colon biopsies were obtained from patients attending outpatient colonoscopy at Manchester 
Royal Infirmary. Patients were prospectively recruited for endoscopic biopsy samples and 
case note review for research purposes after approval from University of Manchester ethical 
committee. Endoscopic assessment of disease activity was made by the endoscopisy. 
Immune cells were liberated from samples by placement in 5mls ice cold PBS after 
collection, and digested over 12hours in 10mls of pre-warmed complete RPMI (RPMI 1640. 
2mM L-glutamine, 100µg/ml penicillin, 100µg/ml streptomycin and 10% FCS) containing 
0.5U/ml Collagenase (Roche) and 0.1mg/ml Type IV DNAse from bovine pancreas 




2.12 Generation of BM Chimeras 
BM chimeras, to restrict Mbd2 deficiency to specific cell types, were generated using 8 week 
old female C57BL/6 (CD45.1+ or CD45.1+ CD45.2+) mice were irradiated with a total dose of 
11 Gy 2hours apart. Mice then received 1x107 BM cells from C57BL/6 (CD45.2+ or CD45.1+ 
CD45.2) or Mbd2-/- (CD45.2+) mice and left for 8 weeks to permit BM engraftment. BM was 
obtained by collecting the tibias and fibulas of donor mice into ice cold PBS. Bones were 
then sterilized using 70% ethanol before washing in PBS to remove trace ethanol. Bone 
ends were removed using a scalpel and 5ml of OBS injected through the bone using a 5ml 
syringe (BD) and 21G needle (BD), flushing the bone marrow into a 50ml falcon tube (BD). 
BM cells were then combined with anti-CD90 beads and passes through a magnetic 
activation cell sort (MACS) column to remove CD90+ cells. Recipient mice were treated from 
7 days prior to irradiation to 4 weeks post irradiation with acidified water, irradiated food and 
enrofloxacin in drinking water to negate opportunistic infections in keeping with local 
guidelines. In some experiments a mixture of donor BM from Mbd2-/- and C57BL/6 mice was 
used to reconstitute chimeric mice. Starting ratios of BM were confirmed by flow cytometry 
by staining for CD45.1 and CD45.2 as described in section 2.7. All mice were screened at 8 
weeks post irradiation to assess for successful engraftment by analysis of CD45.1 and 
CD45.2 expression by flow cytometry from 50 µl of tail vein blood.  
 
2.13 RNA extraction 
2.13.1 Tissue 
1cm of distal colon, inferior right lobe liver or spleen were placed in 500µl of RNALater 
(Invitrogen) for 24hours at room temperature or 500µl of TRizol (Ambion) and kept on dry 
ice, before storage at -80OC. Phase separation of DNA/protein and RNA was performed 
using chloroform. RNA was precipitated using 2-propanol, with 75% ethanol used to wash 
RNA, prior to air-drying and resuspension in RNase free DEPC water (Ambion).  
 
2.13.2 Cells 
Cells purified by flow cytometry were sorted directly into RNA later, cells pelleted at 5000g 
for 5mins, and supernatant aspirated to a residual volume of 100µl, snap frozen on dry ice 
and stored at -80OC. RNA was then extracted using a protocol adapted from Pena-Llopis et 
al. 2013 using the mirVana miRNA isolation kit: 600µl of ice cold Ambion lysis buffer was 
added to the cell pellet and vortexed for 2mins (314). 60µl of miRNA homogenate additive 
was then added, vortexed briefly for 30secs and allowed to sit on ice for 10mins. 600µl of 
acid-phenol:chloroform (Ambion) was then added and the mixture vortexed for a further 
30secs. Samples were then centrifuged at 16,000g for 5 mins at room temperature to 
separate aqueous and organic phases. 700µl of the upper aqueous phase then transferred 
to a new RNAse free 1.5ml tube and mixed with 875µl (1.25 volumes) of 100% ethanol by 
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vortexing for 30secs. The mixture was then passed through a filter cartridge (Ambion) in 
700µl aliquots by centriguation at 10,000g for 30secs. The filter cartridge was then washed 
with 700µl of miRNA solution 1 (Ambion) and then x2 500µl washes of solution 2/3 (Ambion), 
centrifuged at 10,000g at each step. 30µl of 95OC RNAse free DEPC water for 1min was 
then used to elute the RNA. RNA was assessed qualitatively and quantitatively using 
BioAgilent Nano/Pico gel electrophoresis and NanoDrop respectively. Samples with a RNA 
integrity number (RIN) <8 were discarded.  
 
2.14 cDNA synthesis from RNA and qPCR 
50-500ng RNA was used for the synthesis of cDNA using Superscript-III and oligo-dT 
(Invitrogen). Relative quantification was performed by qPCR analysis using the Roche Light 
Cycler 480, with LightCycler SYBR Green I master mix (Roche). Five serial 1:4 dilutions of a 
positive control sample of cDNA were used to create standard curves. Expression was 
normalized to the housekeeping genes (gene expressed constitutively for the maintenance 
of cellular function) glyceraldehyde3-phophate dehydrogenase Gapdh. For primer 
sequences see Table 2.5 
 
2.15 Stool DNA extraction and 16S amplification 
To determine intestinal microbiota diversity, faecal contents from mouse colon was removed, 
snap frozen in dry ice and stored at -80OC. DNA was extracted using the QIAamp Fast DNA 
Stool Mini kit following the manufacturers instructions with one additional step: After the 
addition of InhibitEX buffer to faecal contents, LysisMatrixE (MP biomedical) was added and 
shaken in a TissueLyser for 6mins at 30Hz to increase the yield of capsulate bacteria 
(Kennedy et al 2013). Briefly, the DNA of 80-120mg of WT or Mbd2-/- stool was extracted 
using the QIAamp Fast DNA stool mini kits with 1 notable deviation: “Bead beating”!with inert 
spheres of ceramic, silica and glass 0.1-4mm in diameter at 30Hz has been shown to 
increase the detection rate of capsulate bacteria (Wu et al. 2010). Therefore this additional 
step was incorporated using MP biomedicals Lysing Matrix E. Faecal DNA was quantified by 
Nanodrop mass spectrophotometry, diluted to 5ng/µl and PCR amplified using KAPA HiFi 
HotStart Ready Mix and 16S amplicon primers;  
Forward 5’ TCGTCGGCAGGCGTCAGATGTGTATAAGAGACAG,  
Reverse 5’ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG 
as per 16S metagenomic sequencing library protocol for the Illumina MiSeq platform. Total 
DNA was quantified using a Nanodrop spectrophotometer. 12.5ng of microbial DNA was 
then used to amplify gene-specific sequences targeting the 16S V3 and V4 region using 
primer sequences and protocols described in the Illumina 16S Metagenomic sequencing 




2.16 Illumina Ref6 Mouse Array 
To assess the impact of DSS treatment and mbd2 deficiency on gene expression of FACS 
isolated colonic populations, 50-200ng of RNA was biotin labeled with Illumina TotalPrep 
RNA amplification kit as per the manufacturers instructions. Samples were then hybridized to 
an Illumina Mouseref-6 array. Primary raw data were QC analysed using the 
arrayQualityMetrics Bioconductor package to identify sub-standard or outlier gene 
expression signatures. Arrays were scored on the basis of 3 metrics, namely mapplot, 
boxplot and heatmap. Raw data were then transformed using a variance stabilizing 
transformation method prior to normalization using the robust spline normalization method. 
Expression measures were then summarised in log base2 and presented as the fold change 
(logFC), with positive logFC representing up regulation, and a negative logFC indicating 
down-regulation. Statistical analysis was then performed using linear modeling and p value 
adjustment for multiple testing to control for false discovery (adjusted p<0.01 was deemed 
significant).  
 
2.17 Statistical analysis 
Statistical analyses were carried out using GraphPad Prism 6 and JMP v11 software. Where 
data for individual experiments is presented, ANOVA comparison tests were used to identify 
statistical differences between groups, p<0.05 was deemed significant. To increase the 
statistical power of our analysis and simultaneously comply with the 3Rs of ethical use of 
animals in research we consulted the advice of a local statistician and Professor of 
Ecological genetics, Richard Preziosi.  By employing a fit model construct in the JMP 11 
statistical package we were able to enter experimental day as an ordinal variable in our 
model, alongside nominal variables such as genotype, treatment and continuous variables 
such as weight loss. Thus the fit model platform in JMP allowed us to specify a model with 
complex effect structures to measure our variable of interest. All of the analyses used in this 
way in this thesis therefore used a Two-way analysis of variance fit model, with the model 
producing least square mean values for the y variable of interest.  
 
For example, to assess whether genotype, treatment or experimental day affected weight 
loss, weight loss was our continuous y role variable with genotype, treatment and 
experimental day all construct model effects to assess any affect on y. This permitted us to 
pool experiments of the same format together, using experimental day as a construct model 
effect to ensure day-day variation did not bias the dataset. This method has been published 
by Prof. Preziosi and his lab in the ecological literature (315).  
 
This had the benefit of allowing us to present data from all our experiments combined, rather 
than simply showing data from one experiment, which we felt was more statistically robust 
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Antibody  Fluorochrome Clone Dilution Source 
CD103 BV421 M290 1/400 BD biosciences 
CD103 BV421 2e7 1/400 BD biosciences 
FoxP3 e450 FJK-16s 1/200 eBioscience 
MHC-II e450 M5/114.15.2 1/200 eBioscience 
Rat IgG1 BV421 RTK2071 1/200 BD biosciences 
Rat IgG1 e450 eBRG1 1/200 eBioscience 
Rat IgG2b e450 eB19/10H5 1/200 eBioscience 
Rat IgG2a e450 eBR2a 1/200 eBioscience 
CD45 BV510 30-F11 1/400 BD biosciences 
TNF BV421 MP6-XT22 1/400 BD biosciences 
CD11c BV605 N418 1/600 BD biosciences 
CD45.1 BV650 A20 1/200 BD biosciences 
IL-10 BV650 JES5-16E3 1/100 BD biosciences 
CD11b BV711 M1/70 1/300 BD biosciences 
Rat IgG2b BV711 RTK4530 1/300 BD biosciences 
Rat IgG2a BV605 RTK2758 1/400 BD biosciences 
Rat IgG2a BV650 RTK2758 1/400 BD biosciences 
Ki67 Alexa 647 B56 1/200 BD biosciences 
CD45 Alexa700 30-F11 1/200 Biolegend 
EpCAM PE G8.8 1/400 eBioscience 
MHC-II Alexa700 M5/114.15.2 1/200 Biolegend 
SiglecF PE-CF594 E50-2440 1/400 Biolegend 
CD19 e780 eBio1D3 1/200 eBioscience 
CD11b PE M1/70 1/200 eBioscience 
CD64 PE X54-5/7.1 1/200 BD biosciences 
TNF PE MP6-XT22 1/200 Biolegend 
TLR3 PE TLR3.7 1/200 eBioscience 
IL-5 PE N/A 1/200 BD biosciences 
Rat IgG2a PE N/A 1/200 BD biosciences 
Rat IgG2b PE eB149/10H5 1/200 BD biosciences 
CD45.2 PE B169486 1/200 BD biosciences 
Rat IgG2a PE-CF594 R35-95 1/200 Biolegend 
CD25 PerCP Cy5.5 PC61 1/200 eBioscience 
Ly6G PerCP Cy5.5 1A8 1/400 eBioscience 
IL-10 PerCP Cy5.5 JES5-16E3 1/100 eBioscience 
EpCAM PerCP Cy5.5 G8.8 1/400 eBioscience 
Ly6C A700 HK1.4 1/400 eBioscience 
Rat IgG2a A700 RTK2758 1/400 BD biosciences 
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CD3 e780 17A2 1/200 BD biosciences 
CD11b e780 M1/70 1/200 BD biosciences 
Ly6G APC/Cy7 1A8 1/200 BD biosciences 
NK1.1 e780 PK136 1/200 BD biosciences 
TCRb e780 H57-597 1/200 BD biosciences 
Ter119 e780 TER-119 1/200 BD biosciences 
Rat IgG2a e780 eBR2a 1/200 BD biosciences 
Rat IgG2b e780 N/A 1/200 BD biosciences 
MerTk Biotinylated N/A 1/100 Goat IgG RD systems 
F4/80 APC BM8 1/400 Biolegend 
IL-6 APC MP5-20F3 1/100 Biolegend 
IL-22 APC IL22JOP 1/100 Biolegend 
TLR2 e660 6C2 1/200 BD biosciences 
F4/80 PECy7 BM8 1/400 BD biosciences 
Ly6C PECy7 HK1.4 1/600 BD biosciences 
IL-17 PECy7 N/A 1/200 BD biosciences 
Ly6A/E PECy7 E13-161.7 1/800 BD biosciences 
Rat IgG2a PECy7 N/A 1/200 BD Pharmigen 
Rat IgG2a APC RTK2758 1/200 BD biosciences 
MHC-II FITC M5/114.15.2 1/800 BD biosciences 
IL-1b FITC NJTEN3 1/200 BD biosciences 
TLR9 FITC M9.D6 1/200 BD biosciences 






Parameter   Score 
Weight loss   
(% change of Day 0 weight) None 0 
 
1-5%  1 
 





Occult or Gross Blood Loss None 0 
 
Blood staining around anus 2 
 
Gross bleeding 4 
Stool Consistency Well formed pellets 0 
 
Pasty/semi formed 2 
  Diarrhoea that doesn’t adhere to anus 4 
Table 2.3 Clinical disease score criteria used during DSS-induced colitis 
studies 
Score for each parameter summed to give the total symptom score. Score 
ranges from 0 (healthy) to 12 (maximum severity of colitis). Animals were 
euthanised if body weight loss is greater than 20%, total score is greater or equal 















Criterion Score Add 
Inflammatory cells 0-4 0.5 each ulcer 
Goblet cells 0-4 0.5 each crypt abscess 
Mucosa thickening 0-4 
 Submucosa cell infiltration 0-4 
 Destruction of architecture 0-4   








chgA CACAGCCACCAATACC TCTTCCTCCTCCTCTTC 
lrg5 ACCCGCCAGTCTCCTACATC GCATCTAGGCGCAGGGATTG 
Car2 CAAGCACAACGGACCAGA ATGAGCAGAGGCTGTAGG 
Klf4 GAAATTCGCCCGCTCCGAT CTGTGTGTTTGCGGTAGTGCC 
Car1 TTGATGACAGTAGCAACC CCAGTGAACTAAGTGAAG 
mbd2 CCTTAGCAGTTTTGACTTCAGG GGCCAATGTTGTGTTCAGGT 
gapdh AATGTGTCCGTCGTGGATCT CCCAGCTCTCCCCATACATA 
il5 ACATTGACCGCCAAAAAGAG CACCATGGAGCAGCTCAG 
il4 GAGAGATCATCGGCATTTTGA TCTGTGGTGTTCTTCGTTGC 
il10 CAGAGCCACATGCTCCTAGA TGTCCAGCTGGTCCTTTGTT 
il17 TGTGAAGGTCAACCTCAAAGTC AGGGATATCTATCAGGGTCTTCATT 
ifng GGAGGAACTGGCAAAAGGAT TTCAAGACTTCAAAGAGTCTGAGG 
tnf TGGTGGTTTGCTACGACGT ACCCTCACACTCAGATCAT 
il1b CCGACAGCACGAGGCTTT CTGGTGTGTGACGTTCCCATTA 



























One of the key facets of the vertebrate immune system is an ability to rapidly respond to 
invading pathogens whilst promoting tolerance to self-antigens. The GI tract differs from this 
mantra in that immune reactivity to the commensal microbiota must be restrained to avert 
damaging inflammation. The innate and adaptive compartments of the immune system must 
therefore co-operate to promote tolerance and simultaneously be poised to negate invasive 
pathogens. There is increasing evidence that GI tract myeloid cells, in particular MP cells 
such as DCs and macrophages have a key role in manipulating these dual regulatory and 
pro-inflammatory responses (51), (316). Dysregulation of this innate immune response is a 
key component in the development of chronic, relapsing inflammatory disorders such as UC 
and CD, the mucosal immunology underpinning which is poorly understood (317).  
 
As alluded to in Chapter 1, only 30% of the heritable component to IBD can be accounted for 
despite multiple efforts in large multinational GWAS cohorts (104). Therefore understanding 
a heritable component to GI tract immune function that is not encoded in one s nucleotide 
sequence, for example by epigenetic processes, would represent an attractive, novel 
approach to developing treatments for inflammatory disorders such as IBD. As mentioned in 
Chapter 1.5.4, MBD2 is a methyl-CpG-binding protein that modulates dramatic changes in 
gene expression via recruitment of large chromatin remodelling complexes. Mbd2 has also 
been shown to be pivotal in effective DC and T cell function with its expression tightly 
regulated in the GI tract, the evidence for which is presented below. 
 
Firstly, it has recently been shown that Mbd2 deficient murine bone marrow derived DCs 
(BMDCs) display reduced mRNA transcript of several immunologically important processes 
such as antigen presentation (H2-Aam and Ciita) and co-stimulation (Cd40, Cd80 and Cd86) 
(318). Mbd2 deficient DCs are therefore less able to induce either na ve T cell proliferation or 
an appropriate Th2 response against helminths or allergens (318). As a result, deficient Th2 
inductive ability in Mbd2 deficient DC resulted in significantly ameliorated pathology to house 
dust mite mediated bronchial inflammation in mice (318).  
 
Secondly, it has been shown that Mbd2 deficient na ve T cells display a disordered 
developmental response to in vitro polarization. Both the progenitors and progeny of Mbd2 
deficient T cells express ectopic levels of IL-4 in a GATA-3 independent manner (319). 
Na ve uncommitted T cells cultured in polarising Th1 or Th2 conditions display augmented 
IFN- ! (Th1), IL-4 (Th2) and uniquely dual IFN- /IL-4 (Th1 and Th2) positive cells in the 
absence of Mbd2 (319). As such Mbd2 mediated changes in adaptive immune cells 
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produces excessive cytokine production that could be postulated to alter susceptibility of 
Mbd2 deficient animals to infectious challenge.  
 
Thirdly, Mbd2 is tightly regulated in the GI tract suggesting its expression has important 
physiological roles. Indeed altered Mbd2 expression affects response to infectious colitis and 
colorectal cancer susceptibility. MBD2 is expressed at significantly greater levels in the distal 
compared to proximal GI tract and abrogating high levels of colonic MBD2 in Mbd2-/- mice 
results in the expression of exocrine-pancreas genes in the colon (320). Just as the GI tract 
has evolved along its length to perform different functions, (nutrient absorption in the small 
intestine, water reabsorption in the colon etc.) it is conceivable that the cellular functions of 
these specialised areas are in part dependent on epigenetic-co-ordinated changes in gene 
expression. This suggests relative abundance of Mbd2 is essential in normal gut 
development and in co-ordinating region specific gene expression profiles. 
 
Finally, Mbd2-/- mice have been shown to be resistant to the intracellular protozoan infection 
Leishmania major, but develop florid intestinal inflammation with the gut dwelling helminth 
Trichuris muris. T. muris produces a colitis that is swiftly resolved in immunocompetent mice, 
characterised by parasite clearance and a strong IgG1 antibody response (215). Mbd2-/- 
mice are unable to successfully negotiate parasite expulsion resulting in a chronic colitis 
characterised by mucosal oedema, thickening and presence of intra-luminal worms (321), . 
However it is not clear from previous work what aspects of mucosal immune function are 
perturbed in the absence of Mbd2, underpinning this observation.  
 
Intestinal tumourgenesis in mice is dependent on DNA methylation (322), (323). The Min 
mouse lineage was observed to have multiple intestinal neoplasias, which was subsequently 
found to be caused by an autosomal dominant missense mutation in the tumour suppressor 
gene Apc (ApcMin/+ or Min) (324). Min mice therefore demonstrate GI tract adenoma 
development in a mouse model of colorectal cancer and have been used to study the effects 
of methyl-CpG binding protein deficiency by crossing Min and Mbd2-/- mice. When Min mice 
are rendered Mbd2 deficient, they develop 10fold fewer adenomas compared to Mbd2 
sufficient controls, doubling median life expectancy. The authors therefore suggest MBD2 
interpretation of DNA methylation signals promotes gene silencing required for 
tumourgenesis (325). The mechanism underpinning this observation is unclear, and has not 
been replicated in other models of GI tract cancer.  
 
Taken together these data demonstrate a role for Mbd2 in key facets of the innate and 
adaptive immune system and requirement for GI tract homeostasis. Mbd2 therefore 
represents an attractive regulatory gene of interest but this has not been examined 
immunologically in the GI tract. The focus in this chapter therefore is to identify where in the 
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GI tract Mbd2 expression might be relevant for normal function, simultaneously developing a 
method to characterise the intestinal immune cells robustly in the steady state and under 
experimental models of inflammation:  
 
Chapter aims: 
1. Determine and characterise expression of Mbd2/MBD2 mRNA transcript in the GI tract, 
confirming spatial expression and explore regional changes specifically in the colon 
2. Explore MBD2 GI tract expression changes in IBD, and MBD2 as a candidate risk 
susceptibility locus for IBD 
3. Define and characterise an integrated approach to identifying and phenotyping the 
colonic myeloid immune compartment using flow cytometry 
4. Characterise the colon LP myeloid cells in active IBD 
5. Characterise Mbd2 expression in colon LP myeloid cells 
6. Determine and characterise susceptibility of Mbd2-/- mice to experimental colitis with DSS 
7. Determine and characterise susceptibility of Mbd2-/- mice to infectious colitis with T. muris 
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3.2 Expression of Mbd2/MBD2 in the GI tract 
Previous studies have shown a spatial relationship for MBD2 in the murine GI tract: MBD2 is 
found at levels 5-fold higher in the colon, ileum and jejunum compared to the duodenum by 
Western blot analysis when normalised for GAPDH (320). However, these data do not 
assess if Mbd2 expression is uniform throughout the colon. Gene expression analysis of 
Mbd2 from intestinal tissue was performed by RT-qPCR to define if this spatial relationship 
of expression extended to different parts of the large intestine (Figure 3.1A). Expression of 
Mbd2 at the rectum was 4-fold greater than the duodenum. Similarly there was a significant 
1.8-fold increase in expression when comparing the distal (rectum) to proximal (caecum) 
sections of the colon (Figure 3.1A). These data suggest that Mbd2 gene expression matches 
previously known protein data, and that spatial changes in Mbd2 expression extend to within 
the colon, with the highest levels of Mbd2 in the GI tract found within the rectum.  
 
To address whether MBD2 is regulated in a similar manner in human intestine, previously 
published microarray data from 67 patients with UC and 31 healthy controls was examined 
(326). In this study, patients underwent endoscopic biopsy at specific anatomical locations 
for RNA extraction and whole genome microarray as previously described (326). Firstly we 
analysed healthy control data for mRNA levels of MBD2 comparing the terminal ileum and 
rectum for normalised log2 expression. As in the murine GI tract there was a significant 
increase in expression within distal versus proximal GI tract (mean log2 expression terminal 
ileum 0.068 0.04 versus 0.16 0.02 in rectum, Figure 3.1B). Taken together these data 
suggest that Mbd2/MBD2 is expressed at significantly higher levels in the distal compared to 
proximal GI tract in mice and man. 
 
3.3 Analysis of MBD2 as a candidate risk susceptibility locus in IBD 
As MBD2 follows a tightly coordinated expression pattern in the gut, we hypothesized this 
would alter during tissue inflammation. Analysis of rectal MBD2 expression from the above 
data set of patients with active UC or healthy controls was performed (Figure 3.1C) (326). 
This revealed that patients with active rectal UC had a significantly lower level of MBD2 than 
healthy controls (mean log2 expression 0.078 0.03 versus 0.16 0.02, Figure 3.1C). We 
therefore hypothesized that since Mbd2/MBD2 expression is tightly spatially regulated in the 
GI tract, reduced expression in pathological state could represent an important causative or 
contributing mechanism to inflammation. Given the existing literature suggesting a role for 
Mbd2 in innate and T cells, in addition to the above observation that active IBD is associated 
with reduced MBD2 expression we hypothesised that MBD2 is required for effective mucosal 
homeostasis, particularly in the distal colon which demonstrates the greatest level of mRNA 
transcript (319), (318). 
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The international IBD genetics consortium (IIBDGC) is a multinational organisation that has 
amassed some 20,000 cases for CD and UC, along with a similar number of healthy 
population controls (104). Sequencing single nucleotide polymorphisms (SNPs) from this 
large dataset has revealed great insight into the pathogenesis of IBD by proposing risk-
susceptibility  loci, i.e. SNPs that feature more frequently in cases versus controls to a high 
degree of statistical power. One notable success of this hypothesis-free ! testing has been 
the identification of previously unknown autophagy pathways in the pathogenesis of CD. 
Hypomorphic ATG16L1 was identified from GWAS as enriched at genome wide significance 
thresholds in CD patients and thereafter shown to confer aberrant bacterial handling in 
ATG16L1 mutant DC (112). To assess whether mutant MBD2 confers an increased risk of 
IBD the IIBDGC dataset of 16,054 CD and 12,153 UC cases with 17,575 healthy controls 
was examined (Figure 3.1D).  
 
SNPs at the MBD2 locus were not found more frequently in cases versus controls at 
genome wide significance, suggesting that MBD2 SNPs do not confer an increased 
susceptibility of IBD.  
However, this does not exclude the possibility that MBD2 is regulating other genes 
up/downstream that are required for mucosal homeostasis, or that rare variants in MBD2 
genotype have been excluded from this dataset.  Similarly this data does not exclude the 
importance of changes in MBD2 in IBD or indeed post-transcriptional/translation 
modifications of MBD2 on its function in disease states. However, previous murine studies 
have highlighted the importance of Mbd2 in driving colitis like inflammation mediated by a 
skewed immune response (321). In addition no studies have assessed whether expression 
of Mbd2/MBD2 by specific cell populations, rather than whole tissue expression, in the GI 
tract is important during health or disease.  
 
3.4 Identification of immune populations in the steady state colon LP 
Understanding the repercussions of Mbd2 mediated changes in GI tract immune cells 
requires an understanding of a) the complex and heterogeneous cellular milieu at mucosal 
barrier surfaces and b) the confirmation and characterisation of Mbd2 expression within 
these cell types. Neither of these 2 facets is completely understood, either in the steady 
state or inflammation and is considered below. 
 
There have been substantial recent developments in the ability of researchers to 
discriminate between MPs in mucosal tissue sites using flow cytometry (43), (65). This has 
built upon previous work using a limited number of phenotypic markers such as CD11c, 
CD11b and MHC-II, which are now recognised to be insufficient to sensitively delineate the 
heterogeneous immune populations of the intestinal tract (36). For example CD11c, once 
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thought of as a DC specific marker, is now appreciated to be expressed by a variety of cell 
types, not least tissue resident macrophages (See Table 3.1) (36), (327). GI tract DCs and 
macrophages share many phenotypic and functional facets, but also have very different 
roles in the initiation of tolerance and induction of immune response. Therefore the ability to 
robustly discriminate between these populations will not only enable us to understand their 
role in normal mucosal physiology, but to pinpoint dysregulated responses that manifest in 
disease. In particular, this will allow us to characterise a role for Mbd2 in modulating the 
balance and composition of immune cell types in steady state and inflammatory settings. 
 
Mutli-colour flow cytometry using an array of additional phenotypic markers such as CD103, 
CX3CR1, F4/80, MertK, CD64, SiglecF, LY6G and LY6C have been employed to 
characterise subdivisions of MP cells in the GI tract, predominately in the small intestine LP. 
These include monocytes, macrophages, eosinophils, neutrophils, and DCs based on their 
surface expression of CD11b and CD103. However a robust, integrated strategy to 
discriminate the spectrum of colon LP myeloid cells including eosinophils, neutrophils, 
monocytes, macrophages and CD11b+/- DC subsets simultaneously within the colon has not 
yet been shown. Recent studies have shown expression of the chemokine receptor CX3CR1 
on colon MP cells can distinguish between the maturation stages of blood derived 
inflammatory monocytes through to resident tissue macrophages (43). It is not currently 
possible to detect CX3CR1 directly by flow cytometry due to poor antibody affinity, and thus 
studies have relied upon CX3CR1gfp/+ transgenic mice to investigate expression of this 
receptor (43), (114).  
 
We therefore developed a gating strategy for colon LP myeloid cells that has previously 
been validated using CX3CR1gfp/+ mice (43), to identify different myeloid cells populations 
(Figure 3.2 and Table 3.1). This approach, presented in Figure 3.2 and summarised below, 
permitted analysis of colon LP myeloid cell types. We also adopted a similar approach for 
the characterisation of T, B and innate lymphoid cells and this data is presented in Figure 
3.3.  
 
Neutrophils (Figure 3.2 Population A: CD11b+ LY6G+) 
The first set of myeloid cells identified by our newly developed gating strategy in Figure 3.2, 
was a CD11b+ population positive for the lymphocyte surface antigen 6G (LY6G). LY6G 
identifies neutrophils, but not monocytes or lymphocytes, with anti-Ly6G monoclonal 
antibody offering selective depletion of neutrophils (22). Neutrophils possess an arsenal of 
antimicrobial functions including degranulation and phagocytosis that mitigate against 
invading pathogens by massive release of reactive oxygen species and other toxic 
molecules (21). Although these responses are clearly beneficial, excessive recruitment and 
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accumulation in the intestine under pathological conditions such as IBD is associated with 
mucosal injury and debilitating disease symptoms (21). 
  
Eosinophils (Figure 3.2 Population B: SiglecF+ SCC High) 
Eosinophils possess a characteristic SCC high profile and uniquely express the sialic acid-
binding immunoglobulin lectin. Eosinophils in the GI tract are poorly described, and are 
distinct phenotypically and functionally from those in other tissues (27). An important role is 
suggested by their abundance and low turnover in vivo, with activated eosinophils found in 
greater numbers in those with active IBD compared to quiescent IBD and healthy controls 
((30), (29). Early identification and removal from downstream gating analysis was found to 
be critical to avoid contamination of population E (Macrophages), due to these cells 
expressing CD11b and low levels of F4/80, MHC-II and CD11c.  
 
CD11b- DC (Figure 3.2 Population C: CD11b- CD11c+ CD103+/-) 
This was the only myeloid population seen to not express CD11b, with the majority of cells 
expressing the integrin- E (CD103). Population C1 (CD103+) were the most abundant DC 
population observed (around 1% of intact cells), while population C2 (CD103-) were the least 
abundant (around 0.4% of intact cells). CD11b- CD103+ DCs are CD8 +, require Flt3 and 
GM-CSF receptors for normal development and expand upon exogenous administration of 
their ligands (114). In addition, genetic deletion of the transcription factors Id2, Irf8 or Batf3 
leads to selective loss of SI CD11b- CD103+ cells (64). CD11b- CD103- DCs are poorly 
described, but like CD11b- CD103+ DCs migrate to MLNs in a Ccr7 dependent manner, 
expand in response to Flt3 ligand, prime T cell responses and induce T cell CCR9 (69). 
CD11b- CD103- DCs are observed to be unique amongst colon LP DCs in expressing both 
CD64 and the tyrosine kinase inhibitor MerTK. Both of these markers have been used to 
define DCs in other tissues as monocyte derived DCs (moDCs) with CD64+ DCs in the lung 
able to induce potent chemokine response after allergen challenge (Plantinga et al. 2013).  
  
Monocytes (Figure 3.2 Population D: CD11b+ Ly6C+ MHC-II+/-) 
It has recently been reported that blood monocytes are the precursors for intestinal 
macrophages in adult mice (42), (43). As such LY6C+ monocytes are found constitutively, 
though at low levels identified through our gating panel (around 1% of intact cells). On 
entering the colon LP, the LY6C+ cells enter a monocyte-waterfall !characterised by change 
in surface marker expression and phenotype over 48-96 hours en route to becoming stable 
tissue resident macrophages (43). This process involves the acquisition of MHC-II, loss of 
LY6C, before upregulation of CD11c, F4/80 and finally CX3CR1(43). Monocytes are thought 
to have little other role in the steady state, but accumulate in inflammation, constitutively 
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expressing high levels of IL-1 , IL-6 and TLR to disturb the tolerogenic status quo in 
preference of a vigorous, pro-inflammatory immune response (43), (47).  
 
Macrophages (Figure 3.2 Population E: CD11b+ CD11c+/- F4/80+ CD64+) 
Macrophages were the most populous myeloid cell in the steady state colon LP, accounting 
for just over 5.5% of all intact cells. Differentiating this population from DCs has been 
historically challenging, given the overlap in surface marker expression, particularly of 
CD11c. It is however possible to discriminate macrophages based upon their expression of 
CD11b, CD11c, F4/80 and CD64 (See Table 3.1). Here the inability to discriminate between 
population expression of CX3CR1 may have functional relevance as it has been reported 
that there are minor phenotypic differences between CX3CR1int/high maturation stages of 
macrophage. CX3CR1int macrophages demonstrate numerically lower, though non 
significant, expression changes of Il10 and Tgfb mRNA, and numerically higher, non 
significant changes in Tnf, Nos2 and Ccr2 mRNA versus CX3CR1High macrophages (43). It 
has also been reported that CX3CR1int macrophages possess a small though significant 
reduction in phagocytic ability, with a lower uptake of pHrodo E.coli bioparticles compared to 
CX3CR1High macrophages, though the functional significance of this change in vivo has not 
been shown (42). Therefore with the above caveats, the CX3CR1int and CX3CR1High subsets 
of macrophage are considered together for subsequent analysis.  
 
CD11b+ DCs (Figure 3.2 Population F: CD11b+ CD11c+ F4/80- CD103+/-) 
CD11b+ DCs, like their CD11b- counterparts, can be discriminated based on CD103 
expression. CD11b+CD103+ DCs (Population F1) were found at a frequency of 0.5% of intact 
cells, with CD11b+CD103- DCs (Population F2) found at 0.7% frequency, representing the 
3rd and 2nd most abundant colon LP DC populations, respectively. This observation contrasts 
with the small intestine LP where CD11b+ DCs are the most frequent DC population, 
underlying the heterogeneity of immune cells even with the GI tract, and the caution required 
therefore in generalizing these results (114). This altered balance of DC subsets has 
important implications for intestinal T cell priming, as CD11b- DCs are more potent at cross 
presentation to CD8 + T cells, and far less effective at priming CD4+ T cells than CD11b+ 
DCs (69). Like CD11b- DCs, CD11b+ DCs have been shown able to migrate to MLN in a 
Ccr7 dependent manner, expand to Flt3 ligand and induce T cell CCR9. In addition both 
CD11b+/-CD103- cells have recently been shown to express higher levels of IL-12 and IL-23 
mRNA and induce higher IFN- !and IL-17 production from proliferating T cells compared to 





B Cells (Figure 3.3A Population G: CD19+) 
The role of B-cells in intestinal inflammation and immune homeostasis is not well 
appreciated. At intestinal sites, B cells follow a distinct differentiation pathway and are 
specialised in IgA production as differentiated plasma cells (328). sIgA acts as a barrier to 
protect the epithelium from pathogens, and interacts within the lumen with food, self and 
intestinal antigens (329). As such sIgA limits access of intestinal antigens into the systemic 
circulation, and affects intestinal microbiota composition (329). In addition a subset of CD25 
expressing B cells have been described in other tissue sites and have been termed Bregs 
given their immunosuppressive capabilities, mediated by IL-10 and TGF-β production (330). 
Indeed functional impairment of TGF-β producing B cells is associated with food-allergy 
pathogenesis (331). Interestingly we were unable to detect any CD25 expressing CD19 cells 
in the colon LP.   
 
T cells (Figure 3.3A Population H: Naïve CD8+, I: CD8+ CD44+ CD69+, J: CD4+ FoxP3+, K: 
Naïve CD4+, L: CD4+ CD44+ CD69+) 
CD69 is considered an activation marker of T lymphocytes and is the earliest inducible cell 
surface glycoprotein acquired during lymphoid activation which once expressed acts as a co-
stimulatory molecules for T cell activation and proliferation (332). CD44 participates in cell 
adhesion, migration and lymphocyte activation with T cells expressing CD44 to permit rolling 
and adhesion to intestinal epithelium (333), (334). CD44 has also been extensively 
described as identifying memory T cells with CD44High cells more sensitive than CD44Low 
cells to TCR signaling response to antigen (335). Tregs characterised by the expression of 
FoxP3 may be defined as T cells able to suppress naïve T cell proliferation in vitro and in 
vivo. Tregs are crucially involved in the maintenance of gut homeostasis by suppressing 
abnormal immune responses against the commensal flora or dietary antigens, in part 
modulating this effect by anti-inflammatory cytokine production (IL-10 and TGF-β).  
 
A dysregulated T cell response with disordered development of activated T cell populations 
can lead to an exacerbated mucosal inflammatory response. Increased T cell derived 
cytokines and chemokines derived from IBD mucosa have therefore led to the hypothesis of 
a skewed, pro-inflammatory adaptive immune response in IBD patients. Inflammatory 
lesions develop in foetal gut explants cultured ex vivo with IL-12 and anti-CD3 (336), with 
inhibition of gut activated T cell activation, mediated by T cell specific calcium channel 
blockade, leading to a reduced pro-inflammatory cytokine production  (337). Indeed the 
national institute for clinical excellence (NICE) has recently approved the use of an α4β7 
blocking monoclonal antibody (vedolizumab) which limits activated T cell recruitment to the 
gut mucosa, which has been shown to be superior to placebo in inducing disease remission 
in IBD patients (338).    
 
 74 
ILCs (Figure 3.3B Population M: CD90.2+ CD127+)  
ILCs are an emerging and diverse group of immune cells and derive from an ID2 expressing 
progenitor and have recently been implicated in the development of IBD. Group 3 ILCs have 
been shown to be able to induce colitis in a Helicobacter hepaticus infection characterised 
by IL-17A and IFNγ production in Rag-/- mice (96). Subsequent data suggest that Group 3 
ILCs can induce colitis in an IL-23R, IL-22 dependent mechanism, that Rorγt-/- mice do not 
develop CD40L induced colitis and lastly human ILC’s were found at increased levels in the 
LP in an IL-23 dependent manner (97), (96), (98), (99).  
 
3.5 Assessment of naïve Mbd2-/- mice 
In order to identify any gross pathological difference between WT and Mbd2-/- mice in the 
steady state, 1cm sections of distal colon were taken for histological analysis. We used H&E 
staining transverse sections to determine putative baseline differences in the structural 
architecture of Mbd2 deficient colonic mucosa (Figure 3.4A). There was no difference 
observed between genotypes.  In particular, there was no suggestion of spontaneous colitis 
in Mbd2-/- mice.  
 
We now sought to apply the gating strategy in Figures 3.2 and 3.3 to understand, allowing 
for the fact there was no gross histological difference between Mbd2-/- and WT mice, 
whether Mbd2 deficiency conferred changes in the cellular composition of colon LP immune 
populations.  
 
Firstly, there was a small but significant reduction in the proportion of CD45+ cells in Mbd2-/- 
mice (least square mean 40.1 1.37% versus 50.9 1.46% proportion of intact cells) (Figure 
3.4B). Interestingly in each of the 6 individual contributing experiments, this difference did 
not reach significance; only on linear regression comparing all 6 experiments together was 
the difference statistically significant (Figure 3.4B). This highlights the power of such 
methodology to detect small differences over multiple datasets, but also suggests that 
careful consideration of the biological significance of such small overall changes is required.  
 
T cells, B Cells and ILC 
We then sought to assess whether there was any perturbation of the adaptive immune 
system or ILC compartment in the steady state conferred by the absence of Mbd2. There 
was no difference in the number or proportion of TCRβ+, CD19+, CD4+, CD8+, CD4+ FoxP3+, 
CD4+ CD44+ CD69+ populations (Figure 3.4C), or in CD90+ CD127+ ILCs (Figure 3.4D).  
 
Myeloid Cells 
Within the CD45+ fraction, there was no significant difference observed in colon LP 
neutrophil, eosinophil, or CD11b- DC (CD103+/-) populations, either expressed as the 
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proportion of singlet cells or total cell number per colon, between Mbd2-/- or WT mice (Table 
3.1). There was a small but significant reduction in the proportion and total cell number of 
macrophages in Mbd2-/- versus WT naive mice (Table 3.1). In addition there was a 
significant reduction in the proportion and total cell number of CD11b+CD103+ and 
CD11b+CD103- DCs in Mbd2-/- versus WT mice (Table 3.1).   
 
However, once the reduction in total CD45+ cells was factored into the regression model, 
only the CD11b+CD103+ population differences were significant between genotypes, i.e. 
there was no difference between WT and Mbd2-/- proportion and total number of all other 
assessed cell types (Figure 3.4E and F).  
 
Thus na ve Mbd2-/- and WT mice were largely comparable in both the gross mucosal 
architecture and myeloid composition of immune cells within the colon, with the notable 
exception of a small reduction in total CD45+ cells and CD11b+CD103+ DCs. Given that 
CD11b+ CD103+ DCs did not develop normally in the absence of Mbd2, and that existing 
data support a role in vivo for Mbd2 in CD11c expressing cells, we then sought to assess the 
level of expression in WT colon LP DC and other myeloid cells.  
 
3.6 Assessment of Mbd2 expression in myeloid cells 
The previous expression analysis of Mbd2 shown in Figure 3.1A was performed on RNA 
extracted from whole tissue. Therefore we hypothesised that the contributing cell populations 
within this would demonstrate differing levels of Mbd2 expression. Given that Mbd2 has 
been shown to have a key role in controlling CD11c+ cell responses (318), with existing 
literature also supporting a key role for monocytes in intestinal homeostasis  (43,47), these 
populations were selected for further analysis by simultaneous FACS purification. To assess 
the relative expression of Mbd2 within these populations, the gating strategy in Figure 3.2 
was adapted to simultaneously FACS purify Ly6C+MHC-II+/- monocytes, Ly6C-MHC-II+F4/80+ 
macrophages, CD11b- (CD103+/-) and CD11b+ (CD103+/-) DCs from WT na ve colon LP 
(Figure 3.5A).  
 
RT-PCR of isolated mRNA from these populations revealed higher levels of Mbd2 
expression in myeloid cells than whole liver tissue control, with monocytes and macrophages 
demonstrating the highest levels of expression (Figure 3.5B). Therefore, in addition to 
observing increased Mbd2 at a tissue level in the distal GI tract, we have observed that 
within this, the colon LP monocyte-macrophage axis expresses more Mbd2 than other 
myeloid cells types and indeed other comparable whole tissue specimens.  
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We have therefore built upon previous work describing steady state intestinal MP and DC 
subsets separately, through development of a combined multi-parameter flow cytometry 
phenotyping strategy that enables simultaneous identification of each distinct cell type.  Our 
next step was to apply this new approach to the inflamed Mbd2-/- colon.  
 
3.7 Assessment of Mbd2-/- mice after acute colitis 
To assess whether Mbd2 is important for effective function of the mucosal immune system, 
we utilised the flow panel detailed in Figure 3.2 to assess cellular populations from the colon 
LP in the steady state and after acute colitis induced by feeding 2% DSS b/w in drinking 
water ad libitum for 6 days. As described in Chapter 1.6, this much-studied model of 
experimental colitis is characterised by disruption of colonic barrier integrity beginning 24hrs 
after onset of treatment (165), (164) (Chapter 1.6.1). The exposure of luminal contents and 
microbiota to the underlying LP results in colonic inflammation characterised by progressive 
weight loss, diarrhoea and PR bleeding (167). Experimental colitis induced by DSS is 
considered a T-cell independent model of intestinal inflammation, borne from observations 
that mice lacking T and B cells develop equivalent pathology as those that are 
immunocompetent when treated with DSS (166). Moreover, it has previously been shown 
that the number of colonic CD3+ T cells does not increase significantly during acute colitis, 
only increasing after the removal of DSS in the resolution  phase (339). Thus T cells were 
not considered in subsequent analysis in this model. 
 
3.7.1 Mbd2-/- mice display severe inflammation upon DSS treatment 
Daily assessment was made of weight and symptom score as defined in Table 2.3. At 
necropsy, Mbd2-/- mice had shortened colons with increased macroscopic evidence of 
inflammation (Figure 3.6A) Mbd2-/- mice had increased weight loss at day 6 (16.32 1.17% 
versus 8.90 1.17% least square mean change in day 0 weight) compared to WT mice (See 
Figure 3.6B). There were similarly increases in Mbd2-/- versus WT mean symptom score in 
DSS treated mice at day 4 (3.3 0.3 versus 0.8 0.5) day 5 (6.25 0.48 versus 1.0 0.7) and 
day 6 (12.0 0 versus 3.5 0.3) (Figure 3.6C). This reflected an increase in all parameters of 
the symptom score (PR bleeding, weight loss and diarrhoea). There were no symptoms 
recorded in untreated mice independent of genotype, with a non-significant increase in 
weight of both genotypes at day 6 (Figure 3.6B and C).  
 
Histological analysis (Table 2.4) of 1cm H&E stained sections of distal colon revealed a 
significantly greater tissue architecture destruction, goblet cell depletion and inflammatory 
infiltrate in DSS treated Mbd2-/- versus WT mice in keeping with a severe colitis (least square 
mean histology score 14.6 0.64 versus 4.8 0.54) (Figure 3.6D and E). This would suggest 
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that expression of Mbd2 is required to limit damaging inflammation incurred by DSS 
mediated intestinal barrier breakdown. 
 
3.7.2 mRNA expression of cytokine response 
To characterise the inflammatory cytokine response upon DSS treatment, mRNA was 
isolated from whole colonic tissue and analysed by RT-PCR (Figure 3.7). DSS treated Mbd2-
/- mice displayed significantly greater mRNA transcript for Ifng, Il1b, Il17, Tnf and Il10 with no 
significant difference seen in Il4 and Il5, compared to WT (Figure 3.7). In keeping with other 
na ve phenotyping data, there was no difference in cytokine expression between the 
genotypes in untreated mice.  
 
3.8 Effects of inflammation on the colon LP myeloid compartment 
Together, the above data showed the presence of an acute inflammatory infiltrate in Mbd2-/- 
DSS treated mice with significant tissue architecture disruption corresponding to a profound 
pro-inflammatory cytokine response. To understand the cellular biology underpinning these 
results, we next analysed the impact of MBD2 deficiency on colon LP myeloid populations 
during inflammation, using the logic outlined in Figure 3.2. Given that DSS colitis is 
considered a model of innate immune response, the myeloid compartment was the focus of 
all subsequent analysis (166).   
 
3.8.1 Effect of DSS on WT colon LP myeloid cells 
After the onset of intestinal inflammation with DSS there was a dramatic alteration in the 
cellular composition of the colon LP. At day 6 there was a 1.7 fold increase in the total 
number of CD11b+ cells comparing DSS treated versus control WT mice (Table 3.2). As 
previously reported, the myeloid populations with the largest increase in total number 
conferred by DSS treatment in WT mice were eosinophils (2.21 fold increase), neutrophils 
(8.93-fold increase) and monocytes (3.73 fold increase) (Table 3.2). There were smaller 
increases in the remaining myeloid cells examined, with between 1.2 and 1.8 fold increases 
in WT DC and macrophage total cell numbers. We then sought to compare changes in 
myeloid cells between WT and Mbd2-/- DSS treated mice: 
 
3.8.2 Comparison of Mbd2-/- versus WT colon LP in DSS 
There was a significant increase in the proportion of CD45+ cells comparing Mbd2-/- DSS 
versus steady state, but not in WT DSS versus steady state or Mbd2-/- versus WT in DSS 
(Figure 3.8A). This intriguingly suggested that despite a reduction in Mbd2-/- versus WT 
CD45+ cells in the steady state, DSS preferentially expands the CD45+ compartment in 
Mbd2-/- mice. When analysing the CD45+ compartment further, additional differences 
emerge. There was a 2.49 fold increase in Mbd2-/- CD11b+ cells after DSS treatment which 
represented a significantly greater increase in the number of CD11b+ cells compared to WT 
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mice  (Table 3.2). Given the increased accumulation of Mbd2-/- CD11b+ cells in DSS, we next 
investigated which myeloid populations accounted for this change:  
 
Monocytes and neutrophils, but not eosinophils, were found at significantly greater 
proportion and also in total cell number in Mbd2-/- mice (Table 3.2 and Figure 3.8B and C). 
As in na ve Mbd2-/- mice, there remained a significant reduction in the proportion and total 
number of CD11b+ DC (CD103+/-) after DSS treatment compared to WT, however the Mbd2-/- 
macrophage compartment increased in proportion by 1.6-fold (compared to 1.1-fold in WT 
mice) such that there was subsequently no difference in proportion or total cell number 
between WT or Mbd2-/- DSS treated colon LP macrophages (See Table 3.2).  
 
Thus the myeloid composition in DSS was defined by a substantial increase in monocytes, 
neutrophils and eosinophils, with Mbd2-/- treated mice displaying a significantly greater 
proportion and total number of neutrophils and monocytes compared to WT. 
 
3.8.3 Assessment of the role of Mbd2 in myeloid cytokine production 
Treatment of Mbd2-/- mice with DSS resulted in infiltration of pro-inflammatory cell 
populations along with an increase of gene expression of inflammatory cytokine burden 
(Figure 3.7 and 3.8A). In order to ascertain if the observed myeloid cell influx was a major 
factor in driving pro-inflammatory cytokine production (Figure 3.7), DSS treated or control 
Mbd2-/- or WT colon LP cells were cultured ex vivo with a protein transport inhibitor 
(Golgistop  1ug/ml), to assess IL-1 , TNF and IL-10 production by flow cytometry.  
In line with the total tissue cytokine expression in na ve mice (Figure 3.7), there was no 
difference in the total numbers of myeloid IL-1 + or TNF+ cells between genotypes in 
untreated mice (Figure 3.8D and E). However, the total number of all IL-1 + myeloid cells 
increased significantly in both genotypes after DSS treatment (mean fold change 4.03 in WT 
and 6.52 in Mbd2-/-) (Figure 3.8D). Indeed there was a significantly greater increase in total 
IL-1 + cells in Mbd2-/- versus WT mice (0.51 0.040 versus 0.24 0.038 x106 cells). Similar 
changes were seen in TNF expression, with a significantly greater increase in total TNF+ 
myeloid cells in Mbd2-/- versus WT mice (0.101 0.0083 versus 0.066 0.0080 x106 cells) 
(Figure 3.8E). In keeping with previous data suggesting a pro-inflammatory role for 
monocyte recruitment in DSS, this population was the largest overall contributor to myeloid 
IL-1  and TNF production. 
Alongside this increase in pro-inflammatory cytokine production, there was no observed 
difference in the number of IL-10+ populations between treated groups. Macrophages 
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expressed the greatest levels of IL-10, in agreement with previous studies suggesting they 
are the key IL-10+ regulatory cell type in the colon (least square mean total number IL-10+ 
macrophages 0.012 0.0022 versus 0.017 0.0023 x106 cells in Mbd2-/- and WT respectively) 
(43). These data suggested that the increased pro-inflammatory phenotype in Mbd2-/- DSS 
treated mice was not due to an alteration of IL-10 production, a key regulatory cytokine in the 
GI tract. 
 
Taken together, the colon LP in DSS colitis was defined by a florid influx of IL-1 + TNF+ 
monocytes disturbing the steady state myeloid composition of IL-10+ resident macrophages. 
This imbalance describes an inflamed mucosal surface ready to respond to invading 
pathogens brought about by a breakdown in barrier integrity. Indeed this polarization 
towards a pro-inflammatory response is dramatically increased in the absence of Mbd2, 
suggesting that Mbd2 is required to limit damaging tissue pathology induced by DSS-
associated epithelial challenge.   
 
3.9 Assessment of Mbd2-/- response to Trichuris muris infection 
Despite normal colonic T cell development (Figure 3.4C) in the absence of Mbd2, in vitro 
data suggest that Mbd2-/- naïve T cells have the capability to co-express Th1 (IFN- ) and 
Th2 (IL-4) lineage specific cytokines. We therefore wanted to explore whether there was a 
role for Mbd2 in other experimental models of colitis that rely on the adaptive immune 
system for effective host response (Chapter 1.6.6). In contrast to DSS in which an innate 
immune response predominates, T. muris produces a vigorous T adaptive immune 
response. Successful resolution of infection requires a polarised Th2 immune response, with 
susceptibility conferred by a Th1, IFN- !dominated response (215). The load of infected eggs 
delivered to the host is also critical in determining polarisation of the host immune response 
and thus susceptibility to chronic infection: Low dose (20 eggs) results in a Th1 polarised 
immune response, and therefore chronic inflammation, in immunocompetent animals. 
However, high dose (200eggs) results in a IL-4, IL-13 polarised Th2 response (216) 
(Chapter 1.6.6).  
 
A previous report showed that Mbd2-/- mice are susceptible to high dose T. muris infection 
displaying chronic inflammation, increased worm burden and IFN- !mediated IgG2a antibody 
production (321). However the authors did not assess the infiltrating inflammatory cell types 
in the colon LP, the cellular sources of putative increased IFN- , or indeed if there was a 
dose-dependent effect on pathology. We sought to address these questions utilising our 
newly developed colon LP multi-parameter flow cytometry techniques: 
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3.9.1 General observations and experimental outline 
WT and Mbd2-/- mice were gavaged with either 20 or 200 infective T. muris eggs at day 0 
and monitored for 35 days. The main comparison was to be the effect of genotype at low 
and high dose infection on the development of colonic inflammation, in a pilot experiment. 
The below data therefore represent a single experiment with n=1 for the WT na ve control 
group, which prevented statistical comparison of na ve versus infected animals.  
 
There were no adverse effects (weight loss etc.) noted during the course of the experiment 
in either genotype or infection dose. As expected, in the low dose infection group at day 35 
there was evidence of mild colonic inflammation (caecal dilatation, increased colon weight), 
and scanty intraluminal worms, independent of genotype. Similarly at day 35 in the high 
dose infection group, WT mice as predicted had no evidence of colonic inflammation or intra-
luminal worms, consistent with previous work suggesting immunocompetent mice induce a 
Th2 response favouring worm clearance (215). In high dose infected Mbd2-/- mice, however, 
there was evidence of chronic colonic inflammatory change and heavy intraluminal adult 
worm burden, replicating the findings of Hutchins et al (321). However the worm count and 
therefore burden of parasitology was not formally enumerated in this pilot experiment, as the 
tissues were used for cellular analysis by flow cytometry.   
 
3.9.2 Serum antigen-specific responses in WT and Mbd2-/- mice 
The serum of Mbd2-/- and WT day 35 infected mice was analysed by ELISA for the presence 
of T. muris specific IgG2a and IgG1 to confirm successful infection of the experimental mice 
and to give an indication of the skewing of the T cell response - IgG1 being IL-4 and IgG2a 
being IFNγ driven (Figure 3.9A and B). Consistent with the expected immune response to T. 
muris, there was a significant increase in the presence of parasite specific IgG2a and IgG1 
in all infected versus control mice (Figure 3.9A and B) (321).  In low dose infected mice, 
there was no significant effect of genotype observed on serum IgG2a or IgG1 at any of the 
dilution ranges analysed (Figure 3.9A and B). Similarly, in high dose infected mice there was 
no effect of genotype on the levels of parasite specific Th2 associated IgG1. This is 
consistent with previous published data, suggesting any altered susceptibility of Mbd2-/- mice 
to high dose infection is not mediated by an inability to mount a Th2 response (321). In 
contrast, and again consistent with previous data, there was a dramatic increase in the 
levels of parasite specific, IFN- !associated IgG2a (1.15 0.16 versus 0.22 0.18 relative OD 
units at 1/1280 dilution) (Figure 3.8A) (321). These data confirm that all mice gavaged with 
T. muris were successfully infected, that WT mice produced an appropriate Th1-low dose 
and Th2-high dose antibody response, with Mbd2-/- mice developing an increased Th1 and 
equivalent Th2 antibody response in high dose infection (Figure 3.9).  
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3.9.3 Comparison of Mbd2-/- and WT colon LP cells in T. muris infection 
The colon LP cells from infected and control mice were isolated, enumerated and surface 
stained for the antibody cocktail of myeloid and T-cell markers as described in Figures 3.2 
and 3.3A.  
 
3.9.3.1 Myeloid cells 
The proportion of LP cells expressing CD45 was equivalent between genotypes in low dose 
infection. However, in keeping with a florid inflammatory process and increased total cell 
numbers (Figure 3.10A), there were a significantly greater number of CD45+ Mbd2-/- cells 
compared to WT in the high dose group (65.0 2.48 versus 34.3 3.9% of intact cells, Figure 
3.10B).  Exploring colon LP CD45+ cells in more detail revealed no effect of genotype on the 
total cell number of any of the myeloid sub-populations assessed in the low-dose group. 
However, in the high dose group, there were a significantly greater total number of colon LP 
monocytes (4.50 0.73 versus 0.19 0.17 x106 cells), neutrophils (1.96 0.42 versus 
0.015 0.0050 x106 cells) and macrophages (3.42 0.71 versus 0.56 0.44 x106 cells) in 
Mbd2-/- versus WT mice (Figure 3.10C). Thus, whilst there were increases in monocyte, 
neutrophil and eosinophil number in low dose infected versus na ve control, there was no 
effect of Mbd2 deficiency in altering the myeloid composition between low dose infected 
mice (Figure 3.10C). In stark contrast, the myeloid compartment in high dose infection 
differed greatly depending on the presence or absence of Mbd2. 
 
The colon LP of high dose infected WT mice closely resembled uninfected WT control, in 
keeping with existing data supporting parasite clearance in immunocompetent mice (213). 
However a significant proinflammatory monocyte and neutrophil dominated composition in 
Mbd2-/- high dose infection was observed (Figure 3.10C).   
 
3.9.3.2 T cells 
A robust host response to parasite infection requires an intact adaptive immune system. 
Indeed it has been suggested that the protective immunity against T. muris is almost 
completely dependent on CD4+ T lymphocytes (213).  
 
In the low dose infection group there was no difference in the total cell numbers of any of the 
T cell populations analysed between genotypes. Given this was a pilot experiment it may be 
that numerically greater differences between the genotypes will become statistically 
significant in follow up work. Thus there was no difference in the number of colon LP TCR + 
cells (3.16 0.76 versus 1.77 0.46 x106 cells), which was predominately composed of CD4+ 
T cells (1.98 0.51 versus 1.15 0.56 x106 cells, Figure 3.10D). In addition there was no 
significant difference in the total number of CD8+, FoxP3+ regulatory T cells or CD44+CD69+ 
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effector T cells (Figure 3.10D). Although there was no difference in the total number of Tregs 
between genotypes, Mbd2 deficiency did affect the proportion of CD4+ T cells expressing 
FoxP3; with a significant decrease seen in Mbd2-/- mice (5.33 0.47 versus 12.8 0.66 % of 
CD4+ T cells expressing FoxP3).  
 
In the high dose infection group, there were once again stark differences between genotypes 
(Figure 3.10D). There was a significant increase in the total number of Mbd2-/- TCR + cells 
(3.87 0.50 versus 0.60 0.47 x106 cells) and again this was predominately composed of 
CD4+ T cells (2.47 0.32 versus 0.38 0.34 x106 cells). Because of the substantial increase in 
the global Mbd2-/- T cell compartment, there was in addition a significant increase in the total 
number of Mbd2-/- CD8+ T cells (0.71 0.13 versus 0.055 0.041 x106 cells). However, the 
total number of Tregs and Teff were equivalent between Mbd2-/- and WT mice. In addition, 
and in contrast to low dose infection, the proportion of CD4+ T cells expressing FoxP3 was 
no different between genotypes (Figure 3.10D). 
 
To ascertain whether local (i.e. colonic) changes in T cell populations conferred changes at a 
systemic level, draining mesenteric lymph nodes from low and high dose, WT and Mbd2-/- 
mice were obtained and analysed as above. There was interestingly no difference between 
genotypes in the proportions or total numbers of any of the T cell populations analysed 
(Figure 3.10E).  
 
Thus, similar to the myeloid data, Mbd2 deficiency exerted its greatest effect in the high dose 
infection group, with large increases in the CD4+ T cell compartment. In addition there were 
also large numerical though not significant increases in colon LP T cells numbers in the low 
dose Mbd2 deficient group, which one might expect to reach statistical significance in a 
further work.  
 
3.9.4 Local and systemic cytokine responses in WT and Mbd2-/- mice 
Clearance of T. muris requires an appropriate Th2 response. IL-4 has subsequently been 
identified as the key Th2 cytokine dictating the host response, with IL-4 deficient mice, or 
treatment with IL-4 depleting monoclonal antibody, negating parasite clearance (340). In 
addition IL-13 and TNF mediated effects have also been identified to be required for 
resolution of infection and mediating downstream Th2 responses (341), (342). In contrast, an 
inappropriate Th1 response leads to chronic infection, with transgenic mice producing high 
levels of IFN- , IL-12 or IL-18 demonstrating increased susceptibility to chronic infection 
(215). Thus we next assessed host cytokine responses to help delineate the relative 




3.9.4.1 Antigen specific draining lymph node response 
Draining MLN cells from day 35 low and high dose infected WT or Mbd2-/- mice were isolated 
and cultured for 72 hours with T. muris antigen, the supernatants of which were then 
assessed for Th1/2 cytokines by ELISA (Figure 3.11). In low dose infection, there was no 
difference in IL-4, IL-13 and IFN-  from Mbd2-/- restimulated lymph nodes (Figure 3.11). In 
contrast, high dose infection was associated with significant increases in detected levels of 
IL-4, IL-5, IL-10, IL-13 and IFN- !from Mbd2-/- restimulated MLN (Figure 3.11).  
 
Given that the proportion and number of CD4+ T cells in draining MLN was equivalent 
independent of Mbd2 deficiency or infection load (Figure 3.10E), this suggested the 
increased antigen specific cytokine detection was not a by-product of unbalanced T cell 
proportions in the cultures.  
 
3.9.4.2 CD4+ T cell cytokine production 
To assess whether there was an increased per cell production of cytokines in Mbd2-/- high 
dose infection, we assessed cytokine production by flow cytometry from colon LP or MLN T 
cells. Day 35 colon LP or MLN cells were isolated as described above and cultured with 
PMA/ionomycin for 3 hours before being surface stained with the T cell markers described 
above and thereafter stained intracellularly for the presence of IL-4, IL-5, IL-10, IL-13, IL-22, 
TNF and IFN- . The proportion of CD4+ T cells expressing these cytokines was then 
calculated, and is presented in Table 3.3A and B.  
 
MLN 
In the low dose infected MLN, there was no significant difference in the proportion of CD4+ 
cells expressing any of the cytokines analysed.  
 
However, in the high dose infected MLN there was a significant increase in the Mbd2-/- CD4+ 
production of IFN-  (4.56 0.30 versus 1.09 0.11 % CD4+ cells), IL-4 (6.13 0.21 versus 
3.28 0.97 % CD4+ cells) and IL-13 (4.66 0.65 versus 2.73 0.72 % CD4+ cells) (Table 3.3A).  
 
Colon LP 
Regarding the low dose infected colon LP, there were no significant differences in the CD4+ 
T cell production of any of the cytokines analyzed, with the exception of IL-13. Here there 
was a surprising decrease in Mbd2-/- versus WT CD4+ T cell production of IL-13 (15.0 2.57% 
versus 43.40 4.18% proportion of CD4+ cells).  
 
 84 
Unfortunately, in the high dose infected colon LP there was an unacceptable amount of dead 
cells (defined as >80% LiveDeadBlue staining of all events as assessed by flow cytometry) 
in 2 of the 3 WT samples that prohibited statistical analysis between high dose genotype 
groups (Table 3.3B).  
 
3.9.4.3 CD8+ T cell cytokine production 
Colon LP CD8+ T cells were too few in number to permit analysis independent of genotype 
or infection load. In addition there were no significant differences in any cytokine in each of 
the infection groups between genotypes in isolated MLN cells. This supports previous data 
reporting CD8+ T cells as dispensable for host response to T. muris infection (343). 
 
3.10 Colon LP monocytes in active IBD  
In the work described above, we have observed that both infectious and chemical models of 
murine colitis are defined by a dramatic accumulation of LP monocytes. These effector cells 
capable of producing large amounts of inflammatory cytokines have been the subject of a 
recent study (see below) to assess their role in man, and indeed therefore whether common 
pathways exist between experimental colitis and IBD.  
 
As described in Chapter 1.4, recent studies have identified intestinal monocytes and 
monocyte-derived macrophages as critical perpetrators in driving inflammation in IBD (113), 
(72). There is in addition heterogeneity seen in mice and human monocyte-macrophage 
expression of surface markers depending on their location within the GI tract (50). We 
therefore sought to identify whether CD14High monocyte-like and CD14Low resident 
macrophage populations could be identified in this homogenous colonic dataset both in 
healthy controls, quiescent and active IBD. 
 
3.10.1 Patient Demographics and experimental outline 
20 patients were consented for biopsy sampling for research purposes whilst undergoing a 
clinically indicated endoscopic procedure. Clinical phenotype data was collected on those 
patients with IBD including Vienna (CD) or Montreal (UC) classification of disease 
distribution and Harvey-Bradshaw (HBI) (CD) or Partial-Mayo (UC) clinical assessors of 
disease activity (Table 3.4 and Table 3.5). In addition a drug history was taken detailing the 
presence of any immunomodulator therapy. The mean age of the study population was 40.0 
years, with an equivalent sex distribution. 
 
Healthy controls 
4 of the 20 patients underwent colonoscopy for the investigation of IBS symptoms in the 
absence of any other past medical history, had a normal procedure and were thus 




10 of the 20 patients (3 UC, 7 CD) underwent colonoscopy for IBD assessment, 5 patients of 
which (3 UC, 2,CD) were asymptomatic, the remaining 5 patients (1 UC, 4 CD) had a mean 
HBI of 7.5 or partial Mayo score of 3 indicating mild disease activity. Only 1 patient was on 
immunomodulator therapy (azathioprine and infliximab). All 10 patients had a normal 
procedure; biopsies were taken of the transverse or sigmoid colon in areas of 
macroscopically normal mucosa and were thus considered quiescent IBD.  
 
Active IBD 
5 patients (2UC, 3CD) underwent colonoscopy for IBD assessment (note for 1 case biospes 
were taken from inflamed and uninflamed areas), with only 1 patient (CD) having clinical 
evidence of disease activity (HBI=7). 2 patients were taking azathioprine (1UC, 1 CD) with 1 
patient taking methotrexate and adalimumab (CD). All 5 patients had macroscopic evidence 
of inflammation thought by the treating clinician to be caused by disease activity and were 
thus considered active IBD.  
 
3.10.2 Colon LP analysis of healthy controls and IBD patients 
Colon LP cells were isolated and surface stained for a range of markers (HLA-DR, CD11c, 
CD45, CD163, CD64, CD14 and CD209) before analysis by flow cytometry (See Figure 
3.12A). As in mice, the number of CD14High monocyte-like cells in the steady state human 
colon was very low, accounting for approx. 0.2% of all intact cells (Figure 3.8B and (43)). 
This was similarly low in quiescent IBD, representing 0.4% of all intact cells. However in 
active IBD this population accumulated significantly in number to 2.0% of intact cells. In the 
active IBD group there was concordantly a significant increase in the ratio of CD14High : 
CD14Low cells compared to quiescent IBD (0.90 0.090 versus 0.067 0.070) or healthy 
controls (0.90 0.090 versus 0.11 0.11) (Figure 3.12B). The ratio of 
monocytes:macrophages was similarly disturbed in DSS colitis with day6 DSS treated WT 
mice demonstrating significant bias of this ratio towards monocyte accumulation (Figure 
3.12C). Thus, in mouse and human colonic inflammation there is an accumulation of 





In chapter 3 we identified a key role for Mbd2 in intestinal homeostasis. Mbd2 displayed a 
tightly regulated spatial expression, with mRNA transcript increasing proximally to distally 
through anatomical divisions of murine GI tract (Figure 3.1A). Mbd2 was therefore expressed 
at greatest levels in the rectum, significantly greater than proximal colon and small intestine. 
This relationship was preserved in human GI tract, with significantly greater MBD2 mRNA 
transcript observed in human rectum versus small intestine (Figure 3.1B).  
 
However rectal MBD2 transcript fell significantly in patients with active IBD versus healthy 
controls (Figure 3.1C). We then interrogated the IIBDGC GWAS dataset to address whether 
MBD2 polymorphisms conferred an increased risk of developing IBD.  MBD2 was not seen 
to be a risk susceptibility locus for IBD using this methodology (Figure 3.1D). It should be 
pointed at there are limitations in this observation, namely GWAS rely on the comparison of 
a large number of cases and controls to detect risk susceptibility at genome wide 
significance (104). Rare variants in putative susceptibility loci that are either not in the 
affected cohort, or present at low numbers, will clearly not be detected. In addition IBD is an 
extremely heterogeneous set of conditions. Two patients presenting with similar initial 
disease may have very different disease natural histories reflecting a poor understanding of 
the predictors of disease and treatment response (344). In addition, whilst GWAS will detect 
common variations in DNA sequence, this does not permit us insight into any role of post 
transcription or translation modification or splice variants in altering disease susceptibility.  
 
As such analysing exosome sequencing of cases and controls may allow us to address the 
relationship of MBD2 and IBD pathogenesis more fully. In the case of Mbd2 it is notoriously 
difficult to identify epigenetic regulators without simultaneously monitoring for MBD targets, 
DNA methylation and histone acetylation status (345). Lastly MBD2 may not be a true IBD 
risk susceptibility locus, but has already been shown to control facets of the immune 
response in mice that may influence important areas of intestinal homeostasis in non-IBD 
pathways (318), (321), (319).  
 
Therefore we suggest the next step to address the role of MBD2 as an epigenetic risk locus 
in IBD will be to compare the acetylome, methylome and exosome of human intestinal 
samples comparing active IBD, quiescent IBD and healthy controls. As noted in Chapter 1.7, 
epigenetic processes are plastic, affected at key points in development and open to 
manipulation by environmental stimuli. Therefore it is perhaps more feasible that MBD2 
mediated changes in gene expression will be more likely detected by epigenetic analysis at 
mucosal surfaces, rather than germline changes in DNA sequence.  
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We next built upon previous work by simultaneously identifying multiple colon myeloid 
populations by flow cytometry (Figure 3.2) and used this gating logic to understand 
phenotypic differences in WT and Mbd2-/- mice in the steady state and under two models of 
GI tract inflammation (Figure 3.8 A,B,C and Figure 3.10 A,B,C).  
 
There have been substantial recent developments in the ability of researchers to 
discriminate between mucosal MPs by flow cytometry analysis of surface marker expression. 
We have therefore built upon previous work to produce adapted gating logic from others 
using CX3CR1gfp/+ mice, utilising an array of MP markers to produce an integrated strategy 
for identifying myeloid cells. As noted in Chapter 3.4, the fact that we have not used 
CX3CR1gfp mice in our studies is a limitation to our gating strategy. The absence of this tool 
precludes the discrimination of CX3CR1int and CX3CR1High macrophage stages of 
differentiation, and confirmation that the previously presented CX3CR1 expression data 
matches our dataset. With these caveats, and the resultant time delay that crossing Mbd2 
deficient and CX3CR1gfp mice would have produced, we decided to accept these limitations.  
 
Using these flow cytometry analysis techniques we have found that in the steady state there 
is a small but significant reduction in the proportion and number of CD45+ colon LP cells in 
steady state Mbd2-/- mice (Figure 3.3B). In addition there was a selective reduction in the 
CD11b+ CD103+ DC subset (Figure 3.3C). It has been shown that Notch2 and Irf4 
transcription factors are required for the normal development of CD11b+ CD103+ DCs (68) 
(65). However DC specific deletion of Notch2 for example has been shown to have 
alterations on DC subsets in other tissues (68). Given that DC development in Mbd2-/- mice 
is normal in other tissues (318) we consider 2 possible hypotheses for intestinal specific 
depletion of Mbd2 deficient CD11b+ CD103+ DCs; 1) that Mbd2 is required for appropriate 
DC development that occurs after pre-cDC differentiation or 2) that Mbd2 is required for 
surivival and/or conditioning of resident CD11b+ CD103+ DCs in the intestine.  
 
CD11b+ CD103+ DCs have previously been show to be indispensable for effective clearance 
of the colonic pathogen Citrobacter rodentium, and suggested to be the obligate source of 
IL-23, a cytokine essential in promoting epithelial barrier defense and integrity via their 
stimulation of innate lymphoid cell subsets to produce IL-22 (346). 
 
We then observed a striking susceptibility of Mbd2-/- mice to both chemical and infectious 
colitis. Mbd2-/- mice were exquisitely sensitive to the epithelial toxin DSS, resulting in 
increased weight loss, histological assessment of inflammation (Figure 3.6 B,C,D,E) and 
mRNA transcript of pro-inflammatory cytokines IL-1β and TNF (Figure 3.7). Flow cytometric 
analysis of the inflammatory infiltrate in the colon LP of Mbd2-/- mice revealed a significantly 
greater accumulation of monocyte and neutrophil populations compared to WT (Figure 3.8B 
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and C). In addition there was a significantly increased accumulation in the number of cells 
expressing TNF or IL-1β as assessed by Intracellular flow cytometry, with monocytes and 
neutrophils the largest producers of these cytokines (Figure 3.8D).  
 
Taken together, DSS treated mice demonstrated a marked accumulation of IL-1β and TNF 
expressing monocytes and neutrophils, with Mbd2 deficiency augmenting these aspects of 
the intestinal inflammatory response. Both in murine and human IBD it is now appreciated an 
inflammatory monocyte population accumulates with IL-1β and TNF producing capabilities 
(113).  We speculate that Mbd2 maybe acting in WT mice by directly limiting the pro-
inflammatory potential within monocytes that are recruited to mucosal surfaces.  
 
To test an intrinsic defect within monocytes, we will seek to address whether Mbd2-/- 
monocytes worsen colitis when in the presence of other Mbd2 sufficient cells. Given a 
satisfactory monocyte specific transgenic system or antibody does not currently exist, we 
could employ lethally irradiated WT BM chimeras repopulated with WT and Mbd2 deficient 
haemopoetic cells. This would permit assessment of both Mbd2 deficient and WT monocytes 
in the same inflammatory system, therefore normalising for the overall level of inflammation 
that may be affecting monocyte response in Mbd2-/- mice.  
 
To further pursue a monocyte specific role for Mbd2 we could also assess the pro-
inflammatory potential for these cells before they reach inflamed tissue sites. By performing 
analysis in this way, we negate the level of tissue inflammation as a variable in producing the 
observed phenotype. Alternatively, monocytosis in Mbd2-/- mice may simply represent an 
increased burden of inflammation, i.e. a readout of increased tissue destruction. In this 
hypothesis, other Mbd2 deficient cell types may be the primary catalyst for dysregulated 
immune response. Such candidate cell types would include macrophages, based on their 
known role in tolerating the intestinal surface to the microbiota, DCs based on existing data 
supporting the role of CD11c+ cells in DSS colitis, the epithelium, based on existing data 
supporting its role in barrier function and antigen presentation and lastly neutrophils, which 
have well documented pro-inflammatory potential. These candidates and methods to explore 
their function in Mbd2 deficient states is considered in Chapter 4.   
 
Taken together we have built upon previous work by suggesting a global role for Mbd2 that 
prevents aberrant accumulation of pathogenic cell types to the intestine thereby limiting 
inflammation after barrier disruption. Subsequent analysis in chapters 4 and 5 will seek to 
address the relative role of Mbd2 deficient epithelial and haematopoetic cells in producing 
this effect.  
 
 89 
Whilst DSS is a well-described innate model of animal colitis, we also sought to address 
whether Mbd2 deficiency conferred increased predisposition to colonic inflammation 
mediated by adaptive immune responses. Indeed Mbd2 deficiency resulted in dramatic 
colonic inflammation with T. muris at high dose in contrast to parasite clearance and minimal 
pathology in Mbd2 sufficient mice. This was characterised by dramatic increases in CD4+ T 
cell, monocyte and neutrophil numbers (Figure 3.10B,C,D), in addition to exaggerated 
parasite-specific Th1 associated antibody responses (Figure 3.9A). There was in 
combination increased Th1 cytokine from CD4+ T cells both locally within the colon LP and 
distally in tissue draining lymph nodes (Table 3.3 A and B). However this was juxtaposed to 
an exaggerated Th2 cytokine response, and WT-equivalent Th2 antibody production that 
would normally herald successful parasite expulsion (Figure 3.9B and Table 3.3 A and B). 
Based upon the observed phenotype of increased susceptibility to infection, we expected to 
see an increased Th1-susceptibility conferring response and an absent Th2-resistance 
conferring response in Mbd2-/- mice.   
 
The observation of an augmented bilateral Th1 and Th2 response therefore was surprising. 
That said there are data supporting the role of Mbd2 in dual Th1/Th2 responses. Mbd2-/- 
na ve T cells and in vitro differentiated Th1/Th2 cells are capable of producing both 
increased IL-4 and IFN-  under in vitro culture conditions with the mitogen PMA (319).  
 
An alternate hypothesis however would be that the dysregulated inflammatory response we 
have observed in Mbd2 deficient animals is due to worm persistence. Mbd2 may be required 
by epithelial cells to prevent effacement of worms to the mucosal surface, or indeed for 
appropriate mucus production from colon epithelial goblet cells. Indeed the absence of Mbd2 
may confer a dysbiosis that renders the local environment more favourable for T. muris 
development in the colon. To address this hypothesis we could employ cell specific 
knockdown of epithelial (VillinCre), T cell (VavCre) or macrophage/DC (CD11cCre) Mbd2 to 
restrict Mbd2 deficiency to these cell types and assess the development of infection. 
Similarly pre-treating mice with broad-spectrum antibiotics to remove the gut microflora 
before T. muris infection could address the role of dysbiosis in infection development in WT 
and Mbd2-/-. Lastly we could perform a timecourse experiment assessing worm burden and 
inflammation at Day 5,10,15,20,25 and 30. In this way we could see if excessive 
inflammatory responses occur at equivalent levels of parasite burden.  
 
Taken together, we have expanded on the existing literature regarding the role of Mbd2 in 
modulating response to Th2 infection. We have replicated the findings of Hutchins et al. of 
increased Th1 (IgG1) and Th2 (IgG2a) T. muris antibody responses in chronic high dose 
infection in Mbd2 deficient mice, but in addition have suggested that Mbd2 is required to limit 
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a CD4+ rich colon LP infiltrate and concurrent Th1 and Th2 responses, both locally and 
systemically.  
 
In the work described above, we have observed that both infectious and chemical models of 
murine colitis are defined by a dramatic accumulation of LP monocytes in WT animals. 
These effector cells, capable of producing large amounts of inflammatory cytokines, have 
been the subject of recent study (described below). To assess their role in man, and indeed 
therefore whether common pathways exist between experimental colitis and IBD we sought 
to understand whether analogous populations existed in man. 
  
Human intestinal macrophages express CD68, CD33 and low levels of CD14, CX3CR1, 
CD11c and CD163 (113), (43). However under inflammatory conditions a discreet CD14High 
monocyte population accumulates, which like the analogous Ly6C+ MHC-II- monocyte 
population seen in mice is also present at reduced numbers in the steady state (120). These 
CD14High cells seem to be derived from circulating classical blood monocytes, express higher 
levels of CD11c, CD64, and CD163 and are heterogeneous in expression of HLA-DR and 
CD209 (121), (120). In addition CD14High cells produce large amounts of inflammatory 
cytokines such as IL-6, IL-23 and TNF (347). 
 
There is in addition heterogeneity seen in murine and human monocyte-macrophage 
expression of surface markers depending on their location within the GI tract. Study inclusion 
criteria and reporting of tissue site sampling is therefore critical in interpreting surface 
expression data. Previous studies have employed either the pooling of endoscopic biopsies / 
surgical resection specimens from IBD patients or healthy controls independent of 
anatomical location (43), (113), (120), (347). There are no published data to our knowledge 
that report the phenotype of monocytes/macrophages exclusively sampled from colons of 
IBD patients and healthy controls.  
 
These results support previous data reporting colonic inflammation in mouse and man is 
characterised by accumulation of pro-inflammatory TLR-expressing monocyte populations, 
capable of producing large amounts of IL-6, IL-23 and TNF and distinguished from resident 
inert macrophage populations by discreet surface marker expression (51), (113).  Whilst 
endoscopic assessment of inflammation correlated very well with monocyte influx, with all 5 
patients having a raised CD14High : CD14Low ratio, only 1 patient with monocyte influx 
reported symptoms of disease activity. This disparity is entirely in keeping with the current 
paradigm of objective assessment of intestinal inflammation correlating poorly with clinical 
symptoms, supporting the need for regular mutli-modality assessments of disease activity to 
limit the damaging effects of sustained disease activity (348).   
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We have also replicated previous work in a homogenous patient dataset of colon specific 
sampling, identifying a CD14High monocyte-like cell accumulation in active IBD analogous to 
LY6C+ MHC-II+/- cells in mice (Figure 3.12A). These data employed specific endoscopic 
biopsy sampling of inflamed (and in some cases non-inflamed areas in the same patient) 
tissues, in contrast to previously published data that has used a combination of whole tissue 
resections ± biopsy samples, often again combining multiple sections of GI tract (e.g. small 
and large intestine) and disease behaviours (stricturing, penetrating and pure inflammatory 
disease). One advantage of our dataset therefore is the more specific sampling of affected 
tissue (endoscopic sampling alone), from a single section of GI tract (colon) and from a 
single IBD disease behaviour (inflammatory).  
 
The identification of a CD14High monocyte-like cell infiltrate in IBD highlights perhaps the 
similarity in colon inflammatory responses in mouse and man, suggesting there are 
common, currently poorly understood, pathways of immunological recruitment to mucosal 
surfaces. In particular the cellular sources of chemokines and associated breakdown in 
barrier function remain unanswered questions. 
 
There are clearly caveats to the above observations.  Pilot data from T. muris infection data 
will need to be investigated and replicated in larger group sizes, similarly human colonic 
samples are limited by a small number of cases and controls, with the inherent difficulties of 
IBD patient stratification well documented.  Indeed CD14High expression of surface markers 
CD64 and CD163 has been shown to be increased compared to CD14Low cells in our and 
other cohorts, but not in all, underlining the distinction and perhaps ontogeny of the 
monocyte-macrophage axis is less clear in man.  
 
In the next chapter we sought to refine our investigation of Mbd2 deficiency to specific key 
cell types, to understand the respective roles of haemopoetic versus stromal cells and define 

























































































Figure 3.1 Mbd2/MBD2 expression in the gastrointestinal tract and association with IBD 
A. qPCR of 1cm sections of GI tract taken at measured intervals from the stomach pylorus*. Mbd2 mRNA expression 
was determined by qRT-PCR, the mean value relative to Gapdh expression is presented. Mean values were obtained 
from 4 individual mice, data representative of 3 separate experiments. Primer sequences are in Table 2.5 B. Log2 ratio 
of MBD2 expression from whole human genome microarray analysis of colonoscopic biopsies taken by Noble et al. 
2008 from 31 healthy controls and C. 67 patients with active ulcerative colitis. D. Manhattan plot of the genome-wide 
association meta-analysis of 9 independent IBD case control series (16,054 Crohn’s disease cases, 12,153 ulcerative 
colitis cases and 17,575 healthy controls) assessing MBD2 as a putative risk susceptibility loci for IBD. The x axis is 
position on chromosome 18, the y axis is significance (-log10 P 2 tailed) of association derived by logistic regression, 
the green line shows genome wide significance level (5x10-8). Statistical analysis for (B), (C) was performed by 2-way 
ANOVA, (* p<0.05) 
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Figure 3.2 Flow cytometry gating strategy for colon lamina propria myeloid populations
Colon lamina propria cells were isolated from naive WT mice and analsyed for the expression of the following by flow 
cytometry; Live Dead Blue, CD45, Lineage (NK1.1,CD19,CD3,Ter119), CD11b, Ly6G,SiglecF,CD11c,CD103,Mert-
K,Ly6C,MHC-II and F4/80. Representative contour plots display the following populations (as per Table 3.1) A. Neutro-
phils, B. Eosinophils, C. CD11b- DC (subdivided on CD103 and MertK expression), D. Monocytes, E. Macrophages, 



















































































Figure 3.3 Colon LP Non-myeloid cell comparison in naive Mbd2-/- and WT mice
Colon lamina propria cells were isolated from naive WT mice and analsyed for the expression of the following by flow 
cytometry; Live Dead Blue, CD45, TCRβ, CD19, CD4, CD8, FoxP3, CD44, CD69, CD90, B220, CD3, CD11b, 
CD11c, Ly6G and Ly6C. Representative contour plots display the following populations G. B Cells, H. Naive CD8+ T 







































































Figure 3.4 Naive Colon LP phenotyping in WT and Mbd2-/- mice
A. H&E stained transverse sections of 1cm distal colon from WT or Mbd2-/- mice at x10 magnification. Colon LP cells 
were isolated and surface stained as per gating strategy in Figure 3.2 and 3.3 from WT and Mbd2-/- mice. B. The 
proportion of colon LP singlet cells expressing CD45. C. the total number of cells from populations identified using the 
gating strategy in Figure 3.3A per colon D. The total number of ILCs per colon identified using the gating strategy in 
Figure 3.3B. E. Representative flow cytometry contour plots of colon LP cells isolated from WT or Mbd2-/- mice. Live, 
singlet, CD45+, Lin- (SiglecF, CD3, Ly6G, CD19), CD11c+, F4/80- gated cells showing DC subsets. F. Least square 
mean proportion of singlet cells for selected populations comparing WT and Mbd2-/- mice after adjustment for differenc-
es in total CD45 cells using linear regression modelling. n=15-20 per group analysed over 5 independent experiments 
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Figure 3.5 Mbd2 expression in selected FACS purified colon LP myeloid subsets
A. Contour plots of naive WT colon LP cells stained for expression of Live Dead Blue, CD45, CD11b, CD11c, F4/80, 
MHC-II and Lineage (CD3, NK1.1,Ly6G) markers. Representative pre- and post- sort purity is presented  for the popu-
lations described. B. mRNA expression of Mbd2 assessed by RT-PCR of the myeloid subsets in (A). Mean values are 






































































































































Figure 3.6 Susceptibility of Mbd2-/- mice to DSS colitis
Mbd2-/- or littermate WT mice recieved 2% DSS b/w in drinking water or normal drinking water for 6 consecutive days A. 
Photograph of WT and Mbd2-/- caecum and colon after division at the terminal ileum and anus post dissection. B. Least 
sqauare mean day 6 weight change of DSS treated and naive control, WT and Mbd2-/- mice as a percentage of starting 
body weight, n=15-25 analysed by linear regression modelling of 4 separate experiments. C. Mean symptom score per 
day over the duration of DSS treatment. Cumulative score as per Table 2.3 of weight loss (0-4), diarrhoea (0-4) and per 
rectal bleeding (0-4). n=4 per group, representative of 4 independent experiments D. H&E stained transverse sections of 
distal WT or Mbd2-/- DSS treated colon, x10 magnification. E. Least square mean±SEM blinded histology score of inflam-
mation of (D), as per Table 2.4, comprising inflammatory cell infiltrate (0-4, +0.5 per ulcer), Goblet cell depletion (0-4, +0.5 
per crypt abscess), Muscosal thickening (0-4), submucosal cell infiltration (0-4) and architecture destruction (0-4), n=8 
per group analysed by linear regression modelling of 2 separate experiments. Representative data from 4 independent 






















































Figure 3.7 Colon mRNA expression of selected cytokines during DSS colitis
qPCR of 1cm sections of distal colon from Day6 2%DSS treated or drinking water control WT or Mbd2-/- mice. Selected 
cytokine mRNA expression was determined by qRT-PCR, the least square mean value relative to Gapdh expression is 
presented. Least square mean values were obtained from linear regression of 3 independent experiments, n=8-15 per 









































































Figure 3.8 Flow Cytometry analysis of the colon lamina propria in DSS colitis
Mbd2-/- or littermate WT mice recieved 2% DSS b/w in drinking water or normal drinking water for 6 consecutive days, 
colon LP cells were isolated and assessed for the expression of SiglecF, Ly6G, CD11b, CD11c, F4/80, MertK, CD64, 
CD45, CD103, and Lineage markers (CD3, CD19, NK1.1, Ter119) by flow cytometry. A. The proportion of singlet cells 
expressing CD45 in naive and DSS treated WT and Mbd2-/-  mice. B. The least square mean total number of cells x106 
per colon is presented for the populations outlined in Figure 3.2, n=15-25 per group, analysed by linear regression of 6 
independent experiments.  C. Representative flow cytometry contour plots in Day6 DSS treated WT and Mbd2-/- mice for 
neutrophil and monocyte populations as defined in Figure 3.2. The least square mean number of colon LP myeloid cells 
x106 per colon after 3 hr incubation with 1μl/ml GolgiStop expressing IL-1β (D) or TNF (E) as assesed by intracellular 
staining and flow cytometry compared to isotype antibody control, n=12-15 mice per group analysed by linear regression 










































































































































Figure 3.9 Day35 20 or 200egg T.muris infection Mbd2-/- verus WT antigen specific serum IgG1 and IgG2a
Serum from day 35, 20 or 200egg T.muris infected Mbd2-/- or WT mice was collected and parasite-specific serum 
antibody titers performed by ELISA with T. muris Ag-coated dishes and anti-isotype detection antibody for IgG2a (A) and 
IgG1 (B) mean flouresence data is presented from n=1-4 mice per group analysed in duplicate.  1/1280 dilution data is 
presented in bar chart format, showing data±SEM from 1 pilot experiment n=1-4 per group analysed by 2-way ANOVA. 
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Figure 3.10 Day35 20 or 200egg T.muris infection Mbd2-/- verus WT FACS analysis of T cell and myeloid populations
Colon LP and MLN cells were isolated and assessed for the expression of SiglecF, Ly6G, CD11b, CD11c, F4/80, MertK, 
CD64, CD45, CD103, CD4, Foxp3, CD8, CD44, CD69 and Lineage markers by flow cytometry. A. Mean±SEM total LP cell 
counts enumerated per colon. B. The proportion of intact colon LP cells expressing the surface marker CD45. The mean 
total number of cells x10^6 per colon (C and D) and per MLN (E) is presented for the populations outlined in Figure 3.2 (D) 
and for Treg (CD4+ Foxp3+), Teff (CD4+ Foxp3-, CD44+ CD69+), CD4+ (CD4+, Foxp3- CD44- CD69-) and CD8+ T cells (C and 
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Figure 3.11 Day35 20 or 200 egg T.muris infection WT versus Mbd2-/- MLN antigen specific cytokine response
MLN cells were isolated and stimulated for 72 hours with 1μg/ml T.muris antigen and cytokine levels in supernatants 
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Figure 3.12 Human colon LP CD14+ cells in IBD and healthy controls
Colon LP cells from endoscopic biopsies were isolated from patients with endoscopically active or quiescent IBD or 
healthy controls, enumerated and surface stained with the following antibody cocktail; CD45, HLADR, CD103, CD172a, 
CD141, CD11c, CD1c, CD64, CD163, CD14 and lineage markers CD3, CD19, CD20 and CD56 and analysed by flow 
cytometry. A. Representative FACS contour plots of Live, Lin- gated cells showing CD14high and CD14low populations. B. 
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+p perianal disease, added to B1-3 if concomitant perianal involvement is present
E1 Ulcerative proctitis Involvement limited to the rectum
E2 Left sided Involvement limited to the colorectum distal to the splenic flexure




1 1-2stools/day more than normal
2 3-4stools/day more than normal
3 >4stools/day more than normal
0 None
1 Visible blood with stool less than half the time
2 Visible blood with stool half of the time or more
3 Passing blood alone
Component Score Description
0 very well















erythema nodosum, pypderma gangrenosum or 
apthous ulcers
anal fissures, fistulae or abscesses
other fistula





Vienna Classification for Crohn's disease
Montreal Classification for Ulcerative colitis
Partial Mayo score for Ulcerative Colitis
Harvey Bradshaw Index for Crohn's disease
Rectal Bleeding
General well being
Overview of the classification of IBD phenotype and clinical severity scores
Abdominal pain
abdominal mass
Complications 1 point for each
Stool frequency
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In Chapter 3 we identified a role for Mbd2 in modulating an increased susceptibility to colonic 
inflammation. This was characterised by an accumulation of IL-1 + and TNF+ myeloid cells, 
particularly monocytes and neutrophils. We also identified myeloid cells as displaying high 
levels of Mbd2 transcript. Clearly in animals in which all cell types are Mbd2 deficient, it is 
difficult to make inferences on the respective roles of Mbd2 deficient populations to this 
phenotype. We therefore sought to delineate Mbd2 deficient populations in more detail, and 
hypothesized that Mbd2 deficient haematopoietic cells were likely candidates for further 
analysis for several reasons. 
 
Firstly, there is an increasing body of evidence to suggest inflammatory monocytes as 
directly pathogenic in DSS colitis: mice deficient in CCR2, a chemokine receptor expressed 
by blood monocytes, are less susceptible to colonic inflammation (51). Similarly, 
administration of an anti-CCR2 depleting antibody thought to selectively affect LY6CHigh 
blood monocytes, ameliorates colitis with lower levels of IL-6 and IL-1  in colonic tissue (47). 
Additionally, DSS colitis is significantly reduced in mice whose monocytes are unable to 
produce TNF (71). Supporting a more dominant role in intestinal inflammation for monocytes 
versus neutrophils, mice deficient in CCL2/CCR2 mediated monocyte recruitment are more 
susceptible to Toxoplasma gondii (T. gondii) infection, whereas in vivo neutrophil depletion 
has no effect on disease progression (349), (350), (351). 
 
Other candidate haematopoietic cells for Mbd2 mediated predisposition to colitis include 
macrophages and DCs. Both are critical in maintaining the immunological balance between 
tolerance and inflammation by pivoting the adaptive response through antigen presentation 
and local contribution to the cytokine milieu. DCs have the capacity to manipulate local 
inflammatory responses by release of cytokines and chemokines through activation of 
PRRs, which in turn can influence other myeloid cells (352). Indeed a dysregulated immune 
response to the commensal microbiota is one of the hallmarks of IBD in man, with mutations 
in the NOD2 pathogen recognition molecule (expressed by both DCs and macrophages), 
being the strongest heritable risk factor for CD (107), (108), (353).  
 
Previous data directly assessing the contribution of DCs in the DSS model again suggest a 
role in pathogenesis.  For example, Berndt et al. reported an exacerbated day 7 colitis 
conferred by transfer of BMDCs before DSS treatment, characterised by increased 
histological severity score and earlier development of PR bleeding (354). In addition, using a 
CD11c-DTR/GFP mouse to selectively deplete CD11c expressing cells, they identified a 
reduced severity of day 7 colitis characterised by less rectal bleeding and histological 
severity in those mice depleted of CD11c cells. Abe et al. similarly report an ameliorated 
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phenotype of DSS colitis in CD11c depleted animals, also suggesting that colon DC sources 
of IFN-I induced by TLR9 ligands, have an anti-inflammatory role by reducing neutrophil and 
monocyte trafficking (355).  
 
These data suggest a dual role for DCs in pro- and anti- inflammatory modes of action. It has 
been suggested this dual role permits DCs to respond to a variety of biological signals  
(355). However, as described in Chapter 3.4, whilst the terms CD11c+ cells  and DCs have 
previously been used interchangeably, this issue appears to be much more complex (Table 
3.1). It is therefore conceivable that said dual DC  roles in intestinal inflammation are 
actually conveyed by different CD11c+ populations. Therefore to build upon and clarify 
previous work, in this chapter we sought to interrogate the identity of colonic CD11c 
expressing cells during DSS colitis, before determining the impact of restricting Mbd2 
deficiency to defined populations. As published data would support the role of monocytes 
and CD11c expressing cells as key cell types in controlling host response to colonic 




1. Examine the role of haematopoietic sources of Mbd2 in colonic inflammation 
2. Examine the role of Mbd2 in monocytes   
3. Describe the heterogeneity of CD11c+ cells in the colon LP 
4. Examine the role of CD11c sources of Mbd2 in colonic inflammation 
5. Compare the gene expression of colon MPs in Mbd2 deficiency 
















4.2 The role of haematopoietic Mbd2 in colonic inflammation 
To address the role of Mbd2-/- haematopoietic cells in the induction of DSS colitis, bone 
marrow chimeras were generated. Host haematopoietic cells were depleted by exposure of 
mice to lethal doses of radiation, thereafter mice were administered WT or Mbd2-/- BM such 
that haematopoietic cells were selectively rendered Mbd2 sufficient/deficient whilst non-
haematopoietic cells were Mbd2 sufficient. In addition, by using variant CD45 isoforms for 
host or donor chimera components it was possible to discriminate between residual host and 
donor haematopoietic cells by flow cytometry. 
 
Mice expressing the CD45.1 isoform were lethally irradiated and reconstituted with CD45.2 
WT (CD45.1WT) or Mbd2-/- (CD45.1Mbd2-/-), CD90 depleted bone marrow and monitored for 
successful engraftment (See Chapter 2.12). At 8 weeks post irradiation mice were assessed 
for the proportion of host (CD45.1) versus donor (CD45.2) cells in the colon LP.  
 
The frequency of donor CD45.2+ colon LP monocytes, neutrophils, eosinophils and 
macrophages was equivalent between CD45.1WT and CD45.1Mbd2-/- chimeras, with less than 
5% of each total population expressing the host CD45.1 isoform (Table 4.1). As in global 
Mbd2-/- mice, there was a reduced proportion of CD45.2+ CD11b+ CD103+ DCs in 
CD45.1Mbd2-/- chimeras (0.085 versus 0.189% of all intact cells in CD45.1Mbd2-/- versus 
CD45.1WT chimeras) (See Figure 4.1A). In addition the proportion of donor CD45.2+ colon LP 
CD11b- DCs was lower in CD45.1Mbd2-/- chimeras, however the overall number of host and 
donor CD11b- DCs was equivalent i.e. there were significantly greater CD45.1 host CD11b- 
DCs in CD45.1Mbd2-/- versus CD45.1WT chimeras, (79.1 versus 24.9% of all CD11b- CD103+ 
DCs and 83.8 versus 50.1% of all CD11b- CD103- DCs were CD45.2+) (See Figure 4.1B). 
 
These data suggest there is an inherent defect in the development of Mbd2-/- CD11b+ 
CD103+ DCs, and this is not rescued by the presence of Mbd2 sufficient stromal cells. In 
addition, on the presumption that radioresistance of host CD45.1+ cells was equivalent 
across the irradiated mice, the decreased CD45.2Mbd2-/- CD11b- DC populations would 
suggest these cells are being selectively outcompeted by the remnant CD45.1+ host 
populations.  
 
Thus we have observed both dysregulated development and maintenance of mature Mbd2-/- 
DCs in the colon LP. We next sought to assess the role of Mbd2-/- haematopoietic cells 
during colonic inflammation. 
 
Consistent with best practice in our animal facility, mice were treated with the oral 
fluroquinolone antibiotic enrofloxacin from weeks minus 1 to 4 relative to irradiation, to 
minimise the risk of opportunistic infection. Concurrent antibiotic use with DSS has been 
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shown to produce an ameliorated phenotype consistent with the key role of host microbiota 
in this model (356). Similarly pre-administration with antibiotics immediately followed by DSS 
treatment has been shown to increase susceptibility to colonic inflammation in a MYD88 
dependent manner (162). For these reasons, there was a 5-week washout period between 
cessation of the above prophylactic antibiotics and the commencement of DSS to permit 
commensal recolonisation.  
 
CD45.1WT or CD45.1Mbd2-/- chimeras were treated for 8 consecutive days with 2% DSS and 
monitored for weight loss and symptom severity as defined in Chapter 2.3. CD45.1Mbd2-/- 
chimeras lost a significantly greater percentage of starting weight at day 6 (-1.5 versus 
+2.1 1.4%, CD45.1Mbd2-/- versus CD45.1WT chimeras respectively, p=0.04), though there was 
no significant difference seen by day 8 (Figure 4.1C). There was a significantly increased 
symptom score at day 8 in Mbd2-/- donor chimeras (7.3 versus 2.5 1.5, Mbd2-/- versus WT 
respectively) (See Figure 4.1D). Histological assessment of 1cm sections of distal colon 
similarly revealed an increased severity score in Mbd2-/- donor chimeras (10.3 2.2 versus 
4.4 1.2) (Figure 4.1E and F). Taken together, there was a small but significant increased 
susceptibility of CD45.1Mbd2-/- versus CD45.1WT chimeras to DSS colitis. Assessment of the 
cellular composition of the colon LP by flow cytometry similarly revealed subtle differences. 
Firstly, as in the na ve chimeras, there was a significant reduction in the proportion and total 
number of CD45.2+ CD11b+ CD103+ DCs in CD45.1Mbd2-/- chimeras  (Table 4.1). Similarly, 
there was a significant reduction in the proportion of CD45.2+ CD11b- DCs in CD45.1Mbd2-/- 
chimeras (Table 4.1 and Figure 4.1B). 
 
In assessing the remaining colon LP populations, there were no significant differences seen 
in the total number of CD45.2+ eosinophils, monocytes or macrophages (Figure 4.2A and B). 
There was however a significant increase in the total number of CD45.2+ neutrophils in 
CD45.1Mbd2-/- chimeras  (Figure 4.2C and Table 4.1).  
 
Whilst this experiment did not directly compare DSS treated CD45.1Mbd2-/- chimeras to global 
Mbd2-/- (i.e. global Mbd2 deficient animals), CD45.1Mbd2-/- chimeras displayed an increased 
predisposition to DSS mediated inflammation, though less severe than that seen in global 
Mbd2-/- mice (Figure 3.6).  Overall these data support a role for Mbd2 deficient 
haematopoietic lineage cells in controlling the increased predisposition to colonic 
inflammation seen in Mbd2-/- mice and we therefore sought to understand which Mbd2 





4.3 The role of monocytes in the susceptibility of Mbd2-/- to colonic inflammation. 
Based on the work detailed in Chapter 3, we proposed that infiltrating monocytes are the 
principal inflammatory population in the DSS model of colitis. Monocytes are the largest 
changing population by cell number comparing na ve to DSS treated mice, and are 
simultaneously the largest source of IL-1  and TNF (Figure 3.8D and E, Table 3.2). Despite 
equivalent accumulation of monocytes in CD45.1Mbd2-/- versus CD45.1WT DSS treated 
chimeras (Figure 4.2B and Table 4.1), based on the existing literature presented above and 
the results in Chapter 3, we hypothesized a role for Mbd2 in preventing uncontrolled pro-
inflammatory response in tissue monocytes in Mbd2-/- mice. 
 
4.3.1 Blood and colon LP monocyte cytokine response in Mbd2-/- and WT mice 
To assess this, we exposed WT or Mbd2-/- blood monocytes from na ve or DSS treated mice 
to TLR ligands and assessed cytokine response by flow cytometry. Mbd2-/- or WT whole 
blood was cultured with LPS (TLR4 ligand), Pam3Cys (TLR2 ligand) or CpG (TLR9 ligand), 
surface stained with LY6C, CD68 and CD11b and then stained intracellularly for the 
cytokines IL-1 , IL-6, IL-10, IL-12p40 or TNF. 
  
There was no significant difference between Mbd2-/- or WT na ve monocyte (LY6CHigh, 
CD11b+, CD68+) production of IL-1 , IL-6, IL-12p40, IL-10 or TNF in response to any of the 
TLR ligands as defined by the percentage of monocytes staining positive for these cytokines 
by flow cytometry versus isotype controls (See Figure 4.3A, B and Table 4.2). In addition, 
though we observed blood monocytes independent of genotype displayed a significantly 
increased IL-1  and IL-6 response to LPS and Pam3Cys after treatment with DSS (See 
Table 4.2), there was no significant difference between day 6 DSS treated Mbd2-/- or WT 
monocyte production of the assessed cytokines to TLR stimulation (See Table 4.2). These 
data suggest that circulating Mbd2-/- blood monocytes display equivalent production of 
cytokine for a given TLR stimulus, either in the steady state or during colonic inflammation. 
 
We next sought to assess whether Mbd2-/- monocytes on recruitment to the colon LP more 
readily promoted tissue inflammation. Na ve or day 6 DSS treated colon LP cells from WT or 
Mbd2-/- mice were isolated and cultured ex vivo and cytokine production determined by 
intracellular staining and flow cytometry. Monocytes were identified as in Figure 3.2 and 
assessed for IL-1  and TNF expression compared to isotype controls (See Figure 4.3B): 
 
As with blood monocytes, there was no significant difference in IL-1  or TNF production 
between Mbd2-/- or WT na ve colon LP monocytes (30.0 3.84 versus 23.6 4.42% of 
monocytes IL1 +, Mbd2-/- versus WT respectively). Similarly there was no difference in the 
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IL-1 + production between Mbd2-/- or WT DSS treated monocytes (51.8 3.44 versus 
43.8 3.28 % monocytes IL-1 +, Mbd2-/- versus WT respectively) (See Figure 4.3B & Table 
4.2). These data would support the assertion that like TLR ligand stimulated blood 
monocytes, Mbd2-/- colon LP monocytes are not inherently more able than WT to produce 
damaging cytokines. 
 
Additionally, as in the TLR-stimulated blood monocytes, there were interesting differences in 
the effect of treatment on monocyte cytokine response. Both Mbd2-/- and WT DSS treated LP 
monocytes produced significantly more IL-1  and TNF than monocytes from na ve mice of 
the same genotype, again suggesting that priming of circulating monocytes predisposes to 
an enhanced pro-inflammatory tissue phenotype on migration to inflamed mucosal surfaces 
(See Table 4.2).  
 
4.3.2 Gene expression profiles of colon LP monocytes from DSS treated Mbd2-/- and 
WT mice 
Whilst these data suggest equivalent monocyte pathogenicity in the absence of Mbd2, they 
did not assess the putative role of Mbd2 in monocyte migration, recruitment, or indeed IL-
1 /TNF independent pro-inflammatory pathways. To assess whether Mbd2 deficiency 
conferred such dysregulation, we undertook gene expression analyses of purified colon LP 
monocytes. 
 
We hypothesized that Mbd2-/- monocytes might display aberrant gene expression profiles for 
migration, recruitment or pathogen detection that could explain the increased susceptibility of 
Mbd2-/- mice to colonic inflammation. Using the sort logic in Figure 3.5, LY6CHigh MHC-II+ 
cells were purified by flow cytometry to sort colon LP cells from DSS treated Mbd2-/- or WT 
mice. The RNA component of these cells was isolated, purified and its integrity quantitatively 
and qualitatively assessed by spectrophotometry and gel electrophoresis before 
hybridization to an IlluminaMouseRef6 microarray. To ensure sufficient RNA yield, mice 
were pooled, n=2/3 per pool, with 5 biological replicates per genotype (See Figure 4.4A).  
 
Primary raw data were QC analysed using the arrayQualityMetrics Bioconductor package to 
identify sub-standard or outlier gene expression signatures. Arrays were scored on the basis 
of 3 metrics, namely maplot, boxplot and heatmap. Raw data were then transformed using a 
variance stabilizing transformation method prior to normalization using the robust spline 
normalization method. Expression measures were then summarized in log base2 and 
presented as the fold change (logFC), with positive logFC representing up regulation, and a 
negative logFC indicating down-regulation. Statistical analysis was then performed using 
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linear modeling and p value adjustment for multiple testing to control for false discovery 
(adjusted p<0.01 was deemed significant).  
 
In comparing Mbd2-/- relative to WT monocytes; 98 array features were statistically 
significant (57 genes upregulated, 41 downregulated), of which no genes were logFC>2 
(Table 4.3). 12 GO terms were statistically enriched (Table 4.4). Of the 11 upregulated 
genes logFC> 1, the following were selected for further discussion based on putative 
relationship to monocyte function, and analysing the current literature. 
 
4.3.2.1 Genes upregulated in Mbd2-/- monocytes  
Lyz1 (LogFC+1.8) encodes the lysozyme LYZ, which is a potent bacterolytic enzyme present 
in phagolysosomes that displays activity against Gram negative and positive bacteria (357). 
Lysozyme is found upregulated in the inflamed GI tract in conditions such as IBD, coeliac 
disease and collagaenous colitis, is influenced by the microbiota and is postulated in 
enhance mucosal defense against pathogenic bacteria (358), (359), (357).  
 
Apoc1 (LogFC+1.6) encodes the apolipoprotein C1 (APOC1), which plays a pivotal role in 
lipid metabolism and monocyte-macrophage differentiation. Modified lipoproteins such as 
APOC1 are thought to bind scavenger receptors including FCLRS and SCARB1-3, 
facilitating the clearance and uptake of pathogens and apoptotic cells  (360).  
 
Immunoresponsive gene 1 (Irg1, LogFC+1.6) is an LPS-inducible gene encoding a highly 
conserved enzyme that catabolises short chain fatty acids (361). IRG1 localises to 
mitochondria, is rapidly induced within macrophages on bacterial infection and is required by 
mitochondria to use fatty acid substrates in the formation of reactive oxygen species (ROS) 
and thus effective bacteriocidal activity (362).  
 
Reg3b (LogFC+1.4) encodes the REG3b protein (also known as pancreatitis associated 
protein1 (PAP1)), which is overexpressed in patients with active IBD and experimental 
models of colitis (363). It has anti-inflammatory properties, reducing pro-inflammatory 
cytokine release in a dose-dependent manner from epithelial and monocyte cells by 
preventing TNF induced NF-κB activation (363).  
 
C4a (C4a, LogFC+1.5) is an anaphlyatoxin that can trigger smooth muscle contraction, 
increased capillary permeability and chemotaxis of leucocytes in the direction of increasing 
concentration (364). C4b (C4b, LogFC+1.3) covalently binds to pathogen, thereafter forming 
part of the C3-convertase complex, which catalyses the proteolytic cleavage of C3 into C3a 
and C3b and the eventual formation of the membrane attack complex via C5, 6,7,8 (364). 
Serum C4 levels have been found to be increased in patients with active IBD (365).  
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4.3.2.2 Genes downregulated in Mbd2-/- monocytes  
Mucosa-associated lymphoid tissue (MALT) lymphoma translocation protein 1 (MALT1, 
Malt1, LogFC-1.0) is an intracellular NKKb activator provides both anti-apoptotic and 
proliferative signals (366). MALT1 is also a paracaspase which is able to cleave roquin1, 2 
and regnase-1, all of which are able to negatively regulate pro-inflammatory cytokine mRNA 
including Il6, Tnf, Icos and Tnfrsf4 mRNA by reducing their respective half lives (367).  
 
Fcrls LogFC-1.0 
Fc receptor-like S, scavenger receptor (FCRLS, formerly known as macrophage scavenger 
receptor 2 (MSR2)), is a poorly described transmembrane surface protein with scavenger 
receptor (SR) and immunoglobulin domains. FCRLS has been shown to be upregulated on 
the surface of tumour-associated macrophages (TAM), but its precise functional role is 
unknown (368). 
 
The absence of significant genes >2 logFC suggested a paucity of striking differences 
between the WT and Mbd2-/- gene expression. In particular there was no difference in mRNA 
expression for pro-inflammatory cytokines (IL-1 , TNF, IL-6, IL-12, IL-15, IL-18, iNOS, ROS), 
chemokines (CXCL9, CCR1, CCR2, CCR5), pattern recognition receptors (TLR2, 3, 4, 9), or 
adhesion molecules (CD62L, CD11b, ICAM1).  
 
Taken together these data support the assertion that Mbd2-/- monocytes display small 
increases in pro-inflammatory gene signatures such as Reg3b and Lyz1, but - more notably - 
there was a lack of difference in the majority of other regulatory genes that the existing 
literature would suggest could explain the increased susceptibility of Mbd2-/- mice to DSS 
colitis.  
 
4.3.3 Colon LP monocyte proliferation in na ve and DSS treated Mbd2-/- and WT mice 
To address the upregulated cell cycle and metabolic genes seen in Mbd2-/- monocytes from 
KEGG pathway analyses, we sought to address whether there was increased proliferation of 
Mbd2 deficient monocytes in vivo. Ki67 protein is a cellular marker of proliferation, present 
during all active phases of the cell cycle (G1, S, G2 and mitosis), but is absent from resting 
cells (G0). Colon LP cells were isolated from WT and Mbd2-/-, na ve and day 6 DSS treated 
mice, surface stained for the myeloid markers in Figure 3.2 and stained intracellularly for 
Ki67 (Figure 4.4B). The cells were assessed for the proportion of a given population that was 
in active cell cycle as an indicator of proliferation. There was no significant difference in WT 
or Mbd2-/- Ki67 staining in steady state or DSS treated monocytes (Figure 4.4B). Similarly 
monocyte turnover did not increase substantially with DSS treatment, in keeping with our 
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hypothesis that dramatic increases in this population are mediated by rapid recruitment 
rather than increased proliferation of resident colon monocytes (Figure 4.4B).  
 
4.3.4 Mbd2 deficient and sufficient monocytes in the same inflamed tissue site "
generating mixed BM chimeras 
To further address whether there may be a monocyte intrinsic role for Mbd2, we generated 
mixed BM chimeras to permit concurrent analysis of Mbd2-/- and WT monocytes in the 
presence of Mbd2 sufficient non-haematopoietic cells. We surmised this would permit 
simultaneous functional readouts of monocyte recruitment and pro-inflammatory ability, 
whilst controlling for other confounding factors, most notably the degree of colonic 
inflammation between treated mice.  
 
Mice homozygous for the haematopoietic cell surface marker CD45.1 (CD45host) were 
lethally irradiated and reconstituted with equal proportions of WT BM that co-expressed both 
CD45.1 and CD45.2 isoforms (CD45WT) and Mbd2-/- CD45.2+ (CD45Mbd2-/-) BM. Thus 
CD45host, CD45WT and CD45Mbd2-/- haematopoietic cells could be discriminated by flow 
cytometry based upon their expression of CD45.1 and CD45.2. 8weeks post irradiation, the 
blood of chimeric mice was examined to assess reconstitution of adoptively transferred 
CD45WT and CD45Mbd2-/- cells. To our surprise, there was an almost complete absence of 
CD45Mbd2-/- cells (Figure 4.5A). We hypothesized therefore that Mbd2-/- BM displays a 
developmental disadvantage compared to WT.  To address this possibility, we titrated the 
starting proportion of CD45Mbd2-/- BM.  Despite starting with a 9:1 (CD45Mbd2-/-:CD45WT) 
starting BM ratio, at 8 weeks this ratio had reversed to 2:5, consistent with an increased 
differentiation ability of Mbd2 sufficient derived BM cells (Figure 4.5A).  
 
Examination of Mbd2 mediated changes in haematopoietic development is an intriguing 
prospect, but falls outwith the main aims and focus of this project. With this in mind we 
proceeded to treat mixed BM chimeras with a starting ratio of CD45Mbd2-/-:CD45WT of 9:1, with 
2% DSS or normal drinking water for 8 consecutive days.  
 
We observed that in keeping with our previous titration data, Mbd2-/- cells were significantly 
less frequent in all populations and tissues examined, despite the striking starting excess of 
their BM progenitors (Figure 4.5B and Table 4.5). In keeping with previous DSS 
experiments, there was a significant increase in the eosinophil, monocyte and neutrophil 
populations in the colon LP (Figure 4.6A).  
Intriguingly we also observed that DSS treatment had no effect on the proportion of colon LP 
cells that were CD45WT or CD45Mbd2-/- i.e. colonic inflammation did not result in preferential 
recruitment of Mbd2-/- cells, particularly monocytes or neutrophils given their role in tissue 
inflammation (Figure 4.6B).  
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As Mbd2 deficiency did not significantly alter cellular recruitment to the colon, we next 
sought to address whether Mbd2 deficient myeloid cells displayed a more pro-inflammatory 
phenotype.  Ex vivo culture of LPS stimulated blood, or unstimulated colon LP cells was 
undertaken from DSS treated or na ve chimeric mice. Cells were then surface and 
intracellularly stained for flow cytometry markers as described in chapter 4.2. The proportion 
of CD45WT and CD45Mbd2-/- myeloid populations expressing the cytokines IL1- , TNF and IL-
10 (colon LP) or IL-1 , TNF, IL-6 and IL-12p40 (blood monocytes) is summarized in Table 
4.6 and Figure 4.6C. There was no significant affect of genotype for any of the cytokines 
measured in any of the myeloid populations described. We therefore concluded that Mbd2 
deficient blood monocytes and colon LP myeloid cells have the same pro-inflammatory 
ability as WT cells in the steady state or during DSS colitis.  
 
Taken together Mbd2 deficient monocytes have been observed to have equivalent pro-
inflammatory cytokine expression in the blood after TLR challenge and colon LP, in DSS and 
the steady state. This remained true after internally controlling for inflammatory signals and 
local milieu by combining Mbd2 sufficient and deficient monocytes in the same model. We 
hypothesise that increased susceptibility to DSS mediated inflammation in Mbd2-/- mice may 
therefore be secondary to the kinetics of monocyte recruitment, rather than intrinsic 
inflammatory capacity, and is considered further in the discussion.   
  
4.4 The role of Mbd2 in colon LP CD11c+ cells  
Given that genes coordinating response to bacteria and inflammation were increased in 
Mbd2 deficient monocytes (Lyz1, Ido1, Bdkrb1, Table 4.4) and that APCs such as 
macrophages and DCs are critical in coordinating such responses, not only in the steady 
state but also in DSS, we felt these represented attractive candidates for further investigation 
(355), (354). Indeed data presented in Figure 4.1D, E, F and 4.2C suggest an increased 
susceptibility of mice to DSS where Mbd2 is restricted to haematopoietic cells. Given 
CD11c+ cells are derived from bone marrow progenitors, and their development is altered in 
the absence of Mbd2 (Figure 3.4E and 4.1A), we hypothesized these cells may be important 
in explaining the Mbd2-/-  susceptibility to experimental colitis.  
 
As described above (Chapter 4.1), CD11c+ cells may have dual pro- and anti- inflammatory 
roles in DSS colitis, and it is not clear which CD11c+ cells are responsible. In addition Mbd2 
has been recently shown to control expression of molecules that enable CD11c+ cell 
promotion of Th2 immunity, with Mbd2 deficient CD11c+ cells displaying significantly 
impaired Th2 cytokine induction in response to S. mansoni egg Ag (SEA) or house dust mite 
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(HDM) and down regulated transcript of antigen presentation and co-stimulation genes 
(318).  
 
Thus, given that CD11c expressing cells have the ability to exacerbate or ameliorate DSS 
colitis and that Mbd2 controls key immunological pathways in these cells in other models, we 
hypothesized that Mbd2-/- predisposition to DSS colitis may in part due to dysregulated 
coordination of inflammatory responses by Mbd2 deficient CD11c expressing cells (355), 
(354).   
  
4.4.1 Defining CD11c expressing cells in the colon LP 
To address the range of colonic CD11c+ populations, colon LP cells were isolated from na ve 
mice and surface stained with the antibody cocktail described in Figure 3.2. All singlet, 
CD11c+ cells were then identified and gated as per the logic in Figure 3.2, which successfully 
categorized >95% of cells. Figure 4.7 shows the proportional breakdown of all CD11c+ cells 
(Figure 4.7A) and the MFI of the identified contributing cell types (Figure 4.7B). These data 
revealed that macrophages were the most frequent CD11c expressing cell in the colon LP 
(48.0%) followed by DCs (24.9%). However, per cell, macrophages displayed an overall low 
expression of CD11c as measured by mean fluorescent intensity (MFI) (6620 299), in 
contrast to DCs, which displayed the highest overall expression of CD11c (35660 2423 and 
51591 1898 MFI respectively for CD11b+CD103+ and CD11b-CD103+ DCs) (Figure 4.7B). 
Taken together, macrophages and DCs accounted for 94% of CD11c expressing cells in the 
colon LP. It also underlines the caution one must take in interpreting previous data attributing 
the action of CD11c+ cells in the GI tract to DCs alone.  
 
4.4.2 Selective depletion of Mbd2 in CD11c+ cells 
Given the previous literature supporting a role for Mbd2 in CD11c+ cells, and a role for 
CD11c+ cells in DSS colitis, we sought to restrict Mbd2 deficiency to these cells to 
understand their contribution to our DSS Mbd2-/- phenotype. We took advantage of a CD11c-
Cre+ Mbd2Fl/Fl mouse (CD11cΔMbd2), whereby mice with loxP sites flanking the first exon of 
Mbd2 were generated and bred with mice that express Cre recombinase in CD11c 
expressing cells, as previously described (318). To confirm reduction in Mbd2 transcript in 
CD11c+ cells, colon LP cells were sorted as per Figure 3.5 from CD11cΔMbd2 and CD11c-
Cre- littermate controls and Mbd2 expression assessed by RT-PCR (Figure 4.7C). There was 
an 85% reduction in CD11cΔMbd2 macrophage Mbd2 expression, with a 91% and 93% 
reduction in CD11cΔMbd2 CD11b- and CD11b+ DCs respectively. In comparison monocytes, 
which account for 1.5% of CD11c expressing cells had only a 19% reduction in Mbd2 
transcript. There was therefore a selective depletion of between 85-93% of Mbd2 in those 
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cells that account for 73% of CD11c expressing populations in the colon in CD11cΔMbd2 
mice (Figure 4.7A and C).  
 
4.4.3 The role of CD11c+ cell depletion of Mbd2 in the steady state  
CD11cΔMbd2 mice have been shown to have normal splenic DC development (318). To 
ensure that myeloid development was equivalent between CD11cΔMbd2 and CD11c-Cre- 
littermate controls in non-lymphoid tissue sites we assessed colon LP myeloid cells by flow 
cytometry using the antibody cocktail and gating strategy described in Figure 3.2 (Table 4.7). 
There were no significant differences in any of the populations examined. Indeed in contrast 
to global Mbd2-/- mice, which had a reduced proportion of CD45+ and CD11b+CD103+ cells 
(Figure 3.4B and E), these populations were equivalent between CD11cΔMbd2 and CD11c-
Cre- mice (Figure 4.7D). This data would be in keeping with the BM chimera data presented 
above (Figure 4.1A and B) suggesting a role for Mbd2 in DC progenitors. However, given 
CD11c expression occurs later in development, restricting Mbd2 deficiency to CD11c+ cells 
and thus more differentiated cell types, overcomes this dysregulated development.  
 
To ensure CD11c specific depletion of Mbd2 did not affect the normal intestinal structure or 
confer a spontaneous colitis, we examined transverse sections of colon by histology.  This 
revealed no significant differences between CD11cΔMbd2 and CD11c-Cre- na ve littermate 
controls in gross morphology and structure of the colonic epithelium and LP (Figure 4.7E).  
 
4.4.4 The role of CD11c+ cell depletion of Mbd2 in colonic inflammation  
We then sought to test whether CD11c restricted Mbd2 deficiency influenced the 
development of colonic inflammation by feeding CD11cΔMbd2 and CD11c-Cre- littermate 
controls 2% DSS or normal drinking water for 8 consecutive days.  Daily assessment was 
made of weight and symptom score as defined in Table 2.3. There was a significant increase 
in CD11cΔMbd2! versus CD11c-Cre- mean symptom score in DSS treated mice at day 4 
(2.2 0.3 versus 0.0 0), day 5 (3.6 0.6 versus 0.2 0.2), day 6 (4.2 0.6 versus 0 0), day 7 
(4.6 0.6 versus 1.8 0.5) and day 8 (5.4 1.0 versus 2.4 0.6) (Figure 4.8A). This reflected an 
increase in all parameters of the symptom score (PR bleeding, weight loss and diarrhoea) 
and a significantly increased weight loss at day 8 (8.7 1.17% versus 1.8 1.8% least square 
mean change in day 0 weight) in CD11cΔMbd2!versus CD11c-Cre- mice (Figure 4.8B). There 
were no symptoms recorded in untreated mice independent of genotype. 
 
Histological analysis (Table 2.4 for scoring methodology) of 1cm H&E stained sections of 
distal colon revealed a significantly greater tissue architecture destruction, goblet cell 
depletion and inflammatory infiltrate in DSS treated CD11cΔMbd2 versus CD11c-Cre- mice, 
indicative of elevated colonic inflammation (least square mean histology score 13.5 0.9 
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versus 9.8 0.9)(Figure 4.8C and D).  In keeping with this, whole colonic tissue from DSS 
treated CD11cΔMbd2 mice displayed significantly greater mRNA transcript for the 
inflammatory cytokine Ifng (least square mean expression 0.92 0.21 versus 0.12 0.20), but 
not Il1b or Tnf, as analysed by RT-PCR (Figure 4.8E). 
 
Taken together these data suggest CD11c+ cell expression of Mbd2 is required to limit 
colonic inflammation characterised by increased weight loss, symptom and histology score. 
However, in contrast to global Mbd2-/- mice, Il1b and Tnf colon transcript was equivalent in 
WT and CD11cΔMbd2 mice.  
 
4.4.4.1 Comparison of CD11cΔMbd2" and CD11c-Cre- colon LP cells in colonic 
inflammation 
Once again, DSS induced a significant increase in the number of eosinophils, neutrophils 
and monocytes, compared to untreated mice (Table 4.7).  There was an 11.0 fold change in 
the total number of neutrophils in CD11cΔMbd2 mice (7.0 in CD11c-Cre-), 9.4 fold change in 
monocytes in CD11cΔMbd2 mice (6.2 in CD11c-Cre-) and 1.4 fold change in eosinophils in 
CD11cΔMbd2 mice (1.8 in CD11c-Cre-) (Table 4.7) in DSS animals relative to untreated. 
There was, however, no significant difference between genotypes in total numbers of these 
cells present. 
 
Four independent experiments of CD11cΔMbd2 versus CD11c-Cre- DSS treated and 
drinking water control animals were conducted, with notable variation that may have affected 
statistical significance. Two of the four experiments displayed significant experimental 
variation in the proportion of CD45+ cells, but with no effect of genotype, suggesting that 
inter-experimental variation rather than true biological variation was manifest (Figure 4.9A), 
as this was not present in other DSS experiments presented in Chapter 3, 4 and 5. The 
combination of this variation biased the dataset in linear modeling, which limited the 
interpretation of the enumerated total colon population data. To counter this, statistical 
analysis was performed on the data normalized for the variation in CD45 proportions (i.e. by 
expressing proportional data as a % of all CD45+ rather than intact cells).   Once this was 
performed, we observed a significant increase in the proportion of CD11cΔMbd2 colon LP 
monocytes compared to CD11c-Cre- treated controls (8.63 0.72 versus 6.42 0.80 % of 
CD45+ cells) but not neutrophils (6.21 0.66 versus 4.50 0.74 p=0.06) or any other myeloid 
population (Figure 4.9B and C).  
 
By way of contrast to other assessments of Mbd2 deficiency in DSS colitis, CD11cΔMbd2 
had 1.57 fold more colon LP neutrophils and 1.51 fold more colon LP monocytes relative to 
WT after DSS, compared to 1.61 fold and 1.75 fold increases in Mbd2-/- mice and 1.56 fold 
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and 1.20 fold increases in 100% BM chimeras. Thus Mbd2 deficiency in the haematopoietic 
compartment, CD11c+ cells or all cells resulted in a 1.5-1.6 fold greater colon LP neutrophil 
accumulation post DSS, which was significant in all experiments except CD11cΔMbd2 
(p=0.06). However monocyte accumulation was more variable (range of fold increase 1.2-
1.8) and was significant in all experiments except haematopoietic restricted Mbd2 deficiency. 
These different experiments and animals are clearly not directly comparable, but serve as an 
overview of the effect of Mbd2 deficiency when restricted to different cell types. This 
suggested that increased neutrophil accumulation is consistent independent of the cell types 
that lack Mbd2, in those we have examined, and that the greatest increases in monocyte 
recruitment occur when non-haematopoietic cells are deficient in Mbd2 i.e. in Mbd2-/- 
animals 
 
4.4.4.2 The role of Mbd2 in CD11c+ cell cytokine production.  
We had therefore observed that DSS treatment of either CD11cΔMbd2 and CD11c-Cre- 
littermate controls resulted in eosinophil, monocyte and neutrophil accumulation in the colon 
LP and increased gene expression of Il1b, Tnf and Ifng (Figure 4.8E and Figure 4.9B). 
However there was no significant effect of Mbd2 deficiency in CD11c+ cells on the colonic 
gene expression of Il1b or Tnf after DSS treatment (Figure 4.8E). We next sought to 
understand whether, despite equivalent tissue levels of cytokine mRNA, there were changes 
in individual population cytokine expression conferred by CD11c+ cell Mbd2 deficiency.  
 
Colon LP cells from CD11cΔMbd2 and CD11c-Cre- littermate controls treated either with 2% 
DSS or normal drinking water for 8 consecutive days were surface, then intracellularly, 
stained for the myeloid markers and cytokines detailed in Figure 4.9D, then analysed by flow 
cytometry. Following normalisation of the datasets as mentioned above for inter-experiment 
variation in CD45+ proportions, we observed that there were significant increases in IL-1 + 
(1.95 0.34 versus 0.69 0.34 % of CD45+ cells) and TNF+  (1.00 0.10 versus 0.48 0.11 % of 
CD45+ cells) neutrophils and IL-1 + monocytes (4.47 0.63 versus 2.62 0.59 % of CD45+ 
cells) in DSS treated CD11cΔMbd2 mice, when expressed as % CD45+ cells (Figure 4.9D).  
 
Therefore, we have observed that CD11cΔMbd2 mice were more susceptible to DSS colitis, 
characterised by increased weight loss, symptom and histological score, with significant 






4.4.4.3 Gene expression profiles of colon LP CD11c+ cells from DSS treated Mbd2-/- 
and WT mice 
Given that Mbd2 deficiency in CD11c+ cells appeared to have an important role in the 
response to colonic inflammation, we next sought to identify the genes controlled by Mbd2 in 
CD11c+ cells that might be responsible for the increased inflammation observed in global 
Mbd2-/- or CD11cΔMbd2 mice. We therefore isolated colon LP cells from global Mbd2-/- or WT 
DSS treated mice, and purified macrophages and CD11b- DCs, as per the sort logic in 
Figure 3.5.  RNA was isolated from these cells, purified, and its integrity quantitatively and 
qualitatively assessed by spectrophotometry and gel electrophoresis before hybridization to 
an IlluminaMouseRef6 microarray. To ensure sufficient RNA yield, mice were pooled (n=2/3 
for macrophages and n=5 for CD11b- DCs), with 2-5 biological replicates per genotype.  
 
4.4.4.3.1 Colon LP Macrophages 
There were 40 genes logFC > 1 (38 up regulated and 2 down regulated) in day 6 DSS 
treated Mbd2-/- versus WT colon LP macrophages with an adjusted p value <0.05 that were 
considered for further analysis (Table 4.8). Candidate dysregulated genes based on GOterm 
pathway analysis (Table 4.9) and literature review were selected and presented below 
(Figure 4.10A):  
 
Genes upregulated in Mbd2-/- macrophages  
Lyz1 (LogFc +2.1), Irg1 (LogFc +1.7), Reg3b (LogFc +1.3) and Reg3g (LogFc +1.2) see 
entry in Chapter 4.3.2  
 
IL-1  (Il1a LogFc +1.8) and IL-1 , are the major IL-1 agonists and have been long 
recognised as integral components of innate immune processes (369). IL-1 expression 
corresponds to disease activity in the colons of IBD patients (370), (371).  
 
Transforming growth factor (TGF)- 1 has a decisive role in limiting inflammatory pathways, 
with IBD patients displaying defective downstream TGF-β signaling (372), (373). TGF- 1 
causes expression of TGF-β-induced (TGFBI, Tgfbi LogFc +1.5) which is produced by 
macrophages in response to apoptotic cell ingestion, leading to reduced fibroblast MMP 
levels and subsequent accumulation of collagen, thought to be pivotal in the resolution 
process post-inflammation (374).  
 
Indoleamine 2,3 dioxygenase (IDO1, Ido1 LogFc +1.1) catabolises tryptophan along the 
kynurenine pathway (375). Kynurenine metabolites act to promote T cell tolerance and exert 
antimicrobial effects that are attributed to IDO1 activity. IDO1 expression is stimulated by 
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TNF, IFN-  and IL-1  and is one of the most highly upregulated genes in human IBD and 
animal models of colitis (376), (377).  
 
Genes downregulated in Mbd2-/- macrophages  
Fcrls (LogFc -1.6) see entry in Chapter 4.3.2 
 
Resistin-like molecule (RELM)  (Retnla LogFc -1.1) belongs to a family of secreted 
mammalian proteins with immunomodulatory properties and is upregulated in several 
infectious and inflammatory settings (378), (379). RELM-  administration promotes immune 
cell activation, pro-inflammatory chemokine and cytokine expression in DSS treated mice, 
with reduced IL-23p19 expression from RELM-  deficient macrophages thought to 
exacerbate colitis (380).  
 
Triggering receptor expressed on myeloid cells (TREM-2, Trem2 LogFc -0.99) is a surface 
receptor found on macrophages, DCs and microglia that binds motifs on bacteria and yeasts 
(381). TREM-2 is expressed at higher levels on CD11c+ LP cells isolated from patients with 
active IBD and mice with experimental colitis versus controls suggesting myeloid sources of 
TREM-2 are important in regulating inflammation (382). 
 
4.4.4.3.2 Colon LP CD11b- DCs 
There were 26 genes with logFC >1 (10 upregulated and 16 down regulated) in day 6 DSS 
treated Mbd2-/- versus WT colon LP CD11b- DCs with an adjusted p value <0.05 that were 
considered for further analysis (Table 4.10). Candidate dysregulated genes based on 
pathway analysis (Table 4.11) and literature review were selected and presented below. In 
addition, both significant and pertinent non-significant genes (genes that have previously 
been published to be important in DC responses in inflammation) are presented in heat 
maps of average expression in Figure 4.10B  
 
In total 370 (180 up, 182 down) genes were significantly affected irrespective of fold change, 
it was clear that the absolute difference for the majority of significantly dysregulated genes in 
CD11b- DCs was small. Indeed the mean LogFC for upregulated and downregulated genes 
was 0.41 (median 0.38), suggesting that there are a large number of small effect size 
dysregulated genes in Mbd2-/- CD11b- DCs. Thus significant genes with LogFc>0.5 were 
considered for analysis of candidiate genes. 
 
Given the analysis was limited by the presence of n=2 biological replicates for WT and n=3 
for Mbd2-/- due the rarity of these cells in the LP (aprox. 0.1% of total cells), it is possible that 
a larger sample size may have produced more differentially expressed genes. To investigate 
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the possibility of low sample number excluding genes with large fold changes that did not 
reach significance; the statistical threshold was relaxed to an adjusted p value of 0.1. 
However this did not further the number of candidate dysregulated genes with known 
immunological function.  
 
Genes upregulated in Mbd2-/- CD11b- DCs 
Reg3b (LogFc 0.94) See entry in Chapter 4.3.2 
 
Complement protein C1q (C1qb LogFc 0.75) is able to bind apoptotic cells, opsonizing and 
increasing their removal by phagocytes. Deficiency in C1Q is the strongest genetic predictor 
of systemic lupus erythematosis (SLE) in humans, thought to be due to persistence of 
apoptotic cells contributing to autoimmunity (383). In addition DCs are important cellular 
sources of C1q, its release acting in autocrine fashion to increase DC induction of Th1 cells 
(384), (385).  
 
Genes downregulated in Mbd2-/- CD11b- DCs  
CD103 (Itgae LogFc-1.5) expression defines DC populations that exhibit roles in co-
ordinating effector and Treg responses (386). The function of CD103 is poorly understood, 
thought to facilitate cellular adhesion via its ligand E-cadherin, expressed on the basolateral 
surface of epithelial cells, and affecting cell shape and motility to promote cellular attachment 
(387).  
 
Janus kinase-2 (JAK2, Jak2 LogFc -0.97) is an important component of the IL-12 and IL-23 
signaling pathway (388). Subsequent phosphorylation steps of STAT 1,3,4,5 eventually lead 
to STAT4 mediated changes in gene expression, particularly Th17 differentiation (389). 
Polymorphisms in JAK2 and other components of the IL-23 signaling pathway (IL23R, IL12 
and STAT3) have been identified as risk susceptibility loci for both CD and UC (308).  
 
Leucine-rich repeat kinase 2 (LRRK2, Lrrk2 LogFc -0.7) is large protein with 2 distinct 
enzymatic domains, although the precise physiological function is unknown (390). LRRK2 is 
known to associate with autophagy proteins p62 and LC3, is expressed preferentially by LP 
leucocytes, is found to be upregulated in inflamed CD colonic biopsy specimens, with 
LRRK2-deficient mice been shown to have poorer outcomes in response to DSS (391), 
(392), (393). 
 
4.4.4.3.3 Summary of dysregulated gene expression in Mbd2 deficient CD11c+ cells 
Taken together, colon LP Mbd2 deficient macrophages in DSS colitis displayed differentially 
expressed genes that would be hypothesised to dampen damaging inflammation, with 
increased expression of anti-inflammatory mediators (Il1a, Tgfbi, Reg3b, Reg3g) and 
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decreased pro-inflammatory response mechanisms (Retnla, Trem2, Ido1). However, in 
keeping with the dual role of GI tract macrophages, bacteriocidal pathways are also 
upregulated in Mbd2 deficiency (Lyz1, Irg1) consistent with previous literature supporting 
combined tolerogenic and pro-inflammatory capabilities (51), (43). An unexpected finding 
was the reduction of the scavenger receptor FCLRS. This poorly described scavenger 
receptor has no previous documented function in macrophage function. However given 
deficiency in other scavenger receptors, notably MSR1 confers up to a 50% reduction in 
macrophage phagocytic ability, one would hypothesise other scavenger receptor 
dysregulation could confer altered bacterial handling abilities, resulting in pathogen 
persistence. 
 
As can be seen in principal component analysis (Figure 4.10C), whilst displaying a number 
of significantly dysregulated genes, the effect size of each individual gene in the CD11b- 
analysis was small with few candidate genes with known or hypothesised function logFC 
> 1 between genotypes. As such, the overall gene expression differences conferred by 
Mbd2 deficiency in CD11b- DCs was low. Given that DC-dogma would suggest these cells 
have a dominant role in antigen presentation to the adaptive immune system, and that DSS 
colitis is considered a T cell independent model, it is perhaps unsurprising that these cells do 
not appear to be the dominant Mbd2 deficient cell type conferring increased susceptibility to 
acute colonic inflammation. 
 
Given the above gene expression changes in Mbd2 deficient macrophages, particularly in 
bacterial handling, and previous data underlining the importance of different TLRs in 
macrophage function (51), we sought to consolidate TLR expression data taken from the 
above dataset with detected levels of TLRs ex vivo using flow cytometry.  
 
4.4.5 Assessment of MP cell TLR expression in vivo 
Intestinal macrophages occupy a unique niche in the GI tract by demonstrating an anergy to 
TLR ligands incumbent to their tolerogenic phenotype and role in negating damaging host 
response to the commensal microbiota (51). We thus considered whether PRR and, in 
particular, TLRs were dysregulated in Mbd2-/- MP cells that might contribute to the increased 
myeloid inflammatory response in experimental colitis. Colon LP cells from Mbd2-/- or WT 
DSS treated (Figure 4.11A) or control mice were isolated and analysed by flow cytometry for 
TLR 2,3,4 and 9. In keeping with published data, colon monocytes were overwhelmingly 
positive for TLR2, 4 and 9, with macrophages demonstrating lower levels for these 
receptors, in both naïve and DSS treated settings (51) (Figure 4.11A). There were however 
no significant differences between Mbd2-/- and WT MP either in the steady state or in DSS 
colitis for TLRs as assessed by gene expression for TLR transcript or by flow cytometry for 
detected protein. Indeed the significant changes in TLR 2 and TLR4 protein seen between 
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monocytes and macrophage populations independent of genotype were not reflected in 
significant change in Tlr2/Tlr4 gene transcript.  
 
4.4.6 Assessment of MP cell co-stimulatory molecule expression in vivo 
CD40 is a 48kDa transmembrane glycoprotein that is a member of the TNF receptor 
superfamily (TNFRSF) (394). CD40 signaling in APCs induces upregulation of MHC II and 
co-stimulatory molecules CD80/CD86, and is used to distinguish between inactivated and 
activated DCs the end result leading to production of cytokines such as IL-12p40 and IL-6. 
Indeed Cd40-/- mice or WT mice treated with a CD40-CD40L inhibitor, treated with DSS 
develop attenuated colitis compared to controls, characterized by a reduction in colon 
leucocyte recruitment.  We therefore looked to assess whether Mbd2 deficiency in colon LP 
APCs conferred an increased surface expression of the cell markers (Table 4.12). 
Interestingly, in keeping with the increased level of inflammation seen in Mbd2-/- DSS treated 
mice, all Mbd2 deficient colon LP MP cells examined displayed significantly greater CD40 
expression as assessed by MFI (Table 4.12). In addition, all Mbd2 deficient colon LP MP 
cells, except CD11b- CD103+ DCs, displayed significantly greater CD40 expression in the 
steady state. However there was once again a discrepancy between gene expression and 
observed protein, in that Cd40 differences were not significant in colon LP macrophages and 
CD11b- DCs between Mbd2-/- and WT DSS treated mice.  
 
To understand whether increased CD40 on CD11c+ cells was dependent on Mbd2 deficiency 
in these cells alone, we performed the above analysis of CD40 expression on CD11cΔMbd2 
colon LP cells and controls (Table 4.12). Interestingly in the absence of other Mbd2 deficient 
cell types, the increased CD40 expression was abrogated. This suggested that non-CD11c+ 















In chapter 4 we have identified the importance of haematopoetic Mbd2 in controlling 
susceptibility to colonic inflammation. We have built upon the work in Chapter 3 that 
demonstrated a marked susceptibility of Mbd2-/- mice to chemical and infectious colitis. In 
order to refine our understanding of the cellular sources of Mbd2 that were important in 
producing this observation, we sought to restrict Mbd2 to specific populations.  
 
4.5.1 Haematopoietic sources of Mbd2 and susceptibility to intestinal inflammation 
Firstly, using single BM chimeras, we restricted Mbd2 deficiency to haematopoetic cells and 
observed an increased susceptibility of these mice to DSS colitis. This was characterised by 
increased weight loss, symptom score histological severity score and neutrophil 
accumulation in the colon LP. There was a less severe phenotype in these DSS treated 
chimeric mice compared to Mbd2-/- animals (Weight loss 6.1 3.0 versus 16.32 1.2 % 
change in starting weight, histology score 10.3 2.2 versus 14.6! 3.6, CD45.1Mbd2-/- chimeric 
versus Mbd2-/- day 6 DSS treated mice respectively). Clearly to control for inter-experimental 
variation both these animals should be synchronously exposed to DSS and monitored for 
treatment effect.  Unfortunately, there were no DSS treated global Mbd2-/- mice or global 
Mbd2-/- irradiated host/Mbd2-/- BM reconstituted, control components to this experiment. This 
was considered in the experimental design as it would have served as a comparison for the 
severity of the phenotype observed in the chimeric mice, and in addition would have 
controlled for the effect of irradiation and antibiotic treatment on inflammation severity. 
However, as noted in Table 2.1 Mbd2-/- mice are maintained as a heterozygous line due to 
poor breeding, with a less than Mendelian yield of Mbd2-/- offspring. This meant the requisite 
number of Mbd2-/- mice for Mbd2-/- recipient chimeric controls was prohibitively large to 
undertake this experiment. 
 
Consistent with best practice in our animal facility, mice were treated with the oral 
fluroquinolone antibiotic enrofloxacin from weeks minus 1 to 4 relative to irradiation, to 
minimise the risk of opportunistic infection in the bone marrow reconstitution period. 
Concurrent antibiotic use with DSS has been shown to increase severity of inflammation, 
consistent with the key role of host commensal microbiota in limiting disease severity in this 
model (356). Similarly pre-administration with antibiotics immediately followed by DSS 
treatment has been shown to increase susceptibility to colonic inflammation in a MYD88 
dependent manner (162). For these reasons, there was a 5-week washout period between 
cessation of the above prophylactic antibiotics and the commencement of DSS to permit 
commensal recolonisation.  
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One must be mindful that in the process of generating these chimeric animals, they have 
undergone a) lethal irradiation and b) broad-spectrum antimicrobial treatment, which one 
could argue may have irrevocably altered their subsequent response to inflammatory 
challenge. For example 10-12Gy murine irradiation results in extensive p53 mediated crypt 
shortening, followed by a burst of proliferation in remaining cells and increased MHC-I and –
II expression (395), (396). Whether this perturbation affects future response to, or handling 
of, the commensal microbiota is not well described. Whilst this experiment was not designed 
to compare DSS treated CD45.1Mbd2-/- chimeras versus Mbd2-/- animals, and accepting the 
other above limitations, whilst we have observed an increased pre-disposition of CD45.1Mbd2-
/- chimeras to DSS mediated inflammation, this did not recapitulate the severe phenotype 
seen in Mbd2-/- mice.  Overall these data support a partial role for Mbd2 deficient 
haematopoietic lineage cells in controlling the increased predisposition to colonic 
inflammation seen in global Mbd2-/- mice, but highlight that non-haematopoietic sources of 
Mbd2 may also confer increased susceptibility.  
 
We therefore sought to understand in Chapter 4 the haematopoietic sources of Mbd2 that 
could be important. There is strong literature support for a dominant role of monocytes in the 
pathogenesis in the DSS model (47), (43). We therefore hypothesised that Mbd2 was acting 
in WT mice to limit damaging monocyte driven inflammation, and thus explain the increased 
susceptibility of CD45.1Mbd2-/- BM chimeras to DSS colitis described in Figure 4.1 and 4.2.  
 
4.5.2 The role of Mbd2 in monocytes  
Mbd2 deficient blood or colon LP monocytes from Mbd2-/- DSS treated or na ve mice 
demonstrated equivalent levels of pro-inflammatory cytokines when cultured ex vivo in 
isolation (colon) or with TLR ligands (blood). Interestingly, DSS treatment conferred 
increased IL-1β and IL-6 production from TLR stimulated blood monocytes independent of 
genotype. Whilst it is known that monocyte recruitment is in part CCL2/CCR2 dependent, 
and may depend on type-1 IFN and TLR dependent egress of monocytes from bone 
marrow, activation signals to circulating monocytes are poorly understood (397), (47).  
These data suggest that blood monocytes may receive currently undefined pro-inflammatory 
priming signals from distant inflamed tissue sites; perhaps to permit rapid response either 
locally e.g. to disseminated septiceamia, or once successfully migrated to sites of 
inflammation. Indeed it has recently been shown that monocytes may be pre-emptively 
educated during development based on their micro-environment to promote tissue specific 
function; during acute gastrointestinal infection with T. gondii NK cell derived IFN-γ promoted 
a regulatory program in monocyte progenitors that occurred before bone marrow egress or 
systemic inflammation (398).  
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In addition we undertook gene expression profiling of purified DSS treated colon LP 
monocytes to further understand Mbd2 mediated changes in other monocyte-inflammatory 
pathways such as recruitment, pattern recognition and bacterial handling (Figure 4.4A and 
4.10C).  
  
4.5.2.1 Key differences in Mbd2 deficient monocyte gene expression during DSS 
Lyz1 (Lyz1 LogFC +1.8) encodes a lysozyme enzyme, which is a bacterolytic enzyme 
present in phagolysosomes that displays activity against gram negative and positive bacteria 
(357). Indeed lysozyme was discovered by Alexander Fleming in 1921 during a search for 
medical antibiotics, functioning by damaging bacterial cell walls via hydrolysis of 
peptidoglycan residues (399). Lysozyme is found upregulated in the inflamed GI tract in 
conditions such as IBD, coeliac disease and collagaenous colitis, suggesting that the 
bacterial flora plays an important role in its expression (358), (359). Indeed lysozyme 
production is increased in patients with active colonic IBD, increases postulated to provide 
enhanced mucosal protection against proliferating pathogenic bacteria (357). Increased LYZ 
presence in Mbd2-/- monocytes could therefore be postulated to be a compensatory 
mechanism to the increased inflammation mediated microbial burden seen in Mbd2-/- DSS 
treated mice. To test this hypothesis future work could encompass measuring serum 
lysozyme before and during the induction of colitis to ascertain the kinetics of its expression 
(serum lysozyme has been shown to be a biomarker for monocyte/macrophage activity in 
rheumatoid arthritis) (400), or indeed we could purify monocytes using FACS during colitis 
from our mixed BM chimera mice and compare Lyz1 expression i.e. we would have Mbd2 
deficient and sufficient monocytes from the same inflammatory system. Lastly, to ensure that 
Mbd2 does not affect post-transcriptional modification of Lyz1 to render it less efficient at 
cleaving bacterial proteins (with compensatory increased levels of expression in Mbd2 
deficient cells) we could assess LYZ1 structure and function in Mbd2 deficient and sufficient 
monocytes.  
 
Apoc1 (Apoc1 LogFC +1.6) encodes the apolipoprotein C1 (APOC1), which plays a pivotal 
role in lipid metabolism and monocyte-macrophage differentiation, and was significantly 
upregulated in Mbd2-/- monocytes. Apolipoprotein functions in metabolic processes have 
consistently been found to be one of the most upregulated pathways in the macrophage 
differentiation process, and this is mirrored in our dataset (401). Modified lipoproteins such 
as APOC1 are thought to bind scavenger receptors including FCLRS and SCARB1-3, 
facilitating their function consistent with the role of macrophages in avid clearance and 
uptake of pathogens and apoptotic cells (360). The presence of upregulated metabolic and 
cell cycle pathways in Mbd2-/- monocytes could be hypothesised to suggest an increased 
ability to traverse the macrophage differentiation 'waterfall' via increases in turnover and 
proliferation. It could also be hypothesised that Mbd2-/- monocytes are recruited earlier to 
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inflamed tissue sites and that, at a given time point, Mbd2-/- monocytes may be at a later 
differentiation stage than WT counterparts. 
 
Identified as an LPS-inducible gene in macrophages, immunoresponsive gene 1 (Irg1) (Irg1 
LogFC +1.6) encodes a highly conserved enzyme which catabolises short chain fatty acids 
(361). IRG1 localises to mitochondria, is rapidly induced within macrophages on bacterial 
infection and is required by mitochondria to use fatty acid substrates in the formation of 
reactive oxygen species (ROS) and thus effective bacteriocidal activity (362). Irg1 therefore 
represents a key component of the immunometabolic axis connecting infection, macrophage 
function and the increased lipid metabolic pathways seen in monocyte-macrophage 
differentiation (402). The presence of upregulated Irg1 in Mbd2-/- monocytes would be 
consistent with the hypothesis of increased DSS mediated colonic inflammation, barrier 
breakdown and thus bacterial infiltration seen in Mbd2-/- mice.  
 
The Reg protein family is a group of small secretory proteins classified within the lectin super 
family (403). REG3B (also known as pancreatitis associated protein1 (PAP1)) (Reg3b 
LogFC +1.4), is overexpressed in intestinal tissues during inflammation and is found at 
elevated levels in patients with active IBD and in experimental models of colitis (363). It is 
believed to have anti-inflammatory properties, reducing pro-inflammatory cytokine release in 
a dose-dependent manner from epithelial and monocyte cells in part by preventing TNF 
induced NF-κB activation (363). Similarly, serum REG3B levels in IBD patients correlate with 
clinical and endoscopic assessment of disease severity (404). Thus one could hypothesise 
that elevated monocyte Reg3b levels in Mbd2-/- monocytes may reflect a compensatory anti-
inflammatory control mechanism to counter the vigorous colonic inflammation seen in Mbd2-
/- mice. To test this hypothesis, we could assess the level of Reg3b expression in steady 
state WT and Mbd2-/- monocytes, to confirm that Mbd2 deficient monocytes are not pre-
programmed to have anti-inflammatory tendencies. Similarly a time-course of Reg3b 
monocyte expression, or serum REG3B during DSS colitis might help confirm the dynamics 
of inflammation v compensatory mechanisms in the absence of Mbd2.  
 
Complement component C4 is a large glycoprotein that serves as a opsonin and anchor for 
the proteases of the classical and lectin complement pathways (364). C4a (C4a LogFC +1.5) 
is an anaphlyatoxin that can trigger smooth muscle contraction, increased capillary 
permeability and chemotaxis of leucocytes in the direction of increasing concentration (364). 
C4b (C4b LogFC +1.3) covalently binds to pathogens, thereafter forming part of the C3-
convertase complex, which catalyses the proteolytic cleavage of C3 into C3a and C3b and 
the eventual formation of the membrane attack complex via C5, 6,7,8 (364). Serum C4 
levels are increased in patients with active IBD (365). Increased Mbd2-/- monocyte C4 
expression would be in keeping with increased complement mediated binding to infiltrating 
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pathogens or commensals to control and contain bacterial invasion in a DSS-induced 
barrier-deficient environment. To test the hypothesis that Mbd2 deficient monocytes have the 
same ability to use complement to control invading pathogens, and that increased monocyte 
C4a and C4b in these cells is secondary to an increased bacterial exposure, we propose to 
culture naïve Mbd2 deficient and sufficient monocytes with a known concentration of luminal 
commensals from WT or Mbd2-/- mice and assess C4a/b expression. This would also have 
the benefit of comparing whether the composition of Mbd2-/- intestinal commensals have an 
increased pro-inflammatory effect on the innate immune system compared to WT microbiota.    
 
Mucosa-associated lymphoid tissue (MALT) (Malt LogFC-1.0) lymphoma translocation 
protein 1 (MALT1) is an intracellular NF-κB activator that is involved in human MALT 
lymphoma tumorigenesis via constitutive NF-κB activation (366). This constitutive activation 
induced by translocation provides both anti-apoptotic and proliferative signals. MALT1 is also 
a paracaspase which is able to cleave roquin1,2 and regnase-1, all of which are able to 
negatively regulate pro-inflammatory cytokine mRNA including Il6, Tnf, Icos and Tnfrsf4 by 
reducing their respective half lives (367). In addition Malt1-/- mice are resistant to 
experimentally induced autoimmune encephalitis (405). Thus the reduced Malt1 expression 
seen in Mbd2-/- monocytes would be hypothesised to reduce NF-κB activation and 
expression of pro-inflammatory mediators, consistent with an anti-inflammatory control 
mechanism to counter the vigorous inflammatory environment seen in Mbd2-/- DSS mediated 
colonic inflammation. We therefore hypothesise that Mbd2-/- mice have an earlier onset of 
inflammation during DSS colitis than WT mice. This would be supported by the data in 
Figure 3.6B and C which show an increased weight loss and symptom score from day4. To 
pursue this in more depth however, we propose to measure monocyte Malt1 expression 
earlier in the disease model, and would hypothesise that expression in Mbd2 deficient cells 
is greater at earlier time points compared to WT to permit a robust response to invading 
pathogens, before being switched off in an attempt to limit pathological, damaging 
inflammation.  
 
Fc receptor-like S, scavenger receptor (FCRLS, formerly known as macrophage scavenger 
receptor 2 (MSR2)) (Fclrs LogFC-1.0), is a poorly described transmembrane surface protein 
with scavenger receptor (SR) and immunoglobulin domains. FCRLS has been shown to be 
upregulated on the surface of tumour associated macrophages (TAM), but its precise 
functional role is unknown (368). The SR family however has been shown to have diverse 
roles, including in the innate immune response, cellular adhesion and phagocytosis of 
apoptotic cells, in addition to lipid uptake. MSR1 is the best-described scavenger receptor, 
with critical roles in phagocytosis and bacterial clearance (406). MSR1 and FCLRS share the 
same Cys-rich scavenger receptor domain (smart00202). MSR1 deficient mice are more 
susceptible to intraperitoneal infection with S. aureus, poorly clearing bacteria from the site 
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of infection and eventually succumbing to disseminated sepsis (407). Similarly MSR1 
deficient macrophages are unable to effectively phagocytose gram positive bacteria despite 
normal phagocytosis machinery (407). Monocytes are generally thought to play a limited role 
in phagocytosis, though clearly downregulation of SR in Mbd2-/- macrophage intermediaries 
could be hypothesised to decrease bacterial clearance, propagating inflammatory response. 
To test this hypothesis, we propose to assess the ability of Mbd2 deficient monocytes to 
phagocytose pathogen in comparison to WT. For example, we could assess the monocyte 
uptake of phRodo E. Coli bioparticles by flow cytometry, which fluoresce after uptake into 
phagolysosomes.  
 
However, as suggested by the absence of significant genes that were logFC>2 there were 
not striking differences between the datasets. In particular there was no significant difference 
in the expression of pro-inflammatory cytokines (IL-1β, TNF, IL-6, IL-12, IL-15, IL-18, iNOS, 
ROS), chemokines (CXCL9, CCR1, CCR2, CCR5), pattern recognition receptors (TLR2, 3, 
4, 9), or adhesion molecules (CD62L, CD11b, ICAM1). 
 
4.5.2.2 The role of Mbd2 in monocytes using mixed BM chimeras 
Given the increased severity of inflammation seen in the Mbd2-/- mice and upregulated 
bacteriocidal pathways seen in Mbd2 deficient monocytes, we sought to control for inter-
mouse variation in inflammation by combining Mbd2 deficient/sufficient monocytes within the 
same organism, using mixed BM chimeras. Once again this demonstrated equivalent pro-
inflammatory cytokine producing abilities irrespective of Mbd2 sufficiency or deficiency. 
Clearly we cannot exclude the possibility that Mbd2 sufficient cells, particularly residual 
radio-resistant host cells or WT transferred cells, in these mixed BM chimeras were 
modulating Mbd2 deficient cell types, particularly monocytes, to an ameliorated phenotype. 
To explore this possibility we would seek in future work to perform non-chimeric experiments 
to test the role of Mbd2 in monocytes. This would overcome the issue, albeit low, of 
radioresistant cells and could include the use of monoclonal antibodies to deplete monocytes 
in vivo during intestinal inflammation to address the relative contribution of Mbd2 versus WT 
monocytes in driving inflammation. Similarly we could purify monocytes from WT or Mbd2-/- 
mice and administer them to WT mice during DSS mediated inflammation to address if Mbd2 
deficient monocytes are delivered into a system that lacks any other Mbd2 deficient cell 
types, they can mediate increased susceptibility to colitis. Lastly if administration of WT or 
Mbd2-/- monocytes is performed at different time points one could discern whether a critical 
mass of inflammation is required early in the DSS time course that results in the inherent 
control mechanisms, or ‘brakes’ on the inflammatory cascade being irrevocably removed, 
and thus explain why anti-inflammatory genes are upregulated in Mbd2 deficient 
macrophages (Figure 4.10A).   
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One of the most striking findings derived from the production of mixed BM chimeras, was the 
out competition of Mbd2-/- BM by WT in producing differentiated progeny 8weeks post re-
constitution. Epigenetic changes are crucial in haematopoiesis as they regulate the 
successive gene expression programmes that give rise to all immune cell populations (408). 
Investigation into the participation of epigenetic events in haematopoiesis has revealed that 
both DNA and histone modifications are important in this process (408). For instance, the 
ablation of Hdac1 and Hdac2 in mouse bone marrow progenitor cells impedes the 
development of erythrocytes and megakaryocytes (409). In addition mice with reduced 
DNMT1 activity have a myeloerythroid bias, unable to develop lymphoid progeny (410). 
Given that Mbd2-/- mice display comparable development of terminally differentiated 
haematopoietic cells compared to WT in steady state tissues, it is conceivable that Mbd2 
deficiency renders the differentiation of HSC into myeloid progenitors less efficient, such that 
they are outcompeted in the presence of Mbd2 sufficient stem cells. To test this hypothesis 
we could raise short interfering RNAs (siRNAs) to MBD2 mRNA, and expose HSC from WT 
mice in vitro to MBD2 siRNA or control, assessing for effect on HSC development in 
particular the ability to generate differentiated progeny. We could interrogate this further by 
adding siRNA at defined time points to ascertain at what point in the differentiation pathway 
MBD2 is exerting its effects.  
 
Gene expression analysis of Mbd2-/- monocytes isolated from the site of inflammation 
revealed a subtly more pro-inflammatory signature, with increased expression of 
bacteriocidal genes (C4a, Irg1, Lyz1) and compensatory promotion of anti-inflammatory 
pathways (Reg3b, Malt1). This initially appeared counter-intuitive, that anti-inflammatory 
pathways were upregulated in the presence of a marked pro-inflammatory environment. We 
concluded therefore that the kinetics of inflammatory gene expression were important in this 
model, whereby had we sampled monocytes earlier in inflammation e.g. day 3, the dominant 
pathway may have been a pro-inflammatory, pro-antigen response mediated mechanism, 
and that compensatory anti-inflammatory genes are only expressed later in disease course 
(Diagram 4.1).  
 
We also observed that a monocyte maturation marker (ApoC1) associated with macrophage 
differentiation was increased in Mbd2 deficient monocytes, though this was not associated 
with changes in monocyte proliferation. Indeed monocyte egress to the inflamed colon was 
equivalent when both Mbd2-/- and WT populations were present in the same model. We 
therefore suggest that colon LP monocyte recruitment is a marker of the increased 
inflammatory burden in DSS colitis, and hypothesise that other Mbd2 deficient cell types in 






4.5.3 The role of Mbd2 in CD11c expressing cells 
Given the known role of CD11c expressing cells in DSS colitis, and Mbd2 in DC function, we 
sought to understand the role of Mbd2 expression in CD11c+ cells during colonic 
inflammation (355), (354), (318). First, we confirmed the relative abundance and composition 
of CD11c expressing cells, noting that >75% of this population was composed of 
macrophages and DC subsets (Figure 4.7A). Second, we confirmed that in a Cre-flox 
system of CD11c specific Mbd2 deletion, transcript levels from purified colon LP myeloid 
subsets demonstrated appropriate knock down in CD11c expressing cells to over 85% 
compared to CD11c-Cre- controls.  Interestingly we did not see a reduced number of CD11b+ 
CD103+ DCs in CD11c+ cell deletion of Mbd2. Referring to our early hypothesis in Chapter 
3.11 of 2 possible hypotheses for intestinal specific depletion of Mbd2 deficient CD11b+ 
CD103+ DCs; 1) that Mbd2 is required for appropriate DC development that occurs after pre-
cDC differentiation or 2) that Mbd2 is required for surivival and/or conditioning of resident 
CD11b+ CD103+ DCs in the intestine, we can now refine this hypothesis. Namely appropriate 
development of CD11b+ CD103+ DCs in CD11cΔMbd2 but not chimeric or Mbd2-/- animals 
would suggest it is less likely that Mbd2 is intrinsically required as a survival factor in CD11b+ 
CD103+ DCs. It is perhaps more likely that Mbd2 deficiency in other haematopoietic cells is 
required for impaired CD11b+ CD103+ DC development in chimeric or Mbd2-/- mice, or indeed 
that Mbd2 is required for appropriate development after pre-cDC differentiation but before 
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Proposed kinetics of pro- and anti- inflammatory pathways in DSS coltiis
To explain the increased pro- and anti- inflammatory pathways in Day6 DSS treated 
Mbd2-/- versus WT mice we propose the above hypothetical response to intestinal inflam-
mation. We suggest that pro-inflammatory response is earlier and greater in Mbd2-/- mice, 
expemplifed by greater weight loss at earlier time points in the disease model (Figure 
3.4). This triggers anti-inflammatory control mechanisms at an earlier stage in Mbd2-/- 
mice after reaching tissue limits for physiological infammation. Thus at our observed time 




We then observed that CD11c restricted deficiency in Mbd2 resulted in an increased 
susceptibility to DSS mediated colonic inflammation, characterised by increased weight loss, 
symptom and histology scores, neutrophil and monocyte accumulation with an increased 
proportion of TNF+ neutrophils and IL-1 /TNF+ monocytes. Gene expression analyses of the 
2 largest CD11c expressing colon LP populations (macrophages and CD11b- DCs) revealed 
macrophage Mbd2 deficiency conferred increased expression of bacteriocidal, pro-
inflammatory and anti-inflammatory genes consistent with an ability of these cells to have 
dual roles in tolerance and pathogen response (Figure 4.10A and Table 4.8).  
 
4.5.3.1 Key differences in Mbd2 deficient macrophage gene expression during DSS 
The IL-1 family consists of eleven proteins, which are further organised into 3 subfamilies. 
IL-1α and IL-1β are the major IL-1 agonists and have been long recognised as integral 
components of innate immune processes (369). As such they are implicated in the 
pathogenesis of several inflammatory diseases, with high levels of IL-1 expression 
corresponding to disease activity in the colons of IBD patients (370), (371). There are 3 
approved IL-1 axis blocking treatments in clinical trials. Anakinra, an IL-1R anatagonist 
blocking IL-1α/β activity, Rilonacept, a soluble IL-1-decoy receptor and Canakinumab, a 
neutralising monoclonal anti-IL-1β antibody (411). IL-1α (Il1a LogFC+1.8) is a preformed 
intracellular precursor that can translocate to the nucleus upon inflammatory stimuli to 
control gene expression, proliferation and differentiation (369). Bersudsky et al. have 
recently reported the importance of IL-1α in exacerbating colonic inflammation as mice with 
global (Il1a-/-) or epithelial specific (Villin-Cre+ Il1afl/fl) removal of IL-1α displayed a less severe 
epithelial driven response to DSS (412). However the same study reported IL-1α co-staining 
with MPO+ cells in acute colitis and notably WT BM transplanted into Il1a-/- irradiated mice 
had the same severity of colitis as WT BM transplanted into WT mice, suggesting a 
conflicting role for IL-1α sources, that includes haematopoietic cells.  
 
Indoleamine 2,3 dioxygenase (IDO1) (Ido1 LogFC+1.1) is the first and rate-limiting step in 
tryptophan catabolism along the kynurenine pathway (375). Kynurenine metabolites act to 
promote T cell tolerance and exert antimicrobial effects that are attributed to IDO1 activity. In 
the steady state GI tract expression of IDO1 is low and occurs predominately within LP cells 
(413). IDO1 expression is stimulated by TNF, IFN-γ and IL-1β and is one of the most highly 
upregulated genes in human IBD and animal models of colitis (376), (377). GI tract APCs, 
notably CD103+ DCs, have been shown to demonstrate potent, IDO1 dependent 
suppressive effects on T cell proliferation mediated by Treg induction and by limiting 
Th1/Th17 differentiation (414). Indeed Ido1-/- exhibit greater colitis in a model of graft versus 
host disease, with TLR7/8 agonist mediated increases in APC sources of IDO1, limiting 
colon injury in the same model (415). Thus one would hypothesise increased Ido1 
expression from Mbd2 deficient macrophages is another mechanism for limiting intestinal 
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inflammation in Mbd2-/- colitic mice. To test this hypothesis, we propose culturing day6 Mbd2 
deficient and sufficient macrophages with naïve T cells, to confirm that increased Mbd2 
deficient macrophage sources of Ido1 can inhibit T cell proliferation, particularly the 
development of Th1/Th17 cells. In addition we propose an assessment of colon LP 
macrophages sources of Ido1 in Mbd2 deficient and sufficient animals earlier in the DSS 
inflammation model, to confirm that Ido1 is switched on earlier in Mbd2-/- to mirror earlier 
onset of inflammation, rather than constitutive activation.  
 
Resistin-like molecule (RELM) α (Retnla LogFC-1.1) belongs to a family of secreted 
mammalian proteins with putative immunomodulatory properties (416). RELM-α is 
upregulated in several infectious and inflammatory settings including helminth infection, 
allergic airway inflammation and colitis (378), (379). RELM-α administration promotes 
immune cell activation, pro-inflammatory chemokine and cytokine expression in DSS treated 
mice (379).  In addition, Retnla-/- mice demonstrate less severe DSS and C. rodentium 
induced colonic pathology that has been suggested to be a result of reduced IL-23p19 
expression from RELM-α deficient macrophages (380). Taken together, reduced expression 
of Retnla by Mbd2-/- macrophages in the context of severe intestinal inflammation would be 
hypothesised as a limiting mechanism to further damaging inflammation.  To test this 
hypothesis, as discussed above we could once again assess for expression of Retnla during 
the induction of intestinal inflammation, to confirm increased levels in Mbd2-/- earlier in the 
proposed pure pro-inflammatory stage of disease. Similarly to confirm that decreased pro-
inflammatory response in Mbd2 deficient macrophages is indeed a secondary response 
rather than a constitutive one, we propose to purify naïve colon LP macrophages from Mbd2-
/- and WT mice, culturing them ex vivo with bacterial products to confirm or refute an 
equivalent ability to uptake, process and respond to antigenic challenge.  
 
Triggering receptor expressed on myeloid cells (TREM-2) (Trem2 LogFC-0.99) is a surface 
receptor found on macrophages, DCs and microglia that binds motifs on bacteria and yeasts 
(417), (381). TREM-2 is expressed at higher levels on CD11c+ LP cells isolated from patients 
with active IBD and mice with experimental colitis versus controls suggesting myeloid 
sources of TREM-2 are important in regulating inflammation (382). Indeed Trem2-/- are 
protected from DSS colitis with Trem2 deficient CD11c+ cells demonstrating reduced pro-
inflammatory cytokine production, bacterial killing and T cell activation abilities (382). In 
addition administration of a TREM-1 agonist ameliorates DSS colitis and decreases TNF, IL-
6 and IL-1β production from CD11c+ cultured cells (418). However it has also been shown 
that TREM-2 blockade with mAb impairs apoptosis in microglial cells via a reduced 
interaction with TREM-2 ligands on apoptotic neurons leading to reduced neuronal healing 
(419). Similarly Trem2-/- display reduced wound healing, epithelial proliferation and increased 
M1 macrophage infiltrate (420). It is similarly not understood why increased expression of 
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TREM2 is found in IBD patients if it is indeed a pro-inflammatory mediator. To explore the 
role of TREM2 in DSS colitis further therefore, we would propose to use TREM-2 mAb to 
block TREM-2 downstream effects in WT mice in acute and chronic models of DSS colitis, to 
confirm firstly the results of Correale et al. in ameliorating acute colitis, and thereafter in the 
chronic phase of DSS ingestion its putative role in intestinal wound healing (382).  
 
4.5.3.2 Increased pro- and anti- inflammatory pathways in DSS colitis, possible 
explanations and relation to the literature 
The combination again of both pro- and anti-inflammatory gene dysregulation led us to 
speculate that in the context of severe disease pathology in Mbd2-/- DSS treated mice that a 
complex feedback mechanism may exist (Diagram 4.1). Reduced Mbd2-/- Retnla and Trem2 
macrophage expression for example would be expected to result in ameliorated macrophage 
response by limiting pro-inflammatory cytokine secretion, however increased Il1a should 
favour an increasing inflammation response by promoting further cytokine release. We 
speculate this dichotomous response likely represents a compensatory mechanism to limit 
overwhelming inflammation that is secondary to altered kinetics of immune response in 
Mbd2-/- mice. We suggest that due to an earlier onset of inflammation, precipitated perhaps 
by increased barrier dysfunction to DSS, that the role of pro-inflammatory mediators such as 
Retnla occurs at an earlier timepoint, and this reverses once the inflammatory response 
exceeds a given level and itself becomes pathological. Indeed initial inflammatory response 
is a necessary physiological response to protect the host, a response that must be mitigated 
by resolution of inflammation using anti-inflammatory and pro-resolution pathways (421). 
Inability to resolve inflammation is thought to be one of the key drivers for critical illness, the 
leading cause for admission to intensive care units, irrespective of the initial cause for 
inflammation (422), (423), (421).  Decision fates after acute inflammation depend on 
appropriate class switch of pro-inflammatory eicosanoid mediators such as leukotriene B4 to 
pro-resolution lipid mediators such as lipoxins, resolvins and protectins that promote a return 
to homeostasis versus chronic inflammatory response (424). We therefore consider 3 
different explanations: that increased pro- and anti- inflammatory gene expression in Mbd2 
deficient populations represents an ongoing exposure to the initial inflammatory insult 
mediated by 1) an inability to appropriately clear the influx of antigenic commensals or 2) 
because the initial inflammatory insult is much greater and more rapidly converted from local 
to systemic inflammation due to a primary defect in appropriate host response, namely 
defects in barrier function or lastly 3) that this imbalance represents a failure of pro-
resolution mediators to overcome the level of inflammation in Mbd2-/-  mice that favour a 
chronic inflammatory state.  
 
Interestingly, a novel gene (Fclrs) with scavenger receptor domains not previously known to 
be important in macrophage function was significantly down regulated, in Mbd2 deficient 
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macrophages suggesting Mbd2 may promote bacterial uptake and/or processing by colon 
LP macrophages that may also explain the increased susceptibility of CD11cΔMbd2!mice to 
DSS colitis. To test this hypothesis we would need to perform assays of phagocytosis and/or 
bacterial persistence and this may form the basis of future work. As mentioned above, we 
would propose to investigate this via assays of phagocytosis, pinocytosis and macro-
pinocytosis using E. coli bioparticles, FITC and DQ-OVA labelled beads in ex vivo culture of 
naïve and DSS treated Mbd2 versus WT colon LP macrophages.  
 
Taken together, colon LP Mbd2 deficient macrophages in DSS colitis displayed differentially 
expressed genes that would be hypothesised to dampen damaging inflammation, with 
increased expression of anti-inflammatory mediators (Il1a, Tgfbi, Reg3b, Reg3g) and 
decreased pro-inflammatory response mechanisms (Retnla, Trem2, Ido1). However, in 
keeping with the dual role of GI tract macrophages, bacteriocidal pathways were also 
upregulated in Mbd2 deficiency (Lyz1, Irg1) consistent with previous literature supporting 
combined tolerogenic and pro-inflammatory capabilities (51). An unexpected finding was the 
reduction of the scavenger receptor Fclrs. This poorly described scavenger receptor has no 
previous documented function in macrophage function. However given deficiency in other 
scavenger receptors, notably MSR1 confers up to a 50% reduction in macrophage 
phagocytic ability, one would hypothesise other scavenger receptor dysregulation could 
confer altered bacterial handling abilities, resulting in pathogen persistence. 
 
4.5.3.3 Key differences in Mbd2 deficient CD11b- DC gene expression during DSS 
Janus kinase-2 (JAK2) (Jak2 LogFC-0.97) is an important component of the IL-12 and IL-23 
signaling pathway (388). It is thought to bind to membrane bound IL-23R and IL-12Rβ2 
components in response to the p35 and p19 subunits of IL-12 and IL-23 respectively (388). 
Subsequent phosphorylation steps of STAT 1,3,4,5 eventually lead to STAT4 mediated 
changes in gene expression, particularly Th17 differentiation (389). Polymorphisms in JAK2 
and other components of the IL-23 signaling pathway (Il23r, Il12 and Stat3) have been 
identified as risk susceptibility loci for both CD and UC (308). Whilst it is not understood how 
these loci confer their increased risk in man, it has been shown that IL-23 production from 
murine LP CD11b+ DCs induces production of the antimicrobial peptide REG3G in an IL-22 
dependent manner, suggesting that aberrant IL-23 signaling may impair barrier function 
(346). However IL-23 has also been suggested to have a pro-inflammatory role in innate and 
T cell models of colitis.  Administration of anti-IL-23p19 treatment reduced pathology in a H. 
hepaticus model of intestinal inflammation and, similarly, mice incapable of producing p19 
were less susceptible to a well-established T-cell dependent model of colitis, with ROR-γt+ 
ILC3 suggested as the IL-23 responsive pro-inflammatory cell mediating this effect (96), 
(195). Aberrant IL-23 signaling in Mbd2-/- CD11b- DCs could therefore be hypothesised to 
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confer pro- or anti-inflammatory changes based on Th17 differentiation, ILC function or 
epithelial production of antimicrobial peptides.  
 
Leucine-rich repeat kinase 2 (LRRK2) (Lrkk2 LogFC-0.70) is large protein (2527 amino 
acids), with 2 distinct enzymatic domains, although its precise physiological function is 
unknown (390). It has been identified as a risk susceptibility locus for CD, leprosy and is the 
most common genetic cause for familial and sporadic Parkinsons disease (425). Alterations 
in autophagy have been proposed as potential pathogenic mechanisms in all 3 disorders 
(425). LRRK2 is known to associate with autophagy proteins p62 and LC3, is expressed 
preferentially by LP leucocytes, and is found to be upregulated in inflamed CD colonic biopsy 
specimens, with LRRK2-deficient mice been shown to have poorer outcomes in response to 
DSS (391), (392).  Other autophagy genes have been identified as IBD-susceptibility loci 
(ATG16L1, IRGM and NOD2) with macroautophagy of intracellular microbes hypothesised to 
be one of the defining features of CD (308). Thus dysregulated Lrrk2 mediated autophagy in 
Mbd2-/- CD11b- DCs would be hypothesised to perpetuate intracellular pathogens, potentially 
prompting cell death and further inflammatory response. To test this hypothesis, we could 
induce and compare autophagy in naïve ex vivo Mbd2-/- or WT colon LP CD11b- DCs by 
exerting a state of starvation.  By culturing in nutrient rich medium versus control, and using 
immunohistochemistry assessing induction of LC3 or p62, or scanning electron microscopy 
to detect autophagosomes. Lastly we could cross our existing Mbd2-/- mouse with a GFP 
labelled LC3 transgenic mouse, which would permit the direct visualisation of LC3 in a range 
of colon LP cell types ex vivo without the need to perform FACS to purify cells in advance.  
 
4.5.3.4 Activation of CD11c+ cells in Mbd2 deficiency 
The data presented in Table 4.12 suggested that Mbd2 deficient DCs and macrophages 
displayed higher levels of surface CD40 in DSS colitis and also in the steady state. In 
addition levels of CD80 on all DSS treated colon LP MP cells (except CD11b- CD103+ DCs), 
and in naïve macrophages / CD11b+ CD103+ DCs were higher in Mbd2 deficiency. We 
hypothesise that increased levels of APC CD40 in the steady state and inflamed colon would 
promote pro-inflammatory cytokines release (such as IL-12p40 and IL-6) and further 
leucocyte recruitment (426). Given that CD40/CD80 levels were equivalent to controls in 
CD11c+ cell specific Mbd2 deficiency, this would suggest that non-CD11c+ cell sources of 
Mbd2 are required to increase MP activation phenotype (Table 4.12). IECs have a well 
documented role in antigen presentation to LP APCs, therefore we hypothesise IEC sources 
of Mbd2 may alter the ability of IECs to process and present luminal / dietary antigens to 
colon LP cells, thereby altering their activation and function.  
 
To test this hypothesis, and further address whether increased CD40 in Mbd2 deficient cells 
is a primary (i.e. intrinsic to CD11c+ cells) or secondary (e.g. a byproduct of a more inflamed 
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microenvironment) phenomenon, we could use the CD40-CD40L inhibitor trapidil in naïve 
and DSS treated Mbd2-/- and WT mice. We would propose to assess the response to 
inflammation (e.g. weight loss, pathology score, inflammatory cell recruitment) and function 
of Mbd2 deficient CD11c+ cells (e.g. cytokine release, antigen processing and migration 
capabilities) in a system where CD40 signaling is impaired. Finally we would restrict Mbd2 
deficiency to IECs by generating a VillinCreΔMbd2 mouse, assessing the activation of colon 
LP MPs in the steady state and experimental colitis, thereby addressing a non-CD11c 
source of Mbd2 that might be expected to alter DC/macrophage function.  
 
4.5.4 Caveats to array data and proposed future genomic work 
Whilst microarray data has the advantage of hypothesis-free testing to limit investigator bias 
in understanding the role of key gene expression changes, there are clearly limitations to the 
interpretation of this data. For example, validation of the observed changes in gene 
expression should be performed by correlation to expression assessed by qPCR and then 
continue with assays to measure changes in protein. Similarly it is possible that in the 
analysis of the above array data, we have overlooked important gene expression changes 
due to a) limitation of sensitivity of the array process compared to other techniques, for 
example qPCR and b) an assumption that meaningful changes in cell biology are 
underwritten by large changes in fold expression. This is exemplified by the data presented 
in Figure 4.11, whereby significant differences in protein levels (CD40 and CD80) assessed 
by flow cytometry between Mbd2-/- and controls was not observed in gene expression. This 
underlines the importance of future work to correlate the observed changes in gene/protein 
by analysis of both in tandem, in addition to assessments of post-translational protein 
modification. 
 
Similarly we would look to address the possibility that mRNA alterations do not account for 
the entire phenotype we have observed. For example we have not measured changes in 
miRNAs, non-coding RNAs or pre-stored proteins, all of which may exert an important effect 
on the biology of intestinal inflammation that we have not addressed in these experiments 
thus far. There is an arbitrary limit of fold change that is set by individual investigators being 
deemed as biologically significant, however there is no accepted value for what this level 
might be, underlining the difficulties scientists face in ascribing biological and statistical 
significance. It is similarly conceivable that a multitude of small, yet statistically significant 
changes in a repertoire of key immune-regulatory genes confer together a profound 
biological effect that investigators may overlook by focusing simply on large quantitative 
rather than functional changes in expression.  
 
As can be seen in principal component analysis (Figure 4.10C), whilst displaying a number 
of significantly dysregulated genes, the effect size of each individual gene was small with no 
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candidate genes with known or hypothesised function logFC > 1 between genotypes. As 
such, the overall gene expression differences conferred by Mbd2 deficiency in CD11b- DCs 
was low. Given that DC-dogma would suggest these cells have a dominant role in antigen 
presentation to the adaptive immune system, and that DSS colitis is considered a T cell 
independent model, it is perhaps unsurprising that these cells do not appear to be the 
dominant Mbd2 deficient cell type conferring increased susceptibility to acute colonic 
inflammation. 
 
As noted above, given the rarity of these cell types, it is possible that increasing the number 
of biological replicates would have increased sensitivity of detecting dysregulated genes. 
Similarly, due to the technical limitations of small numbers of the other DC subsets post 
isolation, we have only purified and assessed mRNA expression in CD11b- DCs. Thus, in 
combination with the macrophage data, we have performed expression analysis on 
approximately 65% of CD11c expressing cells, and cannot exclude that the remaining DC 
subsets are the most dysregulated in the absence of Mbd2. Adopting a different 
methodology that is less reliant on cell yield to permit analysis, e.g. single-cell RNAseq or 
laser capture dissection, would be an attractive method to address this. Given the variety of 
antigenic stimuli to APC in the GI tract, it is likely that a single isolated cell may not be 
representative of the entire population, despite recent advances in phenotyping by flow 
cytometry. Indeed a recent review of single cell sequencing technology suggest that 
“hundreds or thousands” of single cells must be analysed so that all representative cell types 
may be observed (427).   
 
RNA-seq offers many additional benefits compared to arrays. For example they permit the 
unbiased detection of novel transcripts. RNA-seq technology does not require species or 
transcript specific probes. It can therefore detect novel transcripts, gene fusions, SNP 
variants and other previously unknown changes that arrays cannot detect, based on their 
reliance on existing probes. There is also a broader dynamic range with RNA-seq 
technology. Array hybridization technology means that gene expression measurement is 
limited by background at the low end and signal saturation at the high end of expression. 
Lastly sequencing coverage depth is increased to detect rare transcripts or weakly 
expressed genes.  
 
It should also be noted that the gene expression analyses were performed from purified 
populations from global Mbd2-/-, not CD11cΔMbd2!mice. Thus whilst we may hypothesise 
the same culprit genes may be dysregulated in both strains, it is possible that Mbd2 
deficiency in other cell types in the global Mbd2-/- mice modulates the mRNA expression 
profiles observed. Quantitative RT-PCR validation of key dysregulated genes identified from 
the global Mbd2-/- microarrays in purified macrophages and DCs from the CD11cΔMbd2!
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mice would be helpful to address this. Taking this a step further, we propose that an 
unselected microarray of all colon LP cells taken at day 0 and day 6 would be helpful in 
discerning the overall balance of gene expression in Mbd2-/- and WT mice. This would also 
have the added benefit of allowing analysis between our existing purified populations and 
the whole tissue, to delineate overlapping and distinct areas of mRNA expression to better 




Diagram 4.2 Proposed mechanisms for Mbd2 mediated changes in haematopoietic 





































































































In the work detailed in this thesis, we have made several interesting observations regarding 
haematopoetic development and Mbd2 deficiency. In Chapter 3 we observed a decrease in 
the abundance of CD11b+CD103+ DCs. In Chapter 4 we similarly observed a decrease in 
this population when Mbd2 deficiency was limited to haematopoetic cells but, in addition, 
CD11b- DCs were found at reduced number when WT radioresistant host cells were present. 
We suggest that whilst CD11b- DCs develop normally in Mbd2-/- mice they are vigorously 
outcompeted when WT counterparts are present, which we speculate is unlikely due to 
intrinsic survival defects given normal levels of differentiated cell types in Mbd2-/- mice, but 
due to defective development from less differentiated progenitors. In support of this, 
CD11cΔMbd2mice showed equivalent proportions and numbers of fully differentiated DCs to 
WT mice, suggesting Mbd2 mediated affects on DC development occur in less differentiated 
precursors. CD11c expression occurs in differentiated DCs, but also in MHC-II- pre-DC 
precursors, but not common lymphoid or myeloid precursor cells. Pre-DCs are a population 
of DC committed precursors present in mouse blood that can fully reconstitute the CD8-, 
CD8+ and plasmacytoid B220+ DC subpopulations after transfer into irradiated recipients 
(428). This would argue that Mbd2 mediated changes in DC differentiation occur at early 
stages of development before CD11c expression occurs, perhaps at the common precursor 
stage.   
 
The most striking changes in DC development, however, were evident in the generation of 
mixed BM chimeras. We observed that equal starting proportions of WT and Mbd2-/- donor 
BM resulted in an absence of Mbd2-/- cells 8 weeks after reconstitution. It was necessary to 
titrate the starting proportion of Mbd2-/- BM to a nine fold excess to overcome this. Despite 
this starting excess, at 8 weeks post reconstitution this ratio had reversed such that WT 
differentiated cells were more now abundant than Mbd2-/- by more than two fold. Given 
starting viability of BM cells was equivalent between genotypes, we hypothesise that Mbd2 
deficiency renders HSC less able to enter lineage specific differentiation pathways, 
particularly given the importance of other epigenetic mechanisms notably in controlling 
differentiation dependent transcription factor function.  
 
Whilst we have used the literature to guide the identification and interrogation of candidate 
haematopoietic cell types important in colonic inflammation it was not possible to analyse all 
cell types. It is therefore possible that there is a role for Mbd2 in regulating additional cell 
types, for example neutrophil, eosinophil or ILC function that we have not accounted for. 
Future work will therefore include the analysis of dysregulated genes identified above in 
monocytes/macrophages and DCs by qPCR, in other purified cell types including eosinophils 
and neutrophils. Similarly the use of in vivo depleting antibodies (such as anti-Ly6G for 
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neutrophil depletion) could be employed to assess the role of other Mbd2 expressing 
populations.  
 
Taken together we have observed an increased susceptibility to colonic inflammation 
conferred by deficiency of Mbd2 in haematopoietic cells. The existing literature would 
support a role for monocytes as a pro-inflammatory cell type in colitis and were thus targeted 
for a role for Mbd2. Whilst colon monocytes isolated for colitic Mbd2-/- mice displayed 
increased expression of some genes involved in inflammatory response (Irg1, Ido1, C2, 
C4a/b) the majority of gene expression was similar between genotypes. Indeed we then 
have shown that Mbd2 deficient monocytes do not possess a more pro-inflammatory 
phenotype compared to Mbd2 sufficient monocytes when present in the same inflamed 
colon using mixed BM chimeras. We therefore suggest that per cell pro-inflammatory 
capacities of monocytes are equivalent independent of Mbd2 deficiency, and that increased 
tissue numbers of these cell types represent a readout rather than primary cause of 
increased DSS mediated colonic inflammation in Mbd2-/-  mice.   
 
Overall we therefore propose a model where Mbd2 mediated changes in gene expression in 
CD11c expressing cells predisposes to pathological inflammation that exceeds local control 
mechanisms in DSS colitis (Diagram 4.2). Candidate gene targets identified by gene 
expression analysis of CD11c+ cells isolated from Mbd2-/- mice suggest predominately 
increased pro- but also some anti- inflammatory processes the balance of which ultimately 
favours increasing monocyte and neutrophil recruitment.  Given that haematopoietic 
restriction of Mbd2 expression did not appear to recapitulate the phenotype of Mbd2-/- 
response to DSS, and the intriguing observation that non-CD11c+ cellular sources of Mbd2 
are required to increase MP activation phenotype, we proposed to investigate further non-
haematopoietic souces of Mbd2 in colonic inflammation. 
 
Given the suggestion from our chimera data that non-haematopoetic sources of Mbd2 may 
confer a significant burden of disease susceptibility of Mbd2-/- mice to colonic inflammation, 
particularly given the pathogenesis of DSS thought primarily due to breakdown of barrier 
integrity, we hypothesised that epithelial sources of Mbd2 may also have an important role in 








Figure 4.1 Susceptibility of CD45.1WT versus CD45.1Mbd2-/- chimeras to DSS colitis
BM chimeras were generated by lethally irradiating CD45.1 congenic mice before reconstituion with either CD45.2+ 
Mbd2-/- (CD45.1Mbd2-/-) or CD45.2+ WT (CD45.1WT) CD90 depleted BM. Chimeras recieved 2% DSS b/w in drinking water 
or normal drinking water for 8 consecutive days. Colon LP cells were isolated and surface stained for the following 
antibodies; CD11b, CD45.1, CD45.2, CD11c, CD103, Ly6G, Ly6C, MHC-II, SiglecF, CD64 and analysed by flow cytome-
try as described in Figure 3.2. CD45.2+, CD11c+, Ly6G-, SigelcF- gated cells are presented (A) comparing DSS treated 
CD45.1WT and CD45.1Mbd2-/- chimeras and B CD11b-, CD11c+, F480-, Ly6G- and SiglecF- DC showing the CD45.2+ (i.e. 
donor) proportion of each CD103 subset. Proportion of  C. Least square mean day 8 weight change of DSS treated and 
naive control, CD45.1WT and CD45.1Mbd2-/-mice as a percentage of starting body weight, n=1-8 analysed by linear regres-
sion modelling of 2 separate experiments. D. Mean symptom score per day over the duration of DSS treatment. Cumula-
tive score as per Table 2.3 of weight loss (0-4), diarrhoea (0-4) and per rectal bleeding (0-4). n=4 per group, representa-
tive of 2 independent experiments E. H&E stained transverse sections of distal CD45.1WT and CD45.1Mbd2-/-DSS treated 
colon, x10 magnification. F. Least square mean±SEM blinded histology score of inflammation of (E), as per Table 2.4, 
comprising inflammatory cell infiltrate (0-4, +0.5 per ulcer), Goblet cell depletion (0-4, +0.5 per crypt abscess), Muscosal 
thickening (0-4), submucosal cell infiltration (0-4) and architecture destruction (0-4), n=8 per group analysed by linear 
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Figure 4.2 Colon LP Flow Cytometry analysis of DSS treated CD45.1WT versus CD45.1Mbd2-/- chimeras
BM chimeras were generated by lethally irradiating CD45.1 congenic mice before reconstituion with either CD45.2+ 
Mbd2-/- (CD45.1Mbd2-/-) or CD45.2+ WT (CD45.1WT) CD90 depleted BM. Chimeras recieved 2% DSS b/w in drinking water 
or normal drinking water for 8 consecutive days. Colon LP cells were isolated and surface stained for the following 
antibodies; CD11b, CD45, CD11c, CD103, Ly6G, Ly6C, MHC-II, SiglecF, CD64 and analysed by flow cytometry as 
described in Figure 3.2. The least square mean total number of cells x106 per colon is presented for the populations (A) 
n=1-8 per group, analysed by linear regression of 2 independent experiments. B. Representative flow cytometry contour 
plots in Day8 DSS treated CD45.1WTand CD45.1Mbd2-/- mice for neutrophil and monocyte populations as defined in Figure 





























































































































































































Figure 4.3 Flow cytometry idenitification of cytokine producing colon LP and blood monocytes 
A. The cellular component of murine blood was isolated from naive WT mice and analsyed for the expression of the 
following by flow cytometry; Live Dead Blue, Ly6C, Lineage (NK1.1,CD19,CD3,Ter119,B220), CD11b and CD68.Rep-
resentative contour plots display the following sequential geting logic to identify blood monocytes; Live, Singlet cells, 
SSC/FSC-A low ‘intact’ cells, Lin- CD11b+, CD68+ CD11b+, Ly6CHi CD11b+ B. Representative contour plots (left) of 
colon LP cells and blood isolated from Day6 DSS treated WT or littermate Mbd2-/- mice and analysed for by flow cytom-
etry for the above markers (blood) or CD11b, CD45, CD11c, CD103, Ly6G, Ly6C, MHC-II, SiglecF, CD64 (colon LP) 
in addition to intracellular IL-1β staining. Cells were stimulated ex vivo for 3 hours with 1ug/ml LPS and GolgiStop 
1ul/ml(blood) or GolgiStop 1ul/ml alone (colon LP),  (right) least mean square proportion of IL-1β+ monocytes analysed 
by linear regression n=12-16 per group, 3 independent experiments. 
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Figure 4.4 Gene expression analysis of DSS treated WT versus Mbd2-/- colon LP monocytes 
Colon LP cells from Day 6 2% DSS treated Mbd2-/- or littermate WT mice were isolated. A. Heat map of normalised 
gene expression from FACS purified WT or Mbd2-/-, Ly6C+ MHC-II+/- monocytes. Each group is comprised of 5 biologi-
cal replicates, n=2-3 mice pooled per bioligical replicate. Significant (adj p<0.01) genes presented (left, gene names 
in bold) with other selected non-significant genes (right). B. Representative flow cytometry contour plots and corre-
sponding bar chart detailing proportion of colon LP Mbd2-/- or WT monocytes idenitifed as CD11b+ CD11c-, Ly6G-, 
SiglecF-, Ly6C+ MHC+/-  expressing Ki67 compared to isotype control. representative data from 2 independent experi-
ments.   










































































































































Figure 4.5 Reconstitution of CD45.2+ WT / 
Mbd2-/- mixed BM chimeras 
A. Representative flow cytometry countour 
plots showing relative proportions of CD45.1
+
 
WT or  CD45.2
+
 Mbd2-/- cells prior to transfer 
into irradiated mice (left) or at week 8 post 
reconstitution using 1:1 (centre) or 9:1 (right) 
starting ratio of donor BM. Representative data 
from 2 independent experiments B. Represent-
ative flow cytometry plots of Day 7 DSS treated 
colon LP cells isolated from mixed BM chimeras 
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phils and SiglecF+ SSC-Hi eosinophils. Repre-






Figure 4.6 Flow Cytometry analysis of DSS treated CD45.2+ WT /  Mbd2-/- mixed BM chimeras
Mixed BM chimeras were generated by lethally irradiating CD45.1+ CD45.2- (host) mice and reconstituted with CD45.1+ 
CD45.2+ (WT) and CD45.1- CD45.2+ (Mbd2-/-) BM. Chimeras were treated for 7 consecutive days with 2% DSS or normal 
drinking water with colon LP and blood cells isolated for analysis by flow cytometry. Cells were stained with the following 
antibodies (CD11b, CD45.1, CD45.2, CD11c, CD103, Ly6G, Ly6C, MHC-II, SiglecF and CD64) The least square mean 
total number of cells x106 per colon is presented for the populations outlined in Figure 3.2 (A). B. Least mean square 
proportion of colon LP monocytes (left) and neutrophils (right) identified as host, WT or Mbd2-/- C. Representative flow 
cytometry contour plots of colon LP and blood CD45.2+ monocytes displaying CD45.1+ (Mbd2-/-) or CD45.1- (WT) cells. 
Cells were cultured for 4 hours with 1ul/ml GolgiStop and 1ug/ml LPS (blood only) surface stained as above and in addi-
tion stained intraceullarly for IL-1β. The least square mean proprotion compared to isotype control of IL-1β+ colon LP or 























































































































Figure 4.7 CD11c expressing populations in the Colon LP and naive phenotyping in CD11cΔMbd2 mice
Colon LP cells were isolated from WT mice and assessed by flow cytometry. Live, intact cells, CD11c+ cells were subdi-
vided into populations based on the surface expression and gating strategy outlines in Figure 3.2. Populations were then 
expressed as the proportion of all CD11c+ cells (A), or by their MFI of CD11c (B). C. Colon LP cells from WT or CD11cΔ
Mbd2 mice were FACS purified based on the sort logic in Figure 3.5, RNA was extracted and  gene expression of Mbd2 
quantified by RT-qPCR normalised to GAPDH, n=5 per group analysed by linear regression of 3 independent experi-
ments (Primer sequences in Table 2.5). D. Colon LP cells from WT or CD11cΔMbd2 mice were isolated and surface 
stained for the following antibodies (CD11b, CD45, CD11c, CD103, Ly6G, Ly6C, MHC-II, SiglecF and CD64), the propor-
tion of CD11b+ CD103+ cells as a proprotion of all DCs is presented, representative of 3 independent experiments. E. 




















































Figure 4.8 Susceptibility of CD11cΔMbd2  mice to DSS colitis
CD11cΔ or littermate WT mice recieved 2% DSS b/w in drinking water or normal drinking water for 8 consecutive days 
A. Mean symptom score per day over the duration of DSS treatment. Cumulative score as per Table 2.3 of weight loss 
(0-4), diarrhoea (0-4) and per rectal bleeding (0-4). n=4 per group, representative of 4 independent experiments B. Least 
square mean day 8 weight change of DSS treated and naive control, WT and CD11cΔMbd2 mice as a percentage of 
starting body weight, n=15-20 analysed by linear regression modelling of 3 separate experiments. C. H&E stained trans-
verse sections of distal WT or CD11cΔMbd2 DSS treated colon, x10 magnification. D. Least square mean±SEM blinded 
histology score of inflammation of (C), as per Table 2.4, comprising inflammatory cell infiltrate (0-4, +0.5 per ulcer), 
Goblet cell depletion (0-4, +0.5 per crypt abscess), Muscosal thickening (0-4), submucosal cell infiltration (0-4) and archi-
tecture destruction (0-4), n=8 per group analysed by linear regression modelling of 2 separate experiments. E. mRNA 
expression of selected cytokines from 1cm sections of distal colon determined by qRT-PCR, the least square mean±SEM 
value relative to Gapdh expression is presented, n=12-18 per group, analysed by linear regression modelling of 3 sepa-


























































































































Figure 4.9 Flow cytometry analysis of CD11cΔMbd2 colon lamina propria cells in DSS colitis
CD11cΔMbd2 or littermate WT mice recieved 2% DSS b/w in drinking water or normal drinking water for 8 consecutive 
days, colon LP cells were isolated and assessed for the expression of SiglecF, Ly6G, CD11b, CD11c, F4/80, MertK, 
CD64, CD45, CD103 and Lineage markers by flow cytometry. The % of CD45+ colon LP cells per experiment (A) and 
least square mean total total number of cells x106 per colon is presented for the populations outlined in Figure 3.2 (B) , 
n=15 per group, analysed by linear regression of 3 independent experiments C. Representative flow cytometry contour 
plots in Day8 DSS treated WT and CD11cΔMbd2 mice for neutrophil and monocyte populations as defined in Figure 3.2. 
The least square mean number of colon LP myeloid cells x106 per colon after 3 hr incubation with 1μl/ml GolgiStop 
expressing IL-1β (D) or TNF (E) as assesed by intracellular staining and flow cytometry compared to isotype antibody 
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Figure 4.10 Gene expression analysis of Mbd2-/- and WT DSS treated colon LP Macrophages and DC
Day 6 2%DSS treated Mbd2-/- or littermate WT mice colon LP macrophage, monocyte and CD11b- DC cells were 
isolated and purified by flow cytometry as described in Figure 3.5. RNA was extracted and gene expression assessed 
by hybridisation to IlluminaMouseRef6 microarray. Heat map of normalised gene expression from WT versus Mbd2-/- 
macrophages (A), or CD11b- DC (B) are presented with genes significantly up (upper panel) or down (middle panel) 
regulated in Mbd2-/- populations presented in bold (adj p<0.01). Selected equivalently expressed, non-significant 
genes are prented in the lower panel. Each individual heatmap represents a biolgical replicate composed of 2-3 (mac-
rophage) or 5 (CD11b- DC) pooled mice. C. Principal component analysis of gene expression profiles from mac-
rophage, monocyte and CD11b- DC populations, each data point representing an individual biological replicate com-
posed of 2-3 (macrophage and monocyte) or 5 (CD11b- DC) pooled mice. 
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Monocytes MΦ CD11b- DC
A
Figure 4.11 TLR production and gene expression in Mbd2-/- and WT DSS treated colon LP cells.
A. Mean percentage±SEM of TLR+ cells per MP population. Day 6 DSS treated Mbd2-/- or WT colon LP cells were 
stained for monoclonal Ab against the named TLR and analysed by flow cytometry. Monocytes, Macrophages (MΦ) 
and CD11b- DC are defined as per Figure 3.2. B. Heatmap of normalised gene expression values for TLR expression 
in  Day 6 DSS treated Mbd2-/- versus WT MP populations purified by flow cytometry as per Figure 3.5 and hybridised 
to IlluminaMouseRef6 array. Significant genes are presented in bold (Adj p<0.01). Each individual heat map repre-
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Host Mbd2-/- WT Host Mbd2-/- WT
CD11b+ CD103+ 0.6 18.5 76.2 1.5 19.9 74.8
CD11b+ CD103- 0.0 15.8 81.5 1.4 17.8 78.4
CD11b- CD103+ 4.0 21.5 68.2 4.7 23.3 67.0
CD11b- CD103- 6.5 18.1 64.4 6.4 18.9 65.8
Macrophages 3.3 23.0 68.0 3.4 23.5 67.9
Monocytes 1.9 21.1 72.7 1.2 24.5 71.1
Eosinophils 0.1 32.2 58.8 0.4 36.4 58.7
Neutrophils 0.9 17.9 58.2 0.1 22.3 67.0
Control DSSPopulation
Mixed BM chimeras were generated by lethally irradiating CD45.1 mice (host) and 
reconstituted with CD45.1+ CD45.2+ (WT) and CD45.1- CD45.2+ (Mbd2-/-) CD90 depleted 
BM. 8 weeks post irradiation colon LP cells were isolated from day 8 DSS treated or normal 
drinking water (control) mixed BM chimeras and anlaysed by flow cytometry to identify the 
populations detailed in Figure 3.2. The proportion of each population is presented that was 
identified as host, Mbd2-/- or WT as defined by the expression of CD45.1 and CD45.2 (See 
Figure 4.5B). 
Table 4.5 Proportions of colon LP myeloid cells in Mbd2-/- : WT mixed BM chimeras
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TOjpxbrtCenh6u78nQ Lyz1 lysozyme 1 10 2.1 7.9 2.00E-04 0.018
xVSgsX2S7KY6Ih7ov4 Gm11560 CCAAT-binding protein 11 1.9 9.6 0.00072 0.035
ukj.SfXnDS5dLTDtSI Gm10880 predicted gene 10880 6 1.8 9.5 3.00E-04 0.022
0JnQoghSVu_eCi_UgE Il1a interleukin 1 alpha 2 1.8 8 0.00036 0.025
ceigFHiUoI3mQQvWJQ Irg1 immunoresponsive gene 1 14 1.7 8.5 0.00019 0.018
HiNjjVE3oN6jgNpQtQ Rgs1 regulator of G-protein signaling 1 1 1.7 8.2 0.0013 0.045
Zj.SfXnDS7dLTDtSKE NA NA - 1.5 8.4 5.80E-05 0.0094
oSfXnDS5dLTHtSKED4 LOC100047316
similar to anti-MOG Z12 variable light 
chain 6 1.5 8.8 0.00023 0.02
cSfXnDS5dLTDtSKED4 Gm10880 predicted gene 10880 6 1.5 8.9 5.00E-04 0.03
rojiekh3lfgN9ASm0k Tgfbi transforming growth factor, beta induced 13 1.5 10 0.00055 0.031
TdDt374UHGyh66EXeQ Serpina3g
serine (or cysteine) peptidase inhibitor, 
clade A, member 3G 12 1.5 11 0.0012 0.043
cUSexDBLOt509_WgtM Gde1
glycerophosphodiester 
phosphodiesterase 1 7 1.4 8.4 8.40E-06 0.0033
9SfXnDS59LTDtSKED4 NA NA - 1.4 8.2 5.50E-05 0.0092
3V0s6UF40qcXS.AUeg Spic
Spi-C transcription factor (Spi-1/PU.1 
related) 10 1.3 8.1 2.30E-09 9.20E-06
EnDS5dLTDtSqED73RU NA NA - 1.3 8.2 3.90E-05 0.008
oSfXnDS5dLXDtSKED4 NA NA - 1.3 8.1 0.00021 0.019
9gVNx5fIW5.e6SftCI Reg3b regenerating islet-derived 3 beta 6 1.3 11 0.00031 0.023
ECIipcXoqZuTotnWSM H2-K2 histocompatibility 2, K region locus 2 17 1.3 9.7 0.00049 0.029
0VckdcNKEiC2XBXC7c Serpina3f
serine (or cysteine) peptidase inhibitor, 
clade A, member 3F 12 1.3 8.2 0.00096 0.039
HKegKHWgKUIQKa.VnY H2afz H2A histone family, member Z 3 1.3 11 0.0012 0.043
xi3iC26XgnhCx5aeiA Mgl2
macrophage galactose N-acetyl-
galactosamine specific lectin 2 11 1.3 9.1 0.0013 0.045
i5LnUoa3xX9S3q3q1Q Isg15 ISG15 ubiquitin-like modifier 4 1.3 9.8 0.0013 0.046
rF6UO00jH1UVKd0H.U Gm5560
solute carrier family 25 member 5 
pseudogene 5 1.3 9.2 0.0015 0.048
xefVO3Uii.jiO1aMuo Stat1
signal transducer and activator of 
transcription 1 1 1.2 8.3 1.00E-04 0.013
c_MoTh18vEyPX_kgdU NA NA - 1.2 9.4 0.00012 0.014
cIRI2UKlOJIv1iol4o H2-Q8 histocompatibility 2, Q region locus 8 17 1.2 9.1 0.00023 0.02
H4uXS0w7UqhA_90VLc NA NA - 1.2 8.5 0.00036 0.025
6PsHyLxXO3kD0KXIsQ Reg3g regenerating islet-derived 3 gamma 6 1.2 8.2 0.00039 0.027
EneSd_Y336Evw3nVHo NA selenoprotein 3 1.2 8.3 0.00092 0.039
xt16dROQdzQQTckF14 AI607873 expressed sequence AI607873 1 1.2 9.3 0.0014 0.047
Wife1LJ9CTES6yOUt0 Vcam1 vascular cell adhesion molecule 1 3 1.1 7.2 1.60E-10 1.90E-06
ZnfeL6Xy7JCdR9zSpE Ido1 indoleamine 2,3-dioxygenase 1 8 1.1 7.5 2.00E-06 0.0013
EdBqKsFMJSoeHF8BRc Arg1 arginase, liver 10 1.1 7.9 2.60E-06 0.0015
NIA9KudKMJ3O3bq6Lo Plin2 perilipin 2 4 1.1 8.4 4.20E-05 0.008
uFxd_p96OE.OL.UIH0 Ndufs2
NADH dehydrogenase (ubiquinone) Fe-
S protein 2 1 1.1 8.3 7.60E-05 0.011
iiK._I6UYied5Cchuo Gm12844 predicted gene 12844 4 1.1 9.9 3.00E-04 0.022
xqefud6NXolPqjPuOE NA NA - 1.1 8 0.00065 0.033
Nnl7rseMBIFfUW7nks Coq10b
coenzyme Q10 homolog B (S. 
cerevisiae) 1 1.1 8.3 0.0011 0.042
DOWN
BYId3fkcu0Ic4EjqXU Retnla resistin like alpha 16 -1.1 9 3.80E-05 0.0079
3VLofUh9J7p819CKHY Fcrls Fc receptor-like S, scavenger receptor 3 -1.4 7.8 1.70E-11 4.00E-07
rmQuKNExO5ep9Tesg4 Fcrls Fc receptor-like S, scavenger receptor 3 -1.6 8.5 1.40E-09 6.80E-06
Table 4.8 Gene expression analysis in DSS treated Mbd2-/- and WT colon LP macrophages
Day 6 2% DSS treated colon LP cells were isolated from WT and Mbd2-/- mice. Macrophage cells were identified and purified by flow cytometry 
as described in Figure 3.5. RNA was isolated and hybridised to IlluminaMouseRef6 array. The details of significant (adj p<0.05) >±1 log FC 
genes are presented. Details of raw data processing and normalisation methods are presented in Chapter 2.16  
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Ontology GO_ID Goterm Enrich_pValue Symbol
CC GO:0005622 intracellular 5.08E-07
3110056O03Rik, 5430437P03Rik, Abhd11, Adcy4, Ahcy, Aimp2, Akr7a5, Alg5, Ankrd54, 
Aprt, Avil, B3galt4, Blvrb, C030006K11Rik, Camk2b, Caskin2, Casz1, Cdk10, Cebpb, 
Chtf18, Cib1, Cox6a2, Cyp8b1, Dph1, Ece2, Ecsit, Edf1, Eif2b5, Eif3k, Etfb, Ets2, Exosc5, 
Fndc5, Gaa, Galns, Gipc1, Grhpr, Gstt2, Hip1r, H ... and others
CC GO:0005737 cytoplasm 2.38E-06
3110056O03Rik, 5430437P03Rik, Abhd11, Ahcy, Aimp2, Akr7a5, Alg5, Ankrd54, Aprt, Avil, 
B3galt4, Blvrb, C030006K11Rik, Caskin2, Cebpb, Cib1, Cox6a2, Cyp8b1, Dph1, Ece2, 
Ecsit, Edf1, Eif2b5, Eif3k, Etfb, Fndc5, Gaa, Galns, Gipc1, Grhpr, Gstt2, Hip1r, Hn1l, Hps5, 




3110056O03Rik, 5430437P03Rik, Abhd11, Ahcy, Aimp2, Akr7a5, Alg5, Ankrd54, Aprt, Avil, 
B3galt4, Blvrb, C030006K11Rik, Camk2b, Caskin2, Casz1, Cdk10, Cebpb, Chtf18, Cib1, 
Cox6a2, Cyp8b1, Dph1, Ece2, Ecsit, Edf1, Eif2b5, Eif3k, Etfb, Ets2, Exosc5, Fndc5, Gaa, 




3110056O03Rik, Abhd11, Ahcy, Akr7a5, Alg5, B3galt4, C030006K11Rik, Cib1, Cox6a2, 
Cyp8b1, Ece2, Ecsit, Eif2b5, Eif3k, Etfb, Fndc5, Gaa, Galns, Gipc1, Grhpr, Gstt2, Hip1r, 
Hsdl1, Map2k2, Mecr, Mrpl16, Mrps12, Mtg1, Ndufb3, Ndufs7, Nit1, Omp, Otof, Pacsin1, 




3110056O03Rik, Abhd11, Adcy4, Ahcy, Akr7a5, Aldh3b1, Alg5, Aprt, B3galt4, Blvrb, 
Camk2b, Cdk10, Chtf18, Cox6a2, Cyp8b1, Ece2, Eif2b5, Epha1, Exosc5, Gaa, Galns, 
Gna15, Grhpr, Gstt2, Haghl, Hsdl1, Impa2, Kdm4a, Map2k2, Mecr, Mras, Mus81, N6amt2, 







3110056O03Rik, 5430437P03Rik, Abhd11, Ahcy, Aimp2, Akr7a5, Alg5, Ankrd54, B3galt4, 
C030006K11Rik, Casz1, Cdk10, Cebpb, Chtf18, Cib1, Cox6a2, Cyp8b1, Dph1, Ece2, 
Ecsit, Edf1, Eif2b5, Eif3k, Etfb, Ets2, Exosc5, Fndc5, Gaa, Galns, Gipc1, Gstt2, Hn1l, 






3110056O03Rik, 5430437P03Rik, Abhd11, Ahcy, Aimp2, Akr7a5, Alg5, Ankrd54, B3galt4, 
C030006K11Rik, Casz1, Cdk10, Cebpb, Chtf18, Cib1, Cox6a2, Cyp8b1, Dph1, Ece2, 
Ecsit, Edf1, Eif2b5, Eif3k, Etfb, Ets2, Exosc5, Fndc5, Gaa, Galns, Gipc1, Gstt2, Hn1l, 
Hsdl1, Ints1, Kdm4a, Mecr, Med18, Mrpl16, Mrps12, Mt ... and others
MF GO:0004832
valine-tRNA 









3110056O03Rik, 5430437P03Rik, Abhd11, Ahcy, Aimp2, Akr7a5, Alg5, Ankrd54, Avil, 
B3galt4, C030006K11Rik, Casz1, Cdk10, Cebpb, Chtf18, Cib1, Cox6a2, Cyp8b1, Dph1, 
Ece2, Ecsit, Edf1, Eif2b5, Eif3k, Etfb, Ets2, Exosc5, Fndc5, Gaa, Galns, Gipc1, Gstt2, 
Hip1r, Hn1l, Hsdl1, Ints1, Kdm4a, Mecr, Med18, Mrpl1 ... and others
CC GO:0005634 nucleus 1.65E-09
Adk, Ank1, Appl1, Bclaf1, Camk1d, Cdk14, Chd1, Clk1, Clk2, Clk4, Dck, Dmtf1, Dyrk3, 
Elf1, Ep300, Ezh2, Gcfc1, Grasp, Gtpbp4, H2afy, Hhex, Jak2, Mdm2, Mll3, Mx1, Nab1, 
Ndel1, Nipbl, Nop2, Nr4a2, Pbrm1, Pbx1, Prkrir, Rabgap1l, Rev3l, Rgs2, Rgs9, Rheb, 
Ruvbl1, Sepsecs, Sesn3, Smg1, Ss18, Stag2, Syap1, ... and others
MF GO:0005488 binding 7.13E-08
Adk, Akap11, Akap9, Alcam, Ank1, Arl6, Arpc5, Atad1, Bclaf1, Camk1d, Car9, Cd81, 
Cdk14, Cetn4, Chd1, Cldn1, Clk1, Clk2, Clk4, Dck, Dmtf1, Dock10, Dyrk3, Elf1, Elmo1, 
Ep300, Ezh2, Fam92a, Fmnl2, G3bp2, Gcfc1, Gfod1, Gphn, Grasp, Gtpbp4, H2afy, Hhex, 




Adk, Akap11, Akap9, Ank1, Appl1, Arpc5, Atad1, Bclaf1, Camk1d, Cdk14, Cetn4, Chd1, 
Clk1, Clk2, Clk4, Dck, Dmtf1, Dnalc4, Dyrk3, Elf1, Elmo1, Eml5, Ep300, Ezh2, Gcfc1, 
Gphn, Grasp, Gtpbp4, H2afy, Hhex, Il17rd, Jak2, Lrrk2, Mdm2, Mll3, Mtap2, Mx1, Myo9a, 
Nab1, Ndel1, Nipbl, Nop2, Nr4a2, Pbrm1, Pbx1, P ... and others
CC GO:0043226 organelle 8.92E-07
Adk, Akap11, Akap9, Ank1, Appl1, Arpc5, Atad1, Bclaf1, Camk1d, Cdk14, Cetn4, Chd1, 
Clk1, Clk2, Clk4, Dck, Dmtf1, Dnalc4, Dyrk3, Elf1, Elmo1, Eml5, Ep300, Ezh2, Gcfc1, 
Gphn, Grasp, Gtpbp4, H2afy, Hhex, Il17rd, Jak2, Lrrk2, Mdm2, Mll3, Mtap2, Mx1, Myo9a, 
Nab1, Ndel1, Nipbl, Nop2, Nr4a2, Pbrm1, Pbx1, P ... and others
CC GO:0005622 intracellular 9.60E-07
Adk, Akap11, Akap9, Ank1, Appl1, Arl6, Arpc5, Atad1, Bclaf1, Camk1d, Cdk14, Cetn4, 
Chd1, Clk1, Clk2, Clk4, Dck, Dmtf1, Dnalc4, Dyrk3, Elf1, Elmo1, Eml5, Ep300, Ezh2, 
Fmnl2, G3bp2, Gcfc1, Gphn, Grasp, Gtpbp4, H2afy, Hhex, Il17rd, Jak2, Larp1b, Lrrk2, 




Adk, Akap11, Akap9, Ank1, Appl1, Arl6, Arpc5, Atad1, Bclaf1, Camk1d, Cdk14, Cetn4, 
Chd1, Clk1, Clk2, Clk4, Dck, Dmtf1, Dnalc4, Dyrk3, Elf1, Elmo1, Eml5, Ep300, Ezh2, 
Fmnl2, Gcfc1, Gphn, Grasp, Gtpbp4, H2afy, Hhex, Il17rd, Jak2, Larp1b, Lrrk2, Map3k8, 




Adk, Arl6, Atad1, Camk1d, Cdk14, Chd1, Clk1, Clk2, Clk4, Dck, Dock10, Dyrk3, G3bp2, 
Gphn, Gtpbp4, Jak2, Lrrk2, Map3k8, Mx1, Myo9a, Rab18, Rab28, Rab5a, Rala, Rbm26, 






Adk, Akap11, Ank1, Arl6, Bclaf1, Camk1d, Car9, Cdk14, Chd1, Clk1, Clk2, Clk4, Dck, 
Dmtf1, Dyrk3, Elf1, Ep300, Ezh2, Gcfc1, Gphn, Hhex, Jak2, Klrk1, Lrrk2, Map3k8, Mdm2, 
Mll3, Mtap2, Mx1, Nab1, Ndel1, Nop2, Nr4a2, Pbrm1, Pbx1, Pkib, Ppap2a, Ppfibp2, Ptpn2, 






Adk, Arl6, Atad1, Camk1d, Cdk14, Chd1, Clk1, Clk2, Clk4, Dck, Dock10, Dyrk3, Gphn, 
Gtpbp4, Jak2, Lrrk2, Map3k8, Mx1, Myo9a, Rab18, Rab28, Rab5a, Rala, Rheb, Riok1, 




Adk, Arl6, Atad1, Camk1d, Cdk14, Chd1, Clk1, Clk2, Clk4, Dck, Dock10, Dyrk3, Gphn, 




Day 6 2% DSS treated colon LP cells were isolated from WT and Mbd2-/- mice. CD11b- DC were identified and purified by flow cytometry as 
described in Figure 3.5. RNA was isolated and hybridised to IlluminaMouseRef6 array. The details of significant (adj p<0.05) pathways as assessed 
by gene onotology (GO) analysis. Details of raw data processing and normalisation methods are presented in Chapter 2.16 . (BP=biological process, 
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In chapter 4 we observed a role for haematopoietic cells in the development of severe 
colonic inflammation mediated by DSS in Mbd2-/- mice. However we also observed that 
restricting Mbd2 deficiency to haematopoietic cells or CD11c expressing cells alone did not 
reproduce the levels of disease severity seen in global Mbd2-/- mice. This led us to 
hypothesise that non-haematopoietic sources of MBD2 may play an important role in the 
control of inflammation responses in the colon. Given that the pathogenesis in DSS colitis is 
due to a primary breakdown of intestinal barrier function, exposing underlying tissues to the 
commensal microbiota, we hypothesised that colon epithelial sources of MBD2 may have 
important roles in epithelial-immune cell crosstalk.    
 
The intestinal epithelium is the largest mucosal surface in the human body. This surface is a 
single cell thick to permit efficient ion and nutrient absorption and yet must shield the host 
from a diverse and sustained antigenic load, including an estimated 1014 commensal bacteria 
(100). At its most basic, IECs regulate GI tract immunity by forming a physical barrier by 
separating luminal contents from the underlying LP. However IECs also display innate 
immune function through the production of anti-microbial products, including defensins, 
cathelicidins and calprotectin (101). Indeed IECs are able to process and present antigen on 
MHC molecules enabling interaction with the adaptive immune system (102). For example, 
IEC MHC expression has been shown to be upregulated in the presence of intestinal 
inflammation supporting a role for barrier surfaces in manipulating T cell responses. Indeed 
IECs from IBD patients promote increased Th1 derived IFNγ!when co-cultured with naïve 
CD4+ T cells (429). Secondly, IECs express a series of PRRs, including TLRs, which are 
down regulated in germfree mice, with MYD88 dependent IEC signaling required to prevent 
translocation of mucosa-associated bacteria (430). Thus presence of intestinal microbiota is 
required for TLR development and host barrier function.  Indeed almost all TLRs are 
expressed at mRNA level in the human colon (unselected populations), but our 
understanding of the precise spatial expression and function of PRRs is incomplete (431), 
(432). Thirdly, IECs secrete a number of immunoregulatory products. Co-culture of DCs with 
IEC supernatant favours a tolerogenic DC phenotype with lower levels of MHC II and CD86 
expression, increased TGFβ!and IL-10 secretion and reduced production of IL-12p70 (433). 
These effects are thought to be largely mediated by thymic stromal lymphopoetin (TSLP) via 
a NF-κB dependent mechanism (434), (435). Indeed, mice carrying an IEC specific deletion 
of IκB kinase, which is required for NF-κB activation, are unable to generate a protective Th2 
response to the colonic parasite T. muris, with increased DC release of TNF and IL-
12/23p40 and down-regulated TSLP expression (436). Finally, IECs are known to secrete 
TGFβ! in response to in vitro models of wound injury, with TGFβ documented to reduce 
alloantigen presentation on epithelial-DCs (437), (438). Indeed CD11c specific deletion of 
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αvβ8, required for TGFβ!activation, render these mice more susceptible to colitis with reduced 
Treg populations (439).  
 
Further evidence for the immunomodulatory properties of IECs is observed in antibody 
responses. Indeed, the GI tract is the largest antibody producing organ in humans, with 
>80% of activated B cells residing in mucosal tissue sites (440). Secretory antibody provides 
crucial defence against pathogens and shapes the ecology of the microbiota (441). Class 
switch of differentiated B cell production of IgM to IgA occurs within PP and is dependent on 
secretion of APRIL and TGFβ, sources of which include IECs (Mora et al. 2006). Indeed, 
increased TLR signaling induces APRIL and TSLP secretion from IECs, with microbial 
signaling also favouring IgA2 class switch which is a more proteolytically resistant IgA (442), 
(443). Thus microbiota-derived signals stimulate IEC release of mediators promoting IgA 
class switching.  
 
The intestinal epithelium is in close proximity to a vast array of gut-associated lymphoid 
cells, most notably in small intestine PP. However ILFs are present throughout the GI tract, 
including the colon. The IECs covering ILF include specialised antigen sampling cells (M 
cells) able to uptake luminal antigen directly by endocytosis (444), (445). As M cells lack 
lysosomes, antigen is presented intact to naïve T cells before their migration in efferent 
lymphatic vessels to other mucosal effector sites such as the LP. In addition, the epithelium 
has evolved to permit the passage of membrane extensions from DCs (dendrites) to directly 
sample luminal antigen without compromising barrier integrity, via the formation of tight 
junction (TJ) like complexes between DCs and IECs (445), and this process is induced via 
IEC TLR activation by microbial stimuli  (444).  
 
The luminal burden of antigen and thus daily challenge to IEC immune function is vast. 
Indeed the GI tract is the most heavily colonised organ in the body, with over 70% of 
bacteria in humans residing in the colon (446,447). Determining bacterial community 
structure in faecal samples through DNA sequencing is therefore an important facet of 
intestinal health research. Differences in intestinal microbial diversity and community 
structure have been implicated not only in GI tract diseases such as CD, UC and IBS but 
also in systemic metabolic disorders such as obesity and type II diabetes mellitus (448), 
(300).  
 
Taken together, it is increasingly appreciated that IECs are critical guardians of host 
immunity: able to sample luminal antigen, respond and function as APCs, secrete 
immunomodulatory proteins including cytokines such as TGFβ!and an array of chemokines, 
and respond to microbial signals via PRRs to augment barrier defence by facilitating 
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antibody and mucin production. Thus IECs represent attractive potential sources of Mbd2 to 
be investigated for dysregulated function.  
 
Chapter aims 
1. Identify and extract IECs from the colon 
2. Develop protocols for the purification of colon epithelial cells (CECs) by FACS 
3. Characterise the surface expression phenotype of Mbd2 deficient CECs in the steady 
state and in experimental colitis  
4. Characterise gene expression profiles of steady state and inflamed CECs in WT and 
Mbd2-/- mice 






























5.2 Identifying and extracting colon epithelial cells 
The emerging field of epithelial-immune cell crosstalk has not yet provided a consensus on 
an accepted, robust extraction method for isolating CECs from murine tissue (449), (450). 
CEC isolation was a novel technique for the MacDonald laboratory, and thus the existing 
literature was interrogated for previously published methodology, as well as seeking local 
expertise. We therefore first sought to address this by developing a reproducible method for 
CEC extraction that permitted identification of a range of CEC types.  
 
The basic premise of colon LP isolation relies upon multiple wash steps to clean the luminal 
surface, exposure to a chelating agent such as EDTA to remove adherent mucus before 
enzymatic digestion to expose underlying LP cells. We therefore hypothesised that earlier 
steps of our existing isolation protocol would result in the extraction of a number of CEC 
subtypes (goblet cells, entero-endocrine cells, stem-cell niche cells and colonocytes). We 
therefore attempted to identify CECs using a modified version of our isolation protocol as 
described in Table 5.1 (protocol #1), assessing cells by flow cytometry (See Figure 5.1).  
 
The existing literature using flow cytometry to profile CECs is poorly described. However 
data suggest these cells are; epithelial cell adhesion molecule (EpCAM) positive, CD45-, with 
a characteristic SSC-AHi, FSC-AHi profile (450), (449). EpCAM is expressed uniquely by 
human epithelium, but the mouse homologue is also expressed by T cells and some APCs 
(451). Therefore to ensure CECs were not contaminated with other EpCAM expressing 
populations, we assessed for the presence of an array of leucocyte markers. Using this 
protocol we indeed identified an EpCAM+ CD45- SSC-AHi population (See Figure 5.1A) that 
was negative for a range of other leucocyte markers (See Figure 5.1B). However, we wished 
to compare this to two other published CEC isolation methodologies to establish differences 
in yield, viability and appearance by flow cytometry (See Table 5.1).  
 
The main points of comparison were the use of Percoll to purify CECs based on size 
(protocol #2), and the use of dispase in preference to collagenase (protocol #3), given 
anecdotal reports of enhanced CEC viability when using dispase (Sheena Cruickshank, 
personal communication). Table 5.1 outlines the differences between the 3 protocols, while 
Figure 5.2A and B detail differences in CEC phenotype based on isolation protocol.  
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We observed a greater viability using EDTA (protocol #1 and #2) versus dispase (protocol 
#3) and a greater yield of CECs using Liberase (protocol #1) versus dispase (protocol#3) 
(See Figure 5.2A and B). In addition we observed a reduction in CECs using protocol #2, 
characterised by a reduction in all SSC-AHi cells, likely due to a poorly optimised Percoll 
gradient step (See Figure 5.2A and B). We also identified an EpCAM+ CD45mid population in 
protocol #2 and #3. EpCAM+ CD45mid cells expressed low levels of F4/80 and CD3 
consistent with known EpCAM expression in both F4/80+ and CD3+ populations, but also 
expressed higher levels of viability dye Live/Dead Blue and had a greater SSC-A, FSC-A 
profile. Taken together we concluded that the longer incubation periods of protocol#3 led to 
a reduced viability of EpCAM+ leucocytes, with resultant reduced CD45 expression (See 
Figure 5.2C).  
 
Having identified that protocol #1 produced the highest yield and most discreet, viable CEC 
population as assessed by flow cytometry, we then sought to confirm protocol #1 EpCAM+ 
CD45- cells displayed a mRNA profile of epithelial cells to add further evidence to our 
argument supporting their identification as CECs, and to confirm our isolation techniques 
weren’t biasing towards a specific epithelial cell type. To pursue this, we optimised a FACS 
protocol to isolate CECs (Figure 3.3). 
 
The colonic epithelium is maintained through a process of continual cellular renewal in which 
stem cells, located at the base of crypts, produce 14 to 21 intermediate cells per hour that 
give rise to all terminally differentiated cell types (452), (453). The three main types of 
differentiated CECs (colonocytes, goblet cells and enteroendocrine cells) differentiate while 
migrating up to the surface epithelium with a turnover period of 4 to 6 days (454). 
Colonocytes possess absorptive and secretory functions, aiding the transport of sodium 
water and short chain fatty acids whilst secreting potassium and bicarbonate (454). Goblet 
cells produce mucins that help protect the mucosa from injury and enteroendocrine cells 
secrete hormones such as secretin and cholecystekinin, that regulate intestinal function 
(454).  
 
Protocol Number #1 #2 #3
EDTA incubation steps x1 x2 Nil
Enzyme Liberase TM Nil Dispase
Enzyme Duration 40mins N/A 120mins
DNAse 0.02mg/ml Nil Nil
Percoll Nil 30% gradient Nil
Table 5.1
Comparison of proposed CEC extraction methods
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Using the sort logic in Figure 5.3, we isolated EpCAM+ CD45- CECs from mouse colon and 
extracted the RNA for analysis by quantitative RT-PCR. We assessed mRNA levels of the 
stem cell marker, leucine-rich repeat-containing G-portein coupled receptor 5, Lgr5, the 
colonocyte marker carbonic anhydrase, Car1, the goblet cell markers mucin-2, Muc2, and 
Krüppel-like factor 4, Klf4, and the enteroendocrine marker chromogranin A, ChgA, 
compared to liver and spleen whole tissue homogenate controls (See Figure 5.4A) (454).  
 
We observed mRNA transcript expression in CECs for colonocyte, goblet cell and 
enteroendocrine markers that were not seen in spleen or liver tissues. There was in addition 
increased expression of the stem cell marker Lgr5 in CECs versus spleen, with equivalent 
levels of liver Lgr5, consistent with its known expression in this tissue (Figure 5.4A)(455), 
(456).  
 
We then sought to compare CEC Mbd2 expression versus other leucocyte populations we 
had previously identified in chapter 3. Using the sort logic in Figure 3.3 and 5.3 we identified 
and isolated CEC, macrophage, monocyte and CD11b+/- DC populations from colon LP, 
comparing expression of Mbd2 transcript versus liver whole tissue control (Figure 5.4B). 
CECs displayed high levels of Mbd2 transcript equivalent with monocytes and macrophages, 
in keeping with known data supporting constitutive expression of Mbd2 in other epithelial 
sites (GeneAtlas entryU133A). 
 
Taken together, we have identified and isolated an EpCAM+ CD45- population from mouse 
colon that displays a characteristic SSC-A profile, lacks expression of other colon LP 
leucocyte markers, and selectively expresses gene transcripts typical of known colon 
epithelial cell types. We also identified CECs as constitutively expressing high levels of 
Mbd2 and, given the data in Chapter 4 supporting a role for non-haematopoietic sources of 
Mbd2 in pre-disposition to colonic inflammation, we now sought to compare CECs from 
Mbd2-/- versus. WT mice.  
 
5.3 Characterisation of naïve CECs in Mbd2-/- and WT mice 
As noted above, CECs express an array of chemokines in response to inflammatory stimuli 
to mobilise immune cells such as neutrophils, T cells, macrophages and DCs to sites of 
tissue damage. In addition, CECs also increase expression of antigen processing molecules 
such as MHC and the LY6 family members on their basolateral surface after the induction of 
colitis (Il10-/- and CD45RBHigh T cell transfer models) (457), (458). LY6 family members are 
GPI anchored cell surface glycoproteins with broad distribution of cells of haematopoietic 
and some non-haematopoietic cells. They are widely used as differentiation markers of 
immune cells, though there exact functions are poorly understood. Data thus far support a 
role in T cell activation, olfaction and cellular adhesion (459), (460). It has recently been 
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demonstrated that LY6A and LY6C expression by IECs is regulated by inflammatory 
cytokines I including IFNγ, TNF and IL-22. Furthermore, cross-linking of LY6 family members 
on CECs increases cholesterol-mediated secretion of chemokines including the neutrophil 
attractant CXCL5 (457). Thus, in addition to forming a physical barrier between host and 
environment, CECs also play an important role in sensing and modulating intestinal 
inflammatory responses, with a suggestion that CEC LY6 molecules are upregulated during 
intestinal inflammation, increasing downstream signaling of leucocyte chemoattractants by 
currently unknown mechanism.  
 
Using the above developed methodology, we next assessed EpCAM+ CD45- cells from WT 
and Mbd2-/- mice using flow cytometry. To our surprise, there was a striking increase in the 
total number of CECs in naïve Mbd2-/- versus WT mice (23.9±1.5 versus 10.4±1.7 % of intact 
cells) (See Figure 5.5A). To address whether the increased frequency of CECs in Mbd2-/- 
was secondary to an increased proliferation of these cells we assessed intracellular 
expression of the cell cycle protein Ki67. However, there was no effect of genotype on the 
proportion of Ki67+ CECs and therefore in active cell cycle (See Figure 5.5B). In addition, 
there was no evidence of epithelial hyperplasia on H&E stained sections of distal colon, 
reviewed in chapter 3 (See Figure 3.4A). We therefore hypothesised that Mbd2-/- CECs were 
more readily released as part of the isolation procedure, perhaps due to defective cell-cell 
adhesion or TJ formation.  
 
Mbd2-/- mice also demonstrated a greater proportion of MHC II+ (23.2±3.1 versus 4.9±3.3 % 
of MHC II+ CECs, Mbd2-/- versus WT respectively) and LY6A/E+ (66.0±3.2 versus 50.0±3.0% 
Ly6A/E+, Mbd2-/- versus WT respectively) CECs compared to WT in keeping with a more 
activated epithelial phenotype (See Figure 5.5C).  
 
Taken together, steady state Mbd2-/- mice displayed an increased number of CECs despite 
equivalent proliferation, which we speculate might be secondary to decreased barrier 
integrity. In addition Mbd2 deficiency resulted in an activated CEC phenotype, with increased 
surface expression of MHC-antigen presenting, and LY6-chemoattract, molecules, 
consistent with a degree of indolent, sub-acute colonic inflammation.  
 
5.4 Characterisation of Mbd2-/- and WT CECs in colonic inflammation 
To address whether Mbd2-/- CECs were further dysregulated in colonic inflammation we 
isolated colon cells from day 6 DSS treated Mbd2-/- and WT mice (See Figure 5.5A, B and 
C).    
 
In contrast to naïve mice, there was no effect of genotype on the frequency of CECs as 
assessed by the proportion of EpCAM+ CD45- Lin- CECs of all intact cells (See Figure 5.5A). 
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Similarly there was no effect of genotype on the proportion of CECs in active cell cycle, as 
assessed by the presence of Ki67+ cells or the proportion of CECs that were MHC II+ (See 
Figure 5.5C). There was however a significant increase in the proportion of Mbd2-/- CECs 
expressing LY6A/E (68.0±3.2 versus 54.8±3.1 % of Ly6A/E+ CECs, Mbd2-/- versus WT 
respectively) (See Figure 5.5B). 
 
We also assessed epithelial activation in a model of infectious colitis with the parasitic 
nematode T. muris (as described in Chapter 3.6). Day 30 High (200egg) and Low (20egg) 
dose T. muris infected Mbd2-/- or WT mice were assessed for the presence of activated, 
MHC II+, CECs. Colon cells were isolated, identified and characterised as described above. 
There was a significantly greater proportion of activated MHC+ CECs in high (9.6±1.6 versus 
1.7±0.1 % of MHC II+ CECs) but not low (15.0±2.1 versus 6.3±2.5 % of MHC II+ CECs, Mbd2-
/- versus WT respectively) dose infected Mbd2-/- mice.  
 
Taken together, in the absence of Mbd2 there was increased CEC activation in naïve Mbd2-/- 
compared to WT mice. This increased CEC activation was only maintained in DSS in the 
LY6A/E analysis of CECs. To understand whether conserved pathways existed between 
naïve and DSS treated Mbd2-/- CECs that predisposed to epithelial activation, and whether 
these putative pathways could explain the increased susceptibility to inflammation, we 
undertook expression analyses of these cells using WT naïve and DSS CEC controls.  
 
5.5 Gene expression analyses of WT and Mbd2-/- CECs 
Colon cells were isolated from WT or littermate Mbd2-/- day 6 DSS treated or naïve drinking 
water control mice. CECs were then purified by FACS as described in Figure 5.3. The RNA 
component of these cells was isolated, purified and its integrity quantitatively and 
qualitatively assessed by spectrophotometry and gel electrophoresis before hybridisation to 
an IlluminaMouseRef6 microarray. Data analysis of gene expression is described in Chapter 
2.16 and 4.3.2. 5 biological replicates (4 for naïve analysis) of individual mice were analysed.  
 
5.5.1 Gene expression in naïve Mbd2-/- and WT mice 
In comparing Mbd2-/- to WT CECs, 351 genes were significantly different at an adjusted 
p<0.01 (191 up, 160 down), of which 61 were >logFC +1.0 and 37 >logFC-1.0 (See Table 
5.2). The most up-regulated pathway by GOterm and KEGG analysis was antigen 
processing and presentation, with leucocyte migration (KEGG) and small metabolic process 
(GOterm) the most down-regulated pathways (See Table 5.3 and 5.4).  
 
The genes below were selected from Table 5.2 as being significantly dysregulated and 




5.5.1.1 Genes upregulated in naïve Mbd2-/- CECs compared to WT 
MHC II loci 
H2-Ab1 LogFC +3.3 (MHC IIa) 
H2-Dmb1 LogFC+3.0 (MHC IIb) 
H2-Dmb2 LogFC +3.2 (MHC IIb) 
H2-Eb1 LogFC +2.7 (MHC IIa) 
H2-DMa LogFC +2.6 (MHC IIb) 
H2-Aa LogFC +2.5 (MHC IIa) 
 
MHC I loci 
H2-Q8 LogFC +2.4 (MHC Ib) 
H2-Q6 LogFC +1.6 (MHC Ib) 
H2-Q7 LogFC +1.4 (MHC Ib) 
H2-K2 LogFC +1.8 (MHC Ia) 
H2-K2 LogFC +1.2 (MHC Ia) 
H2-T23 LogFC +1.6 (MHC Ib) 
 
Other MHC-related genes 
Cd74 LogFC+3.8 
Psmb8 Log FC +2.8 
Psmb9 LogFC +2.1 
Tap1 LogFC +1.6 
Tap2 LogFC +1.2 
 
There was a striking up-regulation in multiple aspects of the MHC in naïve Mbd2-/- versus 
WT CECs. As detailed in Table 5.4, 17 genes and 33% of the known antigen processing 
pathway was dysregulated in KEGG analysis with p=1.32x10-19 significance.  
 
Ly6A LogFC +1.7 
Expression of LY6 molecules has previously focused on haematopoietic cells, used as 
markers of differentiation and activation. Diverse roles for LY6 molecules include T cell 
activation and adhesion but more recently have been described in IEC function (457).  
 
Retnlb LogFC +2.4 
RELMβ!belongs to the family of resistin like cytokine molecules consisting of small, cysteine-
rich secreted proteins. RELMβ! is produced by goblet cells in the intestinal epithelium, where 
it is secreted into the intestinal lumen (461).  
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Reg3b +3.0, Reg3g +1.9 
The antimicrobial peptide REG family is discussed in Chapter 4.3.2 in reference to myeloid 
function. Epithelial expression of REG3γ! and REG3β! is limited to the small intestine in 
steady state mouse and human, but are produced from colon enterocytes during pathogen 
infections or inflammatory conditions (462).  
 
Muc1 LogFC +1.3 
Mucin 1 (MUC1) is a membrane bound mucin expressed by goblet and absorptive cells 
which functions in promoting a cell surface protective barrier with extracellular portions 
cleaved with bioactive function for epithelial restitution (463).  
 
5.5.1.2 Genes downregulated in naïve Mbd2-/- CECs compared to WT 
Cldn4 LogFC-2.7 
Claudin 4 (CLDN4) is a key structural protein and integral component of the TJ complex, not 
only in forming an intact physical barrier between the host and the lumen, but also in 
permitting effective paracellular transport  (464).  
 
Ceacam1 LogFC-1.2 
CAECAM1 is a membrane bound, heavily glycosylated protein found on the apical surface of 
IECs, which has been shown to contribute to mucosal adherent mucus, directly interact with 
bacteria and viruses, and regulate CD8+ T cell activation (465).  
 
Tff3 LogFC -1.0 
TFF3 is the second most abundant goblet cell product with important roles in promoting 
mucosal protection and epithelial restitution (466): TFF3 and mucin together are more 
effective at epithelial protection than either one alone, with TFF3 mediating epithelial 
restitution by blockade of apoptosis, promotion of cell migration and mediating downstream 
effects of TLR2 signaling (467), (468).  
 
5.5.2 Gene expression in DSS treated Mbd2-/- and WT mice 
In comparing Mbd2-/- to WT CECs; 791 genes were significant at an adjusted p<0.01 (366 
up, 425 down), of which 83 were >logFC +1.0 and 52 >logFC-1.0 (See Table 5.5). The most 
up-regulated pathway by GOterm and KEGG analysis was antigen processing and 
presentation with leucocyte migration (KEGG) and small metabolic process (GOterm) most 
down-regulated (See Table 5.6 and 5.7).  
 
The genes below have been selected from Table 5.5 being significantly dysregulated and 




5.5.2.1 Genes upregulated in DSS colitis, Mbd2-/- CECs compared to WT 
MHC II molecules 
H2-DMb1 LogFC +3.2 (MHC IIb) 
H2-DMb2 LogFC +3.0 (MHC IIb) 
H2-DMa LogFC +2.7 (MHC IIb) 
H2-Ab1 LogFC +2.6 (MHC IIa) 
H2-Aa LogFC +2.5 (MHC IIa) 
H2-Eb1 LogFC+2.4 (MHC IIa) 
 
MHC-I molecules 
H2-Q8 LogFC +2.7 (MHC Ib) 
H2-K2 LogFC +2.0 (MHC Ia) 
H2-Q6 LogFC +2.0 (MHC Ib) 
H2-Q7 LogFC +1.6 (MHC Ib) 
H2-K1 LogFC +1.6 (MHC Ia) 
H2-T23 LofFC +1.4 (MHC Ib) 
 
Other MHC-related molecules 
CD74 LogFC +2.8 
Ciita LogFC +1.7 
Psmb8 LogFC +2.2 
Psmb9 LogFC +1.8 
Tap2 LogFC +1.3 
Tap1 LogFC +1.3 
C2 LogFC +1.7 
 
There was, as in naïve analysis, a striking upregulation in MHC expression. In pathway 
analysis, antigen processing and presentation pathways were significantly enriched at 
p=1.9x10-25, with 25 genes and 49% of the pathways up-regulated (See Table 5.6). The 
same 6 MHC IIa/b, 6 MHC Ia/b, and 6 ‘other’!MHC-molecules genes were dysregulated in 
both naïve and DSS treated mice.  
 
Hspa1a LogFC +2.2 
Hspa1b LogFC +2.0 
Hspa8 LogFC +2.0 
Following exposure to noxious stimuli, IECs respond by producing heat shock proteins 
(HSPs) that confer protection to stress, infection and inflammation (469). These effects are 
mediated by preventing the denaturation of intracellular proteins by chaperoning and re-
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folding partially denatured proteins. In addition HSPs participate in protein assembly, 
secretion, trafficking and regulation of transcription factors and kinases (470).  
 
Cxcl9 LogFC +1.5 
Chemokine (C-X-C motif) ligand 9 is encoded by the Cxcl9 gene, induced predominately by 
IFNγ, and is a T cell chemoattractant, binding to CXCR3 (471).  
 
Reg3b LogFC +1.5 
Reg3g LogFC +1.4 
As described in chapter 5.2.1 
 
Nlrc5 LogFC +1.1 
NOD-like receptor, CARD domain containing protein (NLRC) 5 is part of a family of 22 
known NLRs that are cytoplasmic, contributing to innate immune response by recognising 
microbial products and danger signals leading to inflammation and/or cell death (472).  
 
5.5.2.2 Genes downregulated in DSS colitis, Mbd2-/- CECs compared to WT 
Cldn4 LogFC -1.6 
As described in chapter 5.5.1.2 
 
Il1rn LogFC -1.3 
IL-1 receptor anatagonist (Ilrn/ILRA) is part of the IL-1 family mediating susceptibility to 
infection and in the pathogenesis of cancers by competes with the binding of IL-1 to its 
receptor. Polymorphisms in Ilrn producing increased circulating ILRA in humans is 
associated with increased risk of gastric cancer and septic shock, proposed to be due to 
prolonged and strengthened inflammatory response (473).  
 
Taken together, Mbd2 deficient CECs display a striking dysregulation of MHC I / II antigen 
processing and presentation compared to WT intestinal epithelium. An observation 
strengthened by the fact that WT and Mbd2-/- mice used in the above gene expression 
analyses were littermates, co-housed together from birth for a minimum of 2 months to 
minimise inter-group variation.  
 
There is clear evidence in the literature supporting direct and indirect crosstalk between the 
microbiome and host immune response, however the precise mechanism underpinning the 
microbial influence of disease pathogenesis remains elusive and is a current research focus 
(474), (150) (Chapter 1.5). Indeed many IBD susceptibility loci, notably NOD2, suggest an 
impaired response to microbes in disease (309). Gut microbiota is an essential factor in 
driving inflammation in IBD, exemplified by the efficacy of enterically coated antibiotics and 
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faecal diversion in reducing intestinal inflammation (475), (476). Many studies consistently 
report a reduction in biodiversity, or α!diversity, a measure of the species richness and total 
number of species in a community in CD patients versus healthy controls (300). 
 
We hypothesised therefore that the profound changes in antigen handling capabilities in 
naïve Mbd2-/- CECs may alter the composition of the intestinal microflora. To address this we 
performed sequencing of bacterial 16S rRNA genes from naïve WT and Mbd2-/- faeces. 
 
5.6 Composition of the intestinal microbiota in Mbd2 deficiency 
Differences in intestinal microbial diversity and community structure have been implicated 
not only in GI tract diseases such as CD, UC and IBS but also in systemic metabolic 
disorders such as obesity and type II diabetes mellitus (448), (300). 
 
Taken together there is strong evidence that the microbiota are implicated in the 
pathogenesis of IBD, with multiple bacterial handling gene polymorphisms acting as disease 
susceptibility loci (105). In addition, the IBD microbiota demonstrates a reduced biodiversity, 
with resultant changes in host inflammatory and anti-inflammatory responses (477), (478). 
The key question remains however, whether these observations represent a primary, 
disease inducing ability of the microbiota in genetically susceptible individuals, or whether a 
primary dysregulated immune response and subsequent inflammation causes secondary 
changes in the intestinal microbiota. Given identifying the requisite number of patients before 
the onset of IBD in a case-control study has proven thus far prohibitively large, this remains 
a key unanswered question in the development of IBD.  
 
It is well documented that the environment, particularly diet, age, co-habitation all have 
significant effects on the human microbiome (150). Murine experiments allow us to control 
for all these variables, though care must still be taken. Studies which have purported effects 
of genotype in murine microbiome composition have been subsequently shown to be 
secondary to changes in the above variables, particularly co-habitation (479), (480). To 
control for these variables we co-housed the offspring of heterozygous, Mbd2-/+, parents 
from birth before analysis of the microbiome at mean age 26 weeks (See Table 5.8). The 
colon faeces from 3 cages (total 12 mice), each cage containing Mbd2+/+ (i.e. WT) and 
Mbd2-/- littermates, was taken, extracted and processed in tandem to control for 
experimental error. The methods for extraction and analysis are outlined in section 2.15. 
  
Analysis of sequence data was performed using the Mothur software package (481). The 
“trim.seqs”! function was performed to filter reads for quality by truncating them for average 
quality scores. In addition, any reads with primer or barcode sequence mismatches or reads 
with ambiguous “N”!bases were discarded. Chimeras were removed using Perseus software 
 185 
in Mothur before sequence alignment to the SILVA reference database. A distance matrix 
was generated before clustering into operational taxonomic units (OTU) at 97% similarity. 
Each OTU was assigned a taxonomic classification at all levels from phylum to genus, then 
using R and iTOL packages to calculate distance matrices and dendrograms using Jaccard, 
Yue and Clayton and Ward clustering respectively (See Figure 5.8A and B).  
 
5.6.1 iTOL dendrogram analysis 
The Jaccard calculator is used to describe the overlap in community membership between 
different samples and ignores the proportional abundance of each OTU, whilst in contrast 
the Yue and Clayton calculation takes the proportional abundance of each OTU into account 
when comparing similarities (482). Therefore the presence or absence of an OTU in a given 
sample has the same weight in Jaccard calculation, independent of the number of reads. It 
became apparent during the analysis there were a number of unique reads with only 1 or 2 
reads in the entire dataset, therefore to prevent biasing the dataset for only a small number 
of reads, we present the Yue and Clayton calculation to encompass proportional data as a 
more robust representation of the community composition (482). 
 
Figure 5.8A therefore shows the dendrogram of the representation of bacterial families 
derived from the 16S rRNA sequences within each sample clustered by Yue and Clayton 
distances. Mbd2-/- mice clustered together significantly independent of cage (p=0.0190). 
Interestingly, the microbiome isolated from sample #12 was an outlier in age (20weeks), 
compared to the remainder of the dataset (mean=26weeks) (Table 5.8).  The length of the 
dendrograms in Figure 5.8A is also a representation of the Yue and Clayton similarity, 
therefore with the exception of the above outlier, Mbd2-/- mice separate from WT 
counterparts at a very early stage in the analysis, suggestive of sizeable differences in their 
bacterial communities.  
 
5.6.2 Non metric multidimensional scaling analysis 
To display the distance matrices in 2D form, we took advantage of non metric 
multidimensional scaling (NMDS). This permits collapse of multiple dimensions of distance 
into 2 dimensions, using rank orders (483). This method plots every rank order of OTU 
abundance against every OTU in the sample and then condenses that distance to compare 
different samples against one another (See Figure 5.8B). Once again Mbd2-/- mice clustered 
together independently of cage. This was a highly surprising finding, that littermate mice 






5.6.3 Dysbiosis in Mbd2-/- mice 
We then assessed whether there were organisms that were enriched or depleted in Mbd2-/- 
mice that accounted for the changes in Yue and Clayton distances (See Table 5.9). 4 OTU 








Peptococcus, Roseburia and Clostridium_sp_Culture-54 were all enriched with 
Parabacteroides depleted in Mbd2-/- versus WT mice.  
 
Taken together, we have demonstrated that despite using stringent controls for assessing 
differences in bacterial communities, there exists a significantly altered microbiota in naïve 
mice in the absence of Mbd2. This was demonstrated by the effect of genotype on 





In this chapter we addressed the role of Mbd2 in non-haematopoietic cells, focusing on the 
colonic epithelium. Firstly we have built upon previous work in identifying colon epithelial 
cells from existing protocols, using multi-colour flow cytometry. We compared current 
methodologies for CEC extraction, before assessing these cells with a variety of flow 
cytometry markers to ensure our isolation technique was not compromised by the presence 
of other cell types. We have then, for the first time to our knowledge, purified colon epithelial 
cells using FACS and shown sorted EpCAM+ CD45- cells to express goblet cell, enterocyte, 
enteroenterocyte and stem cell niche specific markers (Figure 5.4A). We used these 
techniques to identify clear differences in surface expression of epithelial activation markers 
in Mbd2-/- mice. Namely we observed increased MHC II and LY6A/E molecule expression on 
the surface of Mbd2 deficient CECs (Figure 5.5B).  
 
Expression of LY6 molecules has previously focused on haematopoietic cells, used as 
makers of differentiation and activation (484). Diverse roles for LY6 molecules include T cell 
activation and adhesion but, more recently, have been described in IEC function (457). RNA 
and surface expression of LY6A and LY6C were increased in the IEC of colitic mice, and in a 
YAMC epithelial cell line after exposure to IL-22 and IFNγ (457). The ligands for LY6 
molecules are not well described, but cross-linking LY6A-C using mAbs results in LY6A and 
LY6C up-regulation, in addition to chemokines CXCL1, 5, 10, CCL5 and 7 (485). Given IBD 
is viewed as an unresolved inflammatory response, it is possible that dysregulated Ly6 
upregulation on IEC may cause positive feedback that propagates Ly6-mediated 
chemoattractant properties.  
 
Using genome-wide profiling of naïve and inflamed CECs we were able to identify striking 
differences in gene expression conferred by Mbd2 deficiency, notably up-regulated MHC I/II 
pathways.  Key dysregulated genes that reached genome-wide adjusted significance p<0.01 
are considered below, with the magnitude of change (LogFC) comparing Mbd2-/- to WT 
summarised in Table 5.13. 
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CD74 also known as the invariant chain or ‘Ii’ is a non-polymorphic glycoprotein with diverse 
immunological functions (486). CD74 forms a trimeric protein on which MHC II molecules 
assemble, blocking the peptide cleft of class-II MHC to prevent premature binding of 
antigenic peptides (487). CD74 expression is increased during chronic GI tract inflammation 
including IBD, also acting as an accessory molecule for cell proliferation in GI tract 
carcinogenesis (488). However CD74 is expressed in the absence of MHC II suggesting 
independent function (489). CD74 is a receptor for macrophage inhibitory protein (MIF), and 
CXCR2 in recruiting leucocytes to site of tissue damage and promoting pro-inflammatory 
cytokine release (490).  In addition CD74 can bind directly to GI tract pathogens, such as 
Helicobacter pylori (H. pylori) causing NF-κB mediated pro-inflammatory cytokine release 
including IL-8 (491).  CD74 is also strongly linked to carcinogenesis, with expression and 
associated MIF production increased in gastric and colorectal cancers, mediated perhaps by 
high levels preventing tumour antigen presentation, rendering tumours less immunogenic 
(492). Taken together, CD74 is a versatile molecule with multifaceted roles in immune 
response including antigen processing, perpetuating chronic inflammation and acting as a 
receptor for MIF and the microbiota.  
 
We hypothesise that increased Mbd2-/- CEC expression of CD74 may intensify inflammation 
by increasing free receptors for MIF +/- commensal microbiota attachment or by decreasing 
tolerance to the microbiota via increased epithelial MHC trafficking and presentation to LP 
DC and T cells. To test these hypotheses we propose to analyse sections of naive Mbd2-/- 
and WT colon for MIF by immunoflouresence to establish firstly expression in CECs, and 
then spatial localisation within areas of the crypt-cell niche in a method previously described 
(493). We would then seek to isolate and culture Mbd2-/- and WT CECs ex vivo, exposing 
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with a GFP-tagged CD74 protein crossed to our Mbd2-/- line, we would be able to visualise 
CD74 localisation ex vivo in WT and MBD2 deficient CECs and in addition using electron 
microscopy assess for any direct interaction with the microbiota at the epithelial-luminal 
interface (494).  
 
MHC molecule expression on CECs renders them capable of activating CD4+ and CD8+ 
effector T cells under inflammatory conditions, though the exact mechanisms underpinning 
CEC MHC I and II up-regulation are unknown (429), (495). Both class I and II molecules are 
found at increased levels on IECs in active IBD, with MHC II controlled by a transcriptional 
complex that includes the MHC II transactivator (CIITA) (496). Ciita expression is tightly 
regulated to prevent uncontrolled immune responses. The precise mechanisms co-
ordinating Ciita expression are not known, but factors identified that increase MHC II 
expression include factors that inhibit IL-10 or upregulate IFNγ signalling (497). Ciita was 
found upregulated LogFC+0.97, p=0.03 in naïve Mbd2-/- CECs compared to WT (Figure 
5.6A). Interestingly in a genome wide RNAi screen of MHC control mechanisms, of 9 
transcriptional regulators of Ciita, only 4 altered Ciita expression levels – i.e. up-regulated 
MHC II expression occurred independent of changes in Ciita (498). One such Ciita regulator 
was the HIV Tat-interacting protein HTATIP (aka K(lysine) acetyltransferase 5, (KAT5)), a 
histone acetylase with roles in regulating chromatin remodeling and signal transduction, that 
in turn mediates TAT control of MHC expression (498).  
 
Increased expression of Ciita and multiple aspects of the MHC-II molecules in Mbd2-/- CECs 
may represent a primary dysregulation of Mbd2 mediated changes in Ciita or its regulators, 
such as KAT5, or indeed a manifestation of secondary epithelial inflammation and 
subsequent compensatory up-regulated antigen processing capabilities. To test this 
hypothesis we propose to measure the level histone acetylation at the Ciita promoter using 
antibodies against H3K9/K14ac, an epigenetic marker of active gene transcription as 
previously described (318) assessing FACS purified Mbd2-/- and WT CECs. In addition we 
propose to assess spatial expression of MHC-II ex vivo by confocal microscopy, as 
previously described by (499). Hershberg et al. describe that the normal basolateral function 
of MHC-II presentation IECs can be augmented in the absence of inflammation by co-
expressing Ciita, resulting in increased peptide presentation to T cells (499). Thus confocal 
microscopy staining for MHC-II in ex vivo Mbd2-/- CECs would assess the spatial expression 
of MHC-II molecules i.e. is the normal exclusive basolateral expression disturbed in the 
absence of MBD2. Thereafter we would assess peptide presentation using ex vivo Mbd2-/- 
and WT CECs in transwells cultured with T cells specific for chicken-ovalbumin (from 
C57Bl/6-Tg(TcraTcrb)425Cbn/Crl mice) measuring T cell proliferation as a readout of CEC-
presentation. To address whether MBD2 deficient CECs display an increased activation 
profile in the absence of other MBD2 deficient cell types, a VillinCre mouse will be crossed to 
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our existing Mbd2Fl/Fl mouse, to allow epithelial specific deletion of Mbd2. Assessing 
epithelial activation by flow cytometry and gene expression analyses described in Chapter 
5.3 and 5.4 will then aim to support or refute Mbd2-/- CECs as the primary driver for 
increased intestinal inflammatory responses in Mbd2-/- mice. Lastly it is well documented that 
CAC in IBD is strongly correlated with chronic inflammation. We hypothesise that indolent, 
sub-clinical inflammation in Mbd2-/- mice that is associated with basal activation of CECs will 
increase the incidence of colorectal cancer. To test this hypothesis we propose to age Mbd2-
/- and WT littermate controls to 12months under the same housing conditions that we 
performed the microbiome analyses, and assess the presence of colorectal adenomas by 
histological analysis of intestinal sections.  
 
MHC I antigen presentation pathways play an important role in alerting the immune system 
to infected, particularly virally infected, cells. MHC I molecules are expressed on the cell 
surface of all nucleated cells and present nucleotide fragments from intracellular proteins 
(497).  The majority of peptides presented by MHC I molecules are derived from defective 
ribosomal translation products degraded by the proteasome, as opposed to the turnover of 
mature proteins (497). Peptides are then translocated into the ER lumen by the transporter 
associated with antigen processing (TAP), which also functions as a scaffold for the final 
stage of MHC I assembly. Thereafter loaded MHC I molecules dissociate from TAP and are 
selectively transported in vesicles through the Golgi apparatus to the plasma membrane 
(497). This process has evolved therefore to permit rapid sampling of proteins immediately 
after their synthesis, rapidly alerting leucocytes to infected cells. IFNγ induces the 
expression of 3 additional subunits (PSMB/9 and LMP7), which replace constitutively 
expressed counterparts and are then termed the immunoproteasome (500). It has been 
suggested that enhanced proteasome activity in IBD accelerates NF-κΒ activation that may 
propagate sustained progressive inflammation (501). Indeed PSMB8 has a significant role in 
autoimmune diseases and inflammatory reactions: patients with a homozygous miss sense 
mutation (G197V) suffered from autoinflammatory responses characterised by increased 
assembly intermediates of immunoproteasomes from resultant reduced PSMB8 and 
increased IL-6 (500). Both Psmb8 (LogFC+2.8 and +2.2 in naive and inflamed CECs, Mbd2-/- 
versus WT respectively) and Psmb9 (LogFC+2.1 and +1.8 in naive and inflamed CECs, 
Mbd2-/- versus WT respectively) were upregulated in Mbd2-/- CECs.  
 
Thus we hypothesise that pro-inflammatory signals to Mbd2-/- CECs mediate replacement of 
constitutive proteasome with immunoproteasome subunits which permit an increased ability 
of inflamed epithelium to process and present antigen to cytotoxic T cells. To test this 
hypothesis we propose to measure T cell responses using an OT-I transwell system 
described above, in WT and Mbd2-/- CECs cultured with a selective inhibitor of the 
immunoprotesome subunit LMP-7 of PSMB8. We would hypothesise that negating the 
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increased immunoproteasome:protesome ratio in Mbd2-/- CECs using selective inhibitors 
would ameliorate T-cell responses to WT levels.  
 
In contrast, only MHC II molecules were upregulated in WT DSS versus WT naïve CECs 
(See Table 5.10). There were no MHC I molecules up regulated LogFC>1, with fewer MHC II 
genes upregulated (4; H2-DMa, H2-Aa, H2-Eb1 and H2-Ab1), and those upregulated had 
lower FC difference (LogFC range 1.1-1.8). The most up-regulated pathways when 
comparing WT DSS versus WT naïve CDCs were instead cytokine-cytokine receptor 
interaction and chemokine signaling pathway, with antigen processing not featuring in any of 
the top 10 most enriched pathways (See Table 5.11 and 5.12). Similarly there was no effect 
of treatment on WT expression of any TJ complex proteins (See Table 5.10). Taken 
together, these data are consistent with the hypothesis that Mbd2-/- predisposition to colonic 
inflammation is dependent on up-regulated CEC pathways out with the normal WT 
inflammatory response. We also observed a number of dysregulated cellular structural 
proteins involved in cell adhesion and epithelial barrier integrity, and these are considered 
below, comparing LogFC Mbd2-/- and WT.  
 
IECs are required to be selectively permeable to permit the passage of nutrients whilst 
maintaining a physical barrier. This selective permeability is underwritten by transcellular and 
paracellular capabilities (464). The paracellular pathway is regulated by an apical junctional 
complex, which is composed of TJ and adherence junctions (AJ) (502), (503). TJ barrier 
disruption and increased paracellular permeability, followed by increased translocation of 
luminal pro-inflammatory molecules, can induce activation of the mucosal immune system 
(504). TJs are comprised of 4 transmembrane proteins; occludins, claudins, JAM and 
tricellulin, the intracellular domains of which anchor to cytosolic scaffold proteins (464). 
Numerous studies have now identified claudins as the key component and backbone of TJs 
(505), (506). Cldn1-/- mice (Cldn1 naïve NS, inflamed LogFC -1.0) die within 24hours of birth 
because of dramatic fluid and electrolyte loss from an impaired epidermal barrier (505). 
Claudin 4 (Cldn4 naïve LogFC-2.7, inflamed LogFC-1.6) is a barrier forming claudin and as 
such decreases paracellular permeability (507). Phosphorylation processes are key in 
dictating claudin localisation and permeability function. Claudin 4 phosphorylation by ephrin 
receptor tyrosine kinase, largely expressed on various tumour cells, increases paracellular 
permeability by reducing interaction with the occluding protein, ZO-1 (508). It is well known 
that IFNγ alone, or in conjunction with other cytokines (particularly TNF) disrupts the barrier 
function of TJs across culture epithelial monolayers (509). Emerging evidence suggests this 
may be mediated by internalization of TJ proteins, decreased expression of occludin proteins 
or altered distribution of junctional proteins (510). Thus reduced CEC expression of Cldn1 
and 4, key barrier forming TJ components, would be hypothesised to increase paracellular 
permeability and therefore luminal antigen uptake leading to mucosal inflammation.  
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We would therefore propose Mbd2 as a key regulator of CEC function. It is not currently 
clear whether there is a primary defect in epithelial TJ formation caused by Mbd2 mediated 
dysregulation of CLDN4, leading to a greater influx of luminal antigen or indeed a primary 
dysregulation in antigen processing of the intestinal microbiota, predisposing to an 
inappropriate activation and a resultant inflamed microenvironment.  
 
In a further layer of complexity, we observed the selection of Clostridia and depletion of 
Parabacteroides communities in the Mbd2-/- microbiome. 4 OTU were significantly altered 
including the enrichment of 3 Clostridiales organisms. Interestingly reduced Clostridia 
species in man have been found in patients with IBD and atopy, with a recent study using 
the administration of a mixture of 17 human Clostridiales organisms to mice induced 
increased colon LP Treg numbers and protected against TNBS colitis (147). This mix of 
bacteria did not include any of the significant OTU in our dataset, however. Further, another 
study found an accumulation of Clostridiales species in a Chinese cohort with active UC or 
CD, underlining the difficulties in comparing human microbiota cohorts from different 
geographical areas, with all the resultant ethnic and dietary variation therein (511). 
Parabacteroides, a member of the Bacteroidetes phyla which is the most numerically 
abundant in the human gut and has been shown to predominate at the mucosal surface, is 
by contrast reduced in IBD patients and in Mbd2-/- mice (150). Parabacteroides distasonsis 
has been shown to be more common in healthy controls versus IBD patients, isolated from 
the colon mucosa by endoscopic biopsy (512). Similarly oral treatment of mice with P. 
distasonis significantly reduced the severity of intestinal inflammation mediated by DSS 
thought to be mediated by induction of anti-P. distasonis antibody responses and 
stabilisation of other members of the intestinal microbiota by negating DSS mediated 
changes in a Treg independent manner (513). 
 
An interesting observation was the presence of an outlier in the Mbd2-/- microbiota analyses 
(Figure 5.8A). Mbd2-/- microbiota associated together independent of cage, but whilst efforts 
were made to age-match all mice, 1 mouse was significantly younger and this mouse was an 
outlier in analysis (Table 5.8 and Figure 5.8A). Whilst this may represent outlying data based 
on unknown methodological issues or biological variation, it opens the possibility of 
epigenetic modification of the microbiome during the ageing process. The composition of 
intestinal bacteria changes in the elderly, with a decrease in anaerobes (e.g. Bifidobacteria) 
in both abundance and species diversity, and in increase in facultative anaerobes including 




We speculate this may be a product of increased susceptibility to intestinal Clostridia due to 
inappropriate CEC antigen processing or that these organisms may have been selected due 
to inappropriate host-driven steady state inflammation. This parallels the same key question 
of dysbiosis in IBD pathogenesis, namely whether this is a cause or an effect of 
inflammation. To address the hypothesis of a primary dysbiosis in MBD2 deficiency we 
propose to re-derive Mbd2-/- mice into germ-free conditions, assessing basal epithelial 
activation and response to DSS colitis. To supplement this, we propose to repeat our DSS 
experiments in WT and Mbd2-/- mice that have been pre-treated with broad spectrum 
antibiotics (amplicillin 1g/L, vancomycin 500mg/L, neomycin 1g/L and metronidazole 1g/L in 
drinking water for 4 weeks) to remove the commensal microbiome, as described by Rakoff-
Nahoum et al. (162). Lastly we propose to perform faecal transplantation of Mbd2-/- 
microflora into WT mice, to assess if this microbiome is capable of inducing aberrant CEC 
responses in an Mbd2 sufficient environment.  
 
We would therefore expect that if Mbd2 is controlling intestinal dysbiosis that is required the 
pro-inflammatory phenotype of Mbd2-/- then abrogating this as described above will 
ameliorate intestinal damage to that seen in WT animals.   
 
A significant limitation in our microbiota analyses is the assumption that non-bacterial 
members of the microbiome, namely viruses and fungi amongst others, do not contribute to 
IBD pathogenesis. It is likely this will become a key research focus of unbiased sequencing 
work in the future. Specific taxonomic shifts have been reported in IBD. Enterobacteriaceae 
are increased in relative abundance in both patients with IBD and animal models (152), while 
adherent invasive E. coli strains in particular have been isolated from ileal CD biopsies and 
in are enriched in patients with UC (153). This may simply represent an increased 
preference of these organisms to survive in an inflammatory environment, with 
administration of anti-inflammatory treatments, such as mesalazine, reducing their frequency 
(154). In contrast some bacteria have demonstrated protective effects on host immunity. 
Bacteroiodes and Clostridium species have been shown to induce the expansion of Tregs, 
reducing intestinal inflammation, with other organisms shown to attenuate inflammation by 
regulating NF-κB activation (156). Similarly the Bifidobacterium, Lactobacillus and 
Faecalibacterium genera may protect the host from inflammation by down-regulating 
inflammatory cytokine or augmenting IL-10 production (157). F. prausnitzii has received 
much attention in recent years, underrepresented in IBD patients, with lower levels of 
mucosa associated F. prausnitzii associated with higher risk of recurrent CD after surgery 
(158). In addition to immunomodualtory effects, the Faecalibacterium genus is also 
responsible for the fermentation of dietary fibre to produce SCFA, which are the primary 
energy source for CECs (161). SCFAs have been shown to modify leucocyte recruitment, 
chemotaxis and effector mechanisms (516). SCFAs activate the G protein coupled receptor 
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GPR43 that in turn activates mitogen-activated protein kinases and protein kinase C that 
induce directional migration of neutrophils (517). In addition SCFAs modulate the expression 
of IL-8, CCL2, and CXCL-1 by IEC in response to response to microbial-derived molecules 
such as peptidoglycan (518). Lastly SCFAs, mainly butyrate, have been shown to suppress 
LPS and cytokine stimulated production of pro-inflammatory mediators such as TNF, IL-6 
and NO from macrophages and monocytes (519). The main mechanism for this effect is the 
attenuation of HDAC activity. By directly inhibiting HDAC activity, SCFAs increase histone 
acetylation and therefore modulate gene expression (520). SCFAs may also increase 
prostaglandin E2 (PGE2), production by inflammatory monocytes in response to commensals 
in acute gastrointestinal infection that inhibits neutrophil activation, suggesting dual anti- and 
pro- inflammatory roles for SCFAs and their downstream effectors (46). 
 
Therefore in addition to direct interaction of the microbiota with CECs, metabolism of luminal 
foodstuffs such as SCFAs may directly modulate host response. To assess this further we 
propose the analysis of SCFA content such as acetate, propionate and butyrate in faeces of 
Mbd2-/- and WT mice and thereafter culture of Mbd2 deficient and sufficient CECs ex vivo 
with SCFAs assessing release of chemokines (e.g. CCL2 and CXCL1) and pro-inflammatory 
cytokines (e.g. IL-1β) by ELISA to characterise potential meta-genomic interactions.  
 
Given the gene expression data is taken from Mbd2-/- mice, we also consider an additional 
explanation, that a non-epithelial Mbd2 deficient cell type is facilitating an activated epithelial 
phenotype. Mbd2-/- naïve splenic T cells are known to possess the potential to produce more 
IFNγ than WT when stimulated with PMA/iomomycin in vitro (319).  However it is not clear 
whether Mbd2-/- T cells constitutively express IFNγ without such stimulation. This is 
particularly relevant in the colon LP given TJ function; antigen processing and barrier 
defense mechanisms are all upregulated in an IFNγ rich environment (521). Whilst we 
cannot discount this possibility, given the level of whole colon Ifng transcript was equivalent 
between Mbd2-/- and WT mice, we suggest this explanation is less likely than the others 
considered (Figure 3.5).  
 
Epigenetic regulation of IECs has been described elsewhere in the literature. Alenghat et al. 
documented the role of histone deacteylase 3 (HDAC3) in exacerbating colonic 
inflammation, altering basal gene expression profiles and altering the intestinal microflora 
(449). IECs with an epithelial specific deletion of HDAC3 (HDAC3ΔIEC) displayed up-
regulated PPAR signaling and lipid synthesis with associated increased H3K9 acetylation 
and down-regulated antigen processing genes (including H2-Ab1) (449). However, there 
was no difference in acetylation at downregulated gene sites. HDAC3ΔIEC mice were more 
susceptible to chemical (DSS) and infectious (L. monocytogenes) colitis, had increased 
barrier permeability, reduced Paneth cells and increased levels of Proteobacteria. However 
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these differences were abrogated when HDAC3ΔIEC mice were re-derived into germ free 
conditions, suggesting that commensal-bacteria derived signals are required for HDAC3-
induced dysregulation (449). Similarly Turgeon et al. reported HDAC1/2ΔIEC but not 
HDAC2ΔIEC displayed increased susceptibility to DSS colitis and decreased barrier function 
suggesting not only differing roles for HDACs in IEC function, and also the combination of 
HDACs is important in determining the overall pre-disposition to intestinal pathology (522).  
Lastly, Marjoram et al. showed loss of the epigenetic regulator ubiquitin-like protein 
containing PHD and RING finger domains (UHRF1), itself an IBD risk susceptibility loci, 
predisoposes to intestinal inflammation in zebrafish (523). Mutant Uhrf1 zebrafish 
demonstrated reduced Tnfa promoter methylation and increased Tnfa IEC expression. This 
increase was microbe dependent and resulted in IEC shedding, immune cell recruitment and 
barrier dysfunction and was restored by Tnfa knockdown.  
 
We hypothesise that in a combined model in naïve Mbd2-/-, given the overwhelming 
upregulation of antigen processing and defence pathways, that the most likely primary 
candidate for Mbd2-mediated dysregulation are Cd74 and/or MHC II molecules. We 
speculate this results in inappropriate CEC activation and creation of an inflamed 
microenvironment at the mucosal surface with subsequent TJ breakdown and increased 
barrier permeability mediated by reduced Cldn4. This inflamed microenvironment thereafter 





Figure 5.1 Flow cytometry analysis of CECs
Colon cells were isolated and stained with Live Dead (Blue) and thereafter an antibody cocktail consisting of SiglecF, 
Ly6G, CD11b, CD11c, F4/80, CD64, CD45, CD103 and Lineage markers (CD3, NK1.1 and CD19) and analysed by flow 
cytometry. A. Flow cytometry contour plot of EpCAM+, CD45- CECs after exclusion of CD3+ F4/80+ EpCAM+ cells, with  
SSC and FSC profile of CEC and CD45+ populations for comparison. B. Histogram of selected surface marker expres-
sion comparing CD45+ and CEC populations compared to isotype antibody control.  Representative of 3 independent 
































Figure 5.2 Optimising CEC isolation by comparison of 3 established extraction protocols
Colon cells were isolated using 3 different protocols described in chapter 5.2 and table 5.1. Protocol #1 was our exisiting 
colon cell isolation protocol described in chapter 2.3, protocol #2 utilised a percoll gradient to enrich for CECs, protocol 
#3 involved a longer incubation period (90 versus 45 mins) with dispase instead of colangenase. Cells were stained for 
LiveDead(Blue) and thereafter surface stained with an antibody cocktail consisting of EpCAM, CD45, CD3 and F4/80 and 
analysed by flow cytometry. A. sequential vertical gating comparing protocols, gating live and intact cells before identify-
ing EpCAM+, CD45- CECs. B The number of CECs was enumerated per colon comparing isolation method. C Histogram 

























































Figure 5.3 Pre and post FACS purification analysis of CECs 
A. Contour plots of naive WT colon cells stained for expression of Live Dead Blue, CD45, EpCAM, F4/80 and CD3 
surface markers and then purified by FACS. Cells are pre-gated on Live and intact cells. Representative pre- and post- 




















Figure 5.4 mRNA expression of epithelial cell markers and Mbd2 in CECs
Colon cells were isolated and stained for the following antibody cocktail (CD3, CD45, EpcAM, F4/80) before purification 
of CECs using the sort logic presented in Figure 5.3. mRNA expression of the above epithelial cell markers (A) and Mbd2 
(B) was determined by qRT-PCR, the mean value relative to Gapdh expression is presented. Mean values were obtained 
from 3 independent experiments using 3 individual mice. Primer sequences are in Table 2.5. For the other presented 
populations in B, mice were pooled 3 mice per biological replicate, and 3 biological replicates presented, with whole 

































































































Figure 5.5 Surface marker phenotype of Mbd2-/- CECs in chemical and infectious colitis
WT or Mbd2-/- mice were treated with 2% DSS or normal drinking water for 6 days (A,B,C) or 20 or 200 T. muris eggs 
for 35days (C). Colon cells were then isolated surface stained for the following antibody cocktail (CD3, F4/80, EpCAM, 
CD45, MHC-II and Ly6A/E) and then permeabilised and stained for intracellular Ki67 and analysed by flow cytometry. 
A. EpCAM+ CD45- CECs were identified and enumerated as the proportion of intact cells. B. CECs were analysed for 
the proportion of total CECs that expressed Ly6A/E or Ki67.C. Flow cytometry contour plots of low dose (20eggs) T. 
muris infected or Day6 DSS treated WT and Mbd2-/- CECs at day35 post infection, with the proportion of CECs 
expressing MHC-II presented. 1 T. muris experiment and 3 independent DSS experiments, n=1-5 per group are 
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Figure 5.6 Gene expression analysis of naive WT versus Mbd2-/- CEC
Naive Mbd2-/- or littermate WT mice CECs were isolated and purified by flow cytometry as detailed in Figure 5.3. RNA 
was extracted and gene expression assessed by hybridisation to IlluminaMouseRef6 microarray. Heatmap of normal-
ised gene expression from WT versus Mbd2-/- CECs are presented with genes significantly upregulated (A), downregu-
lated (B) presented in bold (adj p<0.01). Selected non significant genes are presented based on literature review for 
pertient loci (C). Each individual heatmap represents a biological replicate composed of 1 individual mouse. (D) Princi-
pal component analysis of gene expression profiles from CECs each data point representing individual biological repli-







Figure 5.7 Gene expression analysis of DSS treated WT versus Mbd2-/- CEC
Day 6 DSS treated Mbd2-/- or littermate WT mice CECs were isolated and purified by flow cytometry as detailed in 
Figure 5.3. RNA was extracted and gene expression assessed by hybridisation to IlluminaMouseRef6 microarray. 
Heatmap of normalised gene expression from WT versus Mbd2-/- CECs are presented with genes significantly upregu-
lated (A), downregulated (B) presented in bold (adj p<0.01). Selected non significant genes are presented based on 
literature review for pertient loci (C). Each individual heatmap represents a biological replicate composed of 1 individu-
al mouse. (D) Principal component analysis of gene expression profiles from CECs each data point representing 





















































































































Figure 5.8 Analysis of the colonic microbiota in naive WT and Mbd2-/- mice
The colonic contents from co-housed, age and sex matched naive WT and Mbd2-/- mice were obtained, and DNA 
extracted (There was one non-age matched Mbd2-/- sample in the analysis, this is discussed in chapter 5.6.1 and Table 
5.8 and is the outlier at the top of the dendrogram). The 16S region was amplified using primers overlapping the V3 
V4 region (See Chapter 2.15 for primer sequence) and assessed for 550bp product using gel electrophoresis. DNA 
was then sequenced using the IlluminaMiSeq platform and FASTQ files exported to the mothur software for analysis. 
OTUs were identified as described in Chapter 5.6 and analysed for differences in microbial populations by Yue and 
Clayton metrics. (A) Dendrograms were produced using iTOL dendrogram software analysing differences in OTU and 
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The human GI tract has evolved to simultaneously promote efficient nutrient absorption and 
negate pathogen entry. This is achieved by finger-like epithelial projections, villi, to produce 
a vast surface area, co-existing with a highly sophisticated network of specialised immune 
cells. Both innate and adaptive arms of the immune response are located at intestinal 
mucosal surfaces, operating the dichotomous roles of tolerance to the commensal 
microbiota and brisk response to luminal pathogens. Inappropriate, overactive response to 
the former would not only be a wasteful use of resources by the host, but may instigate a 
cascade of damaging inflammation that has the potential to disrupt normal physiological 
function, in particular, nutrient absorption. The components of the intestinal immune system 
therefore demonstrate phenotypes unique to this tissue site. For example intestinal 
macrophages exhibit ‘immune inertia’, poorly responsive to TLR stimuli and secreting large 
quantities of the regulatory cytokine IL-10 (43). IECs also display antigen-processing 
capabilities, with expression of such machinery tightly regulated and spatially expressed 
exclusively on their baso-lateral surface (499). These cells are also able to sense and 
respond to luminal pathogens via PRR, able to secrete a vast array of immune regulatory 
and recruitment products that shape the local immune response and micro-environment 
(100).  
 
These keys facets of intestinal immune response are perturbed in IBD. IBD is thought to be 
the result of a dysregulated immune system in genetically predisposed individuals with 
susceptibility variants described in autophagy, IL-23/Th17 and TGFβ pathways (104). Whilst 
recent studies have also identified intestinal monocytes and monocyte-derived precursors as 
critical perpetrators in driving IBD (113), (43), the immune mechanisms underpinning the 
dysregulated immune response in IBD pathogenesis are not well described. Previous work 
has therefore utilised animal models of IBD to describe the immune response in WT and 
transgenic animals to shed new light on existing control mechanisms, and uncover novel 
areas for therapeutic investigation in man.  
 
Despite large strides forward in our understanding of the genetic contribution to common, 
polygenic conditions such as IBD, we can currently only account for <30% of IBD heritability 
using GWAS disease susceptibility loci (Anderson et al. 2011). Heritable changes in gene 
expression not encoded in DNA sequence and thus not accounted for using existing 
techniques therefore represent an attractive hypothesis for explaining part of this heritable 
component to disease susceptibility. Epigenetic processes such as DNA methylation, 
histone modification and nucleosome remodelling have all been shown to influence the 
regulation of key cell functions, including immune response, and require the presence of 
MBD proteins to exert these effects efficiently (242). MBD2 binds preferentially, though not 
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exclusively, to methylated DNA recruiting a large nucleosome re-modelling complex, 
exerting alterations in chromatin folding and histone motifs that confer significant gene 
expression changes (280). As such MBD2 has been shown to be critical in both innate and 
adaptive immune response; in mediating appropriate T cell differentiation and DC activation 
and function in response to Th2 pathogens and allergens (318), (321), (319).  
 
Previous indications therefore suggest that Mbd2 may play an important role in immune cells 
and in the GI tract in response to infection and predisposition to colorectal malignancy 
((321), (325). However the immune mechanisms and cell types underlying these 
observations has not been explored in the GI tract. 
 
The aims of this project were therefore to delineate, for the first time, the role of Mbd2 in the 
intestinal immune response, specifically in animal models of colonic inflammation. We also 
sought to complement this with assessments of monocyte-like / macrophage populations in 
a homogenous colonic IBD dataset.  This necessitated the optimisation and in some cases 
development of novel techniques to simultaneously assess multiple colon LP innate 


















































































































































































Figure 6.1 Proposed mechanisms for Mbd2 mediated changes in colon homeostasis 
Naïve  
1. Absence of Mbd2 may increase Ag processing and presentation gene expression in naive 
Mbd2-/- CEC (versus naive WT) 
2. Absence of Mbd2 may reduce tight junction protein gene expression in naive Mbd2-/- CEC 
(versus naive WT), though this may be a secondary phenomena (e.g. due to increased local 
IFNγ)  
3. Absence of Mbd2 may increase LY6C A/E/Ly6c expression in naive Mbd2-/- CEC (versus 
naive WT) 
4. Mbd2 is required to prevent the observed reduced number of CD11b+ CD103+ DCs in 
naïve Mbd2-/- LP, the reasons for which are not clear but may include a role for Mbd2 in local 
DC survival or appropriate differentiation 




1. The same process of dysregulated Ag processing, MHC-II, LY6A/E and AMPs (CECs) 
CD40, CD80 expression (CD11c+ cells) seen in naïve Mbd2-/- now occurs in WT, but this is 
less than the increases in the already activated Mbd2 deficient system 
2. The same chemokine/proinflammatory response elements are upregulated independent of 
Mbd2 deficiency in DSS 
3. Decreased Mbd2-/- MΦ Fcrls expression may impair phagocytosis and therefore response 





















6.2 Concluding remarks 
We suggest that Mbd2 acts to limit damaging inflammation in the mouse colon by preventing 
excessive monocyte and neutrophil accumulation. This end-result of colonic inflammation is 
lessened by the action of Mbd2 in a multitude of cell types, underlining its functional 
importance. Firstly, Mbd2-mediated changes in CD11c expressing cells limits colonic 
inflammation (Figure 4.8), and we hypothesise this is due to its promotion of efficient 
phagocytosis in colon macrophages. Secondly, we have identified monocyte-like cells as 
increased in patients with endoscopic evidence of active IBD, irrespective of symptoms 
(Figure 3.12). This may have important implications for IBD management and we speculate 
that in the future phenotyping the proportion of immune cells at inflamed tissue sites may 
provide insight into disease activity, prognosis and disease natural history. Thirdly, our data 
strongly indicate that Mbd2-mediated changes in CECs prevents inappropriate antigen 
processing of luminal contents and promotes epithelial barrier integrity via TJ protein 
expression (Figure 5.6). Lastly, Mbd2 regulation of colonic immune and epithelial cells alters 
the local microbial environment, maintaining species of bacteria that promote intestinal 
health.  
 
One of the key unanswered questions of dysbiosis pathogenesis is whether observed 
dysbiosis in human IBD, or indeed in Mbd2-/-, is a primary or secondary phenomenon. 
Therefore future work, will seek to address whether the microbiota in Mbd2-/- are inherently 
colitogenic, or indeed if by abrogating dysbiosis under germ-free or antibiotic treated 
conditions Mbd2-/- mice continue to demonstrate impaired inflammatory responses.  
 
We foresee the main limitation in generalising these results is understanding the precise 
nature of Mbd2 action. Namely demonstrating that dysregulated gene expression in the 
absence of Mbd2 correlates to local binding of Mbd2 at these loci and subsequent NuRD 
complex mediated changes in epigenetic motifs, altering the binding of transcriptional 
apparatus and ultimately gene expression. Mbd2 chromatin immune precipitation has in our 
experience proved technically challenging due to poor antibody affinity, thus we are currently 
generating transgenic mice wherein a his-tagged Mbd2 protein will permit investigation of its 
binding sites to answer these important questions.  
 
Another limitation is that we have undertaken our gene expression analyses using mice 
globally deficient in Mbd2. At this point, we are therefore not able to exclude the possibility 
that other Mbd2-/- cell types may influence gene expression in our reported cells of 
investigation. For example, whether MBD2 deficient colon LP ILCs, neutrophils or 
eosinophils are directly influencing the gene expression profiles of MBD2 deficient 
macrophages, DCs or epithelial cells. To address this we are seeking to validate Mbd2-
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mediated gene expression changes in animals where Mbd2 deficiency is restricted to 
specific cell types, e.g. epithelial cells (Villin-CreMbd2Fl/Fl) and T cells (Vav-CreMbd2Fl/Fl).   
 
Whilst the gene expression data in chapters 4 and 5 have permitted the use of hypothesis-
free strategies to identify putative genes under the control of Mbd2, one of the most striking 
features in the DC, macrophage and monocyte expression data was the absence of a single, 
consistently dysregulated locus. This is perhaps re-inforces the multitude of small Mbd2 
mediated gene expression changes occurring within multiple different cell types. This further 
underlines simultaneously the importance of Mbd2 in a spectrum of immune cells, but also 
the difficultly in identifying the presence of a primary regulatory pathway. The second most 
striking feature was the complicated balance of pro- and anti-inflammatory feedback 
mechanisms (See Diagram 4.2). Despite a more severe disease phenotype in response to 
chemical colitis, Mbd2-/- cells displayed both enhanced inflammatory and regulatory 
pathways. We therefore speculate that the biological kinetics of macrophage and monocyte 
responses to inflammatory challenge change over time, with pro-inflammatory pathways 
predominating early in the response, with a tipping-point whereby inflammation is no longer 
physiological but pathological, with a rise in anti-inflammatory mechanisms to limit further 
tissue damage. Evidence for this hypothesis is seen in the upregulation of anti-inflammatory 
pathways in active IBD and adult respiratory distress syndrome (ARDS), both characterized 
by aberrant inflammation and failure of anti-inflammatory control mechanisms (524), (525).  
 
The data presented herein suggest that heritable changes in mucosal immune function may 
not be encoded in an organisms DNA sequence. ‘Epigenetic stress’, defined here as the 
perturbation on the host epigenome caused by environmental pressure, may explain the 
limitations of existing genetic techniques to explain common heritable disease susceptibility 
(250). We hypothesise therefore that environmental pressures at mucosal surfaces may lead 
to alterations in the epigenome, which is inherently more plastic than the genome, leading to 
altered expression of key regulatory immune processes and thus disposition to diseases 
characterised by aberrant inflammatory responses.  
 
Rather than suggesting that MBD2 is the ‘smoking gun’ for IBD pathogenesis, we speculate 
that our data support the principle of epigenetic processes forming a fundamental control 
mechanism for host defence and appropriate mucosal responses. This may in turn provide a 
plausible hypothesis for the observation that most NOD2 mutants, the largest genetic risk 
factor identified for CD, do not develop IBD (107). Indeed perhaps in a multi-hit hypothesis of 
heritable contribution to common disease, genetically susceptible individuals require either 
an inherited or environmentally-disturbed mutant epigenome that impairs host responses. 
Just as there is no one cell type that is dysregulated in IBD, our work using Mbd2-/- animals 
strongly suggests that Mbd2 regulation of gene expression impacts a network of mucosal 
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cell types that together are key for limiting excessive intestinal inflammation, underlining the 
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